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The Dreamcatcher
Native Americans believe that the night air is filled with dreams both good and bad. 
The dream catcher when hung over or near your bed swinging freely in the air, 
catches the dreams as they flow by. The good dreams know how to pass through 
the dream catcher, slipping through the outer holes and slide down the soft feathers 
so gently that many times the sleeper does not know that he/she is dreaming. The 
bad dreams not knowing the way get tangled in the dream catcher and perish with 
the first light of the new day.
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(Auto)inflammation and autoimmunity 
To protect the integrity of an organism against environmental and endogenous 
dangers nature has developed a complex system of defence mechanisms. This 
defensive system is known as inflammation. Inflammation is induced when 
(immune) cells recognize danger signals and start producing inflammatory 
mediators such as chemokines, cytokines and antimicrobial peptides. This 
attracts specialised immune cells to the compromised site in order to mount an 
inflammatory cascade aimed at containing the threat and consequently restoring 
immunological balance. Since pathogens, such as viruses and bacteria, are 
capable of causing major damage to the organism and can evolve rapidly, the 
immune system has to be capable of responding quickly and with great force. 
This poses the organism with an immense challenge since an exaggerated and 
prolonged inflammatory response can be deleterious and cause extensive 
damage by itself. Long-lasting or excessive inflammation might even lead to the 
induction of a self-perpetuating cycle known as autoimmunity, a sustained 
process in which constituents of the organisms’ own tissues are recognized by 
the immune system as if they were foreign1. Another proposed model that might 
lead to chronic inflammation and consequent tissue damage is known as autoin-
flammation, herein tissue specific factors, including microtrauma and stress 
responses, lead to regional innate immune activation and persistent inflammation. 
It is essential to notice that an impaired immune reaction toward pathogens might 
also culminate in chronic inflammation due to the aberrant removal of these 
microbes or other inciting factors. 
 Autoimmune diseases are characterized by the presence of antibodies aimed 
at (disease-specific) endogenous ligands. Although the aetiology of autoimmune 
diseases is still largely unknown, it is widely recognized that a loss of immune 
tolerance to self components due to aberrant B and T cell reactivity is the shared 
basis of all autoimmune diseases. It is hypothesized that in genetically predisposed 
individuals an aberrant activation of the immune system might lead to a breach in 
tolerance, culminating in autoimmune disease. Other proposed models for the 
induction of autoimmunity are based on de-novo formation of autoantigens 
through mutations or protein modification, for example by citrullination, or on the 
observation that bacterial antigens can resemble self antigens. A large body of 
evidence points towards a seminal role for antigen-presenting cells (APCs) in the 
development of autoimmune diseases by forming a bridge between innate and 
adaptive immunity. In autoimmunity APCs appear to direct immune responses 
towards self by inducing the differentiation and proliferation of auto-reactive T 
cells, a crucial event in the pathogenesis of autoimmunity2. 
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 In contrast, (auto)inflammatory diseases are characterized by a lack of anti- 
bodies aimed against self antigens. The term autoinflammatory disease describes 
a group of disorders characterized by seemingly unprovoked inflammation without 
significant levels of autoantibodies and autoreactive T cells. While the disorders 
mostly associated with the term autoinflammation are rare inherited diseases 
such as familial Mediterranean fever, familial cold autoinflammatory syndrome 
and Muckle-Wells syndrome, other diseases such as Crohn’s disease, Psoriasis, 
Psoriatic Arthritis (PsA) and Ankylosing Spondylitis also comply to this definition3. 
These diseases seem to be dictated by the innate immune system although it is 
clear that T cells also play an important role in their induction and maintenance. 
Until now the tissue site-specific factors that activate the immune system are 
unknown. These might be endogenous danger signals which induce aberrant 
immune responses or bacteria(l components) deposited at selective sites.
 Two highly prevalent autoimmune and (auto)inflammatory diseases are, 
respectively, Rheumatoid Arthritis (RA) and Psoriatic Arthritis (PsA). RA and PsA 
share clinical features like the preferential inflammation of the small diarthrodial 
joints of the hands. However, the aetiology of both diseases seems to be clearly 
distinct. In the following chapters both diseases are discussed concerning their 
pathogenesis and the role APCs, such as dendritic cells and macrophages, and 
their Toll-like and Fc gamma receptors (TLRs, FcγRs) play in this. In the final 
chapter the aim and setup of this thesis is discussed.      
Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by 
chronic symmetrical synovial inflammation of primarily the metacarpophalangeal, 
proximal interphalangeal and metatarsophalangeal joints of the hands and the feet. 
The aggresive front of the tissue, called pannus, invades and destroys local cartilage 
and bone resulting in characteristic focal bone loss and ultimately the complete 
destruction of the integrity of the joint. RA is a frequent disorder that affects 1% of the 
population worldwide thereby representing the most common inflammatory 
rheumatic condition. While RA existed in early native American populations several 
thousand years ago it seems to have made an appearance in Europe only after the 
16th century, indicating that an infectious agent might play a role in the etiology of RA4. 
Despite the marked increase in the last decade in the armamentarium available to 
the modern rheumatologist only in a minor proportion of RA patients disease 
remission is achieved and a substantial number of RA patients are still therapy 
resistant, leading to severe disability and a decreased life expectancy. 
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 During RA there is a massive influx of immune cells into the synovium and 
synovial cavity, including monocytes, macrophages, dendritic cells (DCs), 
neutrophils and T and B cells. Tissue damage and cell stress during synovial 
inflammation can lead to the production of heat shock proteins (HSPs), altered 
fibronectin or low molecular weight hyaluronan fragments and RNA release from 
necrotic cells. These are endogenous danger signals that in turn can activate 
synovial fibroblasts and APCs stimulating chronic inflammation5,6. The etiology of 
RA is still unclear although it is apparent that antigen-presenting cells and 
autoreactive T and B cells play a crucial role. This is exemplified by the therapeutic 
effect of CTLA4-Ig (Abatacept) which prevents the activation of T cells by APCs7. 
RA is typified by polyclonal B cell stimulation and production of autoantibodies 
targeting the synovial membrane, cartilage and underlying bone. Despite a 
longstanding effort to understand and control the deranged immune process, the 
crucial events by which T cell and B cell tolerance is breached are poorly defined. 
 Genetic evidence is supportive of an important role for APCs and their 
antigen-uptake receptors in the pathogenesis of RA. The strongest association 
with RA susceptibility and disease severity has been found in the HLA-DRB1 
gene. Multiple RA risk alleles within the HLA-DRB1 gene share a conserved 
amino acid sequence and are therefore known as ‘shared epitope’ alleles. These 
polymorphisms are present in the epitope binding region of the major histocom-
patibility complex II (MHCII) and thereby probably influence antigen presentation 
by APCs and autoantibody production. More recently also non-HLA genes, such 
as PTPN22, FcγRs, STAT4 and IRF5, have been linked to RA susceptibility and 
1
 Figure 1
Representation of an afflicted joint in Rheumatoid Arthritis and a photograph of RA synovial 
villi growing into a joint cavity, as seen by knee arthroscopy.
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disease severity8. Since STAT4 and IRF5 are intricately involved in type I interferon 
signaling pathways it appears that the type I IFN system might play a role in the 
breaching of tolerance in RA. Supportive of this is the selective up regulation of 
type I IFN-response genes in peripheral blood cells from a subgroup of RA 
patients. In addition, it was recently reported that SLE features are common in RA 
patients given sufficient observation time and that these were associated with 
increased mortality. 
 Numerous autoantibodies have been discovered in sera and synovial fluid of 
RA patients. These antibodies may be directed to immunoglobulin G (rheumatoid 
factor (RF)), cartilage components, stress proteins, enzymes, nuclear proteins 
and citrullinated proteins such as fibrin or vimentin. In contrast to other antibodies 
including RF, anti-citrullinated protein antibodies (ACPAs) are almost exclusively 
found in RA patients, being the most specific serological markers of RA9. About 
75% of RA patients have auto-antibodies against the Fc portion of IgG molecules 
(Reumatoid Factor, RF) and citrullinated proteins. The presence of RF and ACPAs 
is associated with a more aggressive disease course suggesting a pathogenic 
role in RA or common pathways leading to inflammation and tissue destruction 
and the production of these autoantibodies. Recent data shows that shared 
epitope alleles of the MHC-II are specifically associated with RF and ACPA 
positive RA. The most frequent proteins against which anti-citrullinated protein/
peptide antibodies are produced are fibrinogen, vimentin and α-enolase, which 
are abundantly present in the RA synovium10,11. Necrotic cells in the RA synovium 
may release citrullinated proteins and activated citrullinating peptidylarginine 
deaminases (PADs). These enzymes can citrullinate proteins present in the 
inflamed joint. When these proteins are not degraded properly, they can be taken 
up by APCs and presented to T cells which in turn can trigger autoreactive B cells 
to produce ACPAs. Another major antigen against which immune responses are 
invoked in RA is heterogeneous nuclear ribonucleoprotein (hnRNP) A2. The 
hnRNPs are RNA binding proteins and they complex with heterogeneous nuclear 
RNA. These proteins are associated with pre-mRNAs in the nucleus and appear 
to influence pre-mRNA processing and other aspects of mRNA metabolism and 
transport. HnRNP-A2, like citrullinated proteins and IgG, was found to be highly 
overexpressed in arthritic joints12. Locally produced ICs can fix complement and 
release chemotactic factors such as C5a, next to the induction of proinflamma-
tory cytokine (e.g. TNFα) production by monocytes, DCs and macrophages, 
thereby aggravating local inflammation and promoting chronicity.
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Psoriatic Arthritis
Psoriatic arthritis (PsA) is an inflammatory disease of the skin, joints and entheses 
leading to discomfort, pain and in some cases the aggressive destruction of 
joints (arthritis mutilans). Approximately 15-25% of psoriasis patients develop 
arthritis, the incidence of which rises with disease severity13-15. However, as 
revealed by ultrasound examination of tendons, many people with psoriasis also 
have (asymptomatic) abnormalities usually seen in psoriatic arthritis. In about 
15% of people the arthritis starts before the psoriasis and may for that period of 
time be mislabelled. PsA in general involves fewer joints than RA. It is not 
uncommon to see just one or two joints involved. Inflammation of the distal inter-
phalangeal joints is characteristic to PsA, especially in the presence of nail 
disease. In addition, spondylitis resembling Ankylosing Spondylitis is common in 
PsA and may be present in up to 30% of patients with PsA. The major enthesis in 
the human body is the Achilles tendon and this is commonly involved in PsA. 
However every singly tendon in the body may be affected explaining why some 
patients present with widespread pain. 
 Although the events leading to the development of psoriasis and PsA are 
unclear the underlying chronic inflammatory immune response is thought to be 
triggered by unknown environmental factors on a polygenic background with 
increased susceptibility. Predisposition to psoriasis and PsA is most strongly 
conferred by the HLA class I region. Other genetic risk factors implicate the 
IL-12p40/IL-23 pathway in the pathogenesis of both diseases. Resident 
keratinocytes and DCs, consisting of epidermal Langerhans cells and dermal 
DCs, make up the first line of defense in the skin against microbial pathogens and 
trauma16. Upon the encounter of danger signals these cells readily release 
antimicrobial peptides, chemokines and cytokines crucial for the induction of 
protective immune responses17. Recent studies have implicated an impaired 
barrier function of the skin as a major determinant in the induction of psoriasis. It 
was shown that mutations and polymorphisms in keratinocyte-expressed genes 
involved in physical barrier function or innate immunity are risk factors for 
developing psoriasis18,19. In addition GWAS studies demonstrated associations 
between inhibitors of Toll-like receptor (TLR) signaling (TNFAIP3 (A20), TNIP1) 
and psoriasis20. Current available data do not support the notion that auto- 
antibodies or autoreactive T and B cells play an important role in causing PsA16,21. 
However, 15% of PsA patients have low titers of ACPAs while they demonstrate all 
the characteristic features of PsA22,23. T lymphocytes are shown to be important 
in the instigation and persistence of the chronic inflammatory response. Th1 and 
Th17 effector cells are thought to infiltrate the superficial perivascular skin early in 
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the development of psoriatic disease. There the T cells are activated by mono-
cyte-derived APCs and subsequently produce copious amounts of inflammatory 
mediators24. The pathogenic role of activated CD4+ T cells has been demonstrated 
by the clinical efficacy of drugs that inhibit T cell activation or deplete activated T 
cells25. Psoriatic lesions are further characterized by the presence of CD8+ 
cytotoxic T cells in the epidemis, the segregation of neutrophils in epidermal 
microabscesses and, in early lesions, the accumulation of plasmacytoid DCs. 
These findings appear to imply that the aetiology of PsA is based on aberrances 
in the innate immune system followed by a dysregulated adaptive immune 
response. The interplay of innate and adaptive immunity in PsA is seen in the 
Koebner phenomenon. In this phenomenon physical trauma is thought to activate 
the innate immune system provoking the recruitment of immune cells, including T 
cells, and the subsequent development of a psoriatic lesion.
 Recently, in Crohn’s disease a primary innate immunodeficiency of 
macrophages leading to an impaired innate immune response and bacterial 
clearance has been demonstrated26. Like PsA, Crohn’s disease is thought of as a 
dysfunctional barrier disease and both diseases share a remarkable overlap. PsA 
and Crohn’s disease are, for example, both associated with HLA-B27 positivity, 
(sub)clinical  eye and gut inflammation and the formation of tortuous vessels at 
sites of inflammation13. The compartments mostly affected during PsA, namely 
the skin, joints and entheses, are sites where bacterial components are likely 
preferentially deposited27-29. Microbial products are profoundly present in 
psoriatic skin lesions, but they also appear as thin deposits along the skin 
basement membrane of unaffected skin from psoriasis patients. No microbial 
products are found in skin from non-psoriatic individuals29. In synovial fluid from 
PsA patients a higher variety and concentration of bacterial DNAs are found 
compared to serum27. Furthermore PsA patients have higher antibody levels 
against various bacteria and bacterial constituents than psoriasis patients without 
articular involvement, Rheumatoid Arthritis (RA) patients or healthy controls30-32. 
Normal enthesis organs are avascular but tissue microdamage to entheses is 
common and appears to be associated with tissue repair responses and vessel 
ingrowth. This makes the enthesis organ a site where (molecules derived from) 
bacteria may preferentially localize. In the context of susceptibility-increasing 
genetic factors this might lead to the characteristic inflammatory responses of 
PsA. Altogether, the trapping of microbial products at specific compromised sites 
and the high levels of antibodies appear indicative of at least a perpetuating role 
for pathogens in PsA. 
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Dendritic cells and macrophages
Under the influence of distinct cytokines monocytes differentiate into specific 
effector cells, such as macrophages and DCs with distinct phenotypes and 
apparent roles in inflammation and immunity33. Through the production of a vast 
array of mediators and the instruction of the adaptive immune system the resulting 
subsets of monocyte-derived antigen-presenting cells control the progression or 
resolution of inflammatory processes34. GM-CSF and M-CSF are two cytokines 
important in the control of the numbers and function of macrophage lineage 
populations in steady state as well as in inflammatory conditions35-37. Both 
GM-CSF and M-CSF are survival factors for myeloid cells and induce their dif-
ferentiation, resulting in discrete macrophage lineage populations. Human mono-
cyte-derived macrophages have been divided in pro-inflammatory type-1, 
GM-CSF cultured macrophages (mf-1) and anti-inflammatory type 2, M-CSF 
cultured macrophages (mf-2). Mf-1 produce high levels of the pro-inflammatory 
cytokines TNFα, IL-6, IL-1b and IL-23 whereas mf-2 mainly produce IL-10 and 
trophic factors such as TGFb and VEGF34,38. To study the biology of human DCs 
in vitro, monocytes are usually cultured in the presence of GM-CSF and IL-4. The 
resulting monocyte-derived DCs have the ability to take up, process and present 
foreign antigens and are, in contrast to mf-1 and mf-2, capable of readily inducing 
marked T cell responses39.  
 Dendritic cells (DCs) are the professional antigen-presenting cells of the 
immune system and are considered key regulators of T and B cell immunity owing 
to their superior ability to present antigens. DCs continuously probe their 
environment and are crucial for upholding tolerance or inducing adaptive immune 
responses aimed against invading pathogens40. A failure in one of these critical 
processes would have detrimental effects for the host, either by destruction of 
organs due to auto-reactivity or by invasion of harmful microorganisms. Upon 
encounter of a threat DCs take up the pathogen, process its antigens and then 
migrate through afferent lymphatic vessels into draining lymph nodes where they 
present the encountered antigen to T cells. The adaptive immune response 
evoked at that time is specifically aimed at the pathogen sensed by the DCs and 
should fit the level of intensity needed. To accurately restrain the threat but not 
culminate in excessive inflammation, which might lead to tissue damage and 
possibly even tolerance breakthrough, a balanced and well-controlled appearance 
of pro-inflammatory T cells is of paramount importance41. 
 The function of DCs depends upon their state of maturation. As immature 
DCs they are distributed in the peripheral tissues were they sample the 
environment for so-called ‘danger signals’ that can be of exogenous and 
1
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endogenous nature. For this crucial task, DCs possess a specialized endocytic 
system consisting of a plethora of uptake receptors designed to deliver antigen to 
their compartments of processing. Upon the encounter of danger signals DCs 
commence a complex process generally termed as “maturation” which involves 
numerous pathways and greatly enhances their capacity for antigen processing, 
antigen presentation to naive T cells and the priming of specific T cell responses. 
In contrast to immature DC, mature DC home to the lymph nodes or secondary 
lymphoid organs guided by specific chemokine receptors such as CCR7 the 
expression of which is initiated by the maturation process. The general features 
encompassing DC maturation include the upregulation of co-stimulatory 
molecules, such as CD80 and CD86, the translocation of MHC molecules to the 
cell surface and the production of pro-inflammatory mediators, which latter is 
particularly dependent on the nature of the stimulus encountered. DCs not only 
play a role in the initiation of immunity but are also indispensable for the 
maintenance of tolerance. For this aim, DC capture antigens, even in the absence 
of overt infection or inflammation and present them in their steady-state immature 
phenotype to T cells rendering them anergic or inducing a regulatory T cell 
phenotype. Auto-immune diseases, such as RA, are characterized by a loss of 
tolerance to the body’s own constituents which results in a destructive process 
directed to a specific organ site. Since DC are believed to be key regulators in 
directing the fine balance between tolerance and immunity, a major goal in the 
treatment of autoimmune diseases would be to restrain autoimmunity-inducing 
antigen-presentation of self by DC and to generate tolerogenic DC capable of 
restoring homeostasis42.
 Activated macrophages and their inflammatory products play an important 
role in innate immunity and in the pathogenesis of autoimmune and inflammatory 
diseases. M-CSF is ubiquitously expressed during steady state conditions and is 
found in high levels in serum. M-CSF is thought to regulate the development and 
maintenance of tissue macrophage subpopulations that have important trophic 
and scavenger roles in tissue morphogenesis and function43. Macrophages 
resident at mucosal surfaces and the peritoneum have been demonstrated to 
display clear functional characteristics of mf-2. Mf-2 express the scavenger 
receptors CD163 and stabilin 1 and are highly phagocytic44. In addition to this it 
has been suggested that mf-2 might have a role in the suppression of tissue 
inflammation due to their preferential secretion of IL-10 and their ability to induce 
regulatory T cells38,45. GM-CSF has been depicted as a crucial mediator in both 
Th1 and Th2 mediated diseases46,47. Whereas under steady-state conditions 
GM-CSF is barely present, locally at sites of inflammation, such as the arthritic 
joint, GM-CSF is clearly detectable48. GM-CSF is produced by a wide array of 
19
G
en
er
al
 in
tr
od
uc
tio
n
cells (Th1/Th17 cells, monocytes, fibroblasts, endothelial cells) upon activation 
with various inflammatory stimuli such as the cytokines IL-1b and TNFα (49-51). In 
its turn GM-CSF primes cells from the myeloid lineage for the release of pro-in-
flammatory cytokines thereby creating a self-perpetuating pro-inflammatory loop 
(52). Neutralization of GM-CSF inhibited lipopolysaccharide (LPS) induced lung-
inflammation, with drastically lowered numbers of eosinophils and monocytes at 
the site of inflammation, and repressed the occurrence of inflammation and 
destruction in arthritis models (53-55). Underscoring the pro-inflammatory role of 
GM-CSF, Rheumatoid Arthritis disease severity flares during GM-CSF treatment 
of neutropenia (53,54,56,57). 
 
Dendritic Cell induced T cell differentiation
With all their available tools, DCs are designed to control the T cell pool consisting 
of billions of different lymphocytes, which if left uncontrolled, will lead to severe 
disease conditions (reviewed in58,59). Therefore, DCs are often referred to as the 
‘generals’ of the immune system controlling several immunological check- points 
both centrally as well as peripherally. Under steady-state conditions or after the 
resolution of infections T lymphocytes subjected to so-called ‘tolerogenic DC’ are 
deleted or made anergic. In situations which require an immune response helper 
T cells acquire the capacity to produce specific cytokines under direct supervision 
of DC. The adaptive immune response evoked is specifically aimed at the 
pathogen sensed by the DCs. To battle intracellular pathogens Th1 responses, 
characterized by IFNγ production, are mainly invoked while resistance to helminths 
is dependent on Th2 responses (IL-4, IL-5, IL-13) while Th17 (IL-17, IL-22) are 
important to fight extra-cellular pathogens. To accurately restrain a threat a 
balanced appearance of Th1, Th2 and Th17 cells at the compromised site is thus 
of paramount importance. However, next to their profitable role in the immunity 
against pathogens, Th1 as well as Th17 cells have been described as mediators 
of autoimmune pathology. It was recently suggested that the conditions during 
the initial exposure to antigens primes antigen-presenting cells thereby 
determining whether the resulting effector phase is either mainly a Th1 or a Th17 
response, placing DCs in the centre of (auto)immunity60,61.        
 How DCs are capable of inducing and controlling such a wide range of 
distinct T cells is still subject of research. The cytokines produced by DCs upon 
the activation with specific ligands has been shown to influence the CD4+ T cell 
differentiation. For example, a high production of IL-12p70 strongly favors the 
development of Th1 while the absence of IL-12p70 production appears to favor 
1
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Th2 responses. In addition to Th1 and Th2 cells DCs have also been implicated in 
the promotion of Th17 cells, although the bacterial components and the type of 
pattern recognition receptors involved are not evidently recognized62-64. Recently 
the activation of the intracellular bacterial sensor nucleotide oligomerization 
domain 2 (NOD2) was found to be implicated in the differentiation of Th17 cells by 
the enhanced production of TLR induced IL-1 and IL-2365. In addition, whereas 
type 1 interferon signalling was found to be pivotal for the induction of Th1 
responses it constrains Th17 development66,67. The cell surface expression of 
costimulatory molecules also has specific effects on the differentiation of CD4+ T 
cells. The absence of CD28 activation by CD80/CD86 is thought to induce 
regulatory T cells while the expression of Jagged-1 on DCs favors the development 
of Th268. The variety in immune deviation perfectly illustrates the necessity of the 
DC driven immune response for survival of the host. However, a failure to control 
or counter-act these pathways would lead to the opposite. Uncontrolled Th1 or 
Th17 responses lead to exaggerated tissue damage and possibly breakdown of 
tolerance, initiating autoimmunity or the creation of an inflammatory vicious circle 
leading to chronic (auto)inflammation. An exaggerated Th2 response might lead 
to hypersensitivity, asthma and fibrosis. Altogether, DC are crucial in maintaining 
immune homeostasis, upholding tolerance at the one hand and eliminating 
infections at the other. 
Dendritic cells and macrophages in experimental arthritis
The first direct evidence for the involvement of DC in experimental arthritis 
originated probably from the experiments performed by Leung et al69. Here, the 
transfer of collagen-pulsed DC induced arthritis that was both DC as well antigen 
specific since the transfer of T cells and/or non-pulsed DC had no effect. Only 
very recently, an adoptive transfer model in adjuvant induced arthritis showed 
that the influx of CD45+MHCII+ (DC like cells) was already apparent at day 3 far 
before the influx of PMNs that usually occurs at day 12-1470. Interestingly, by day 
14, the CD45+MHC-II+ cells constituted approximately half of all CD45+ cells in 
the synovial compartment suggesting the implication of these cells as early as 
the initiation of the inflammatory circle.
 Another well-defined mouse model for RA is collagen-induced arthritis (CIA). 
CIA is a multifaceted, immunologically mediated disease involving T cells, B cells 
and populations of inflammatory cells that infiltrate the joint tissue and induce 
pathology71. CIA is induced through immunization with bovine type II collagen 
(CII) emulsified in CFA. DC will present the CII to T cells leading to T helper cell 
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(Th) activation. Type II collagen (CII)-specific Th cells are necessary to help the B 
cells to produce anti-CII specific antibodies. The presence of CII-specific 
antibodies is crucial for the disease induction, as B cell-deficient mice are not 
able to develop arthritis72 and as transfer of CII-specific antibodies is already 
sufficient to induce arthritis73,74. The main CII-specific antibodies that are 
produced are of the IgG2a isotype, which are produced with the help of Th cells. 
Recently it was unequivocally demonstrated that myeloid DCs are the APCs 
crucial for the breaching of tolerance in another experimental mouse model. The 
formation of autoantibodies was prevented when DCs were removed indicating 
their pivotal role in the induction of autoreactive T and B cells. In addition to this 
treating mice with modulated “tolerogenic” DCs reduces arthritis severity in the 
CIA model via various pathways. TNFα and IL-10 modulated DCs were 
demonstrated to skew the immune response towards a Th2-like phenotype 
thereby probably inhibiting the deleterious Th1 and Th17 responses. Dexametha-
son-treated DCs inhibit the pathogenic Th1 responses by the induction of IL-
10-producing T cells. Furthermore DCs genetically engineered to express IL-4 are 
able to inhibit and suppress established CIA75-78, presumably by promoting the 
Th2-axis. Also unmodulated immature DC exhibit tolerogenic properties and 
repetitive injections of immature DC suppresses CIA79-81. This suppression was 
mediated by expansion of regulatory T cells with high immunosuppressive 
potential82,83. Altogether, these data clearly indicate that DC are involved in the 
onset and perpetuation of the inflammatory circle of synovitis and suggest that 
DC targeting is a challenging approach to treat arthritis.
Dendritic cells and macrophages in Rheumatoid Arthritis
The first evidence that highlighted the potential role of DCs in RA came from the 
observation that DCs are able to infiltrate the synovial tissue and fluid, potentially 
contributing to disease initiation and/or perpetuation by mediating T cell activation84-
86. Next to this, histopathological evidence from combined analysis of RA synovial 
sections and RA experimental models indicated that macrophages and DCs are 
abundantly present in RA synovial tissue and that DCs drive the formation of 
ectopic lymphoid organs often observed in RA synovium87. In the synovium, DCs 
are located in the perivascular regions and both immature and mature DCs are 
present in the synovial tissue. Whether myeloid DCs mature locally or are attracted 
both as immature and mature cell types remains a matter of debate although 
local maturation is likely, based upon the markers found in the synovial tissue 
compared with that seen in draining lymph nodes88,89.  The number of circulating 
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myeloid DCs in peripheral blood is lower in RA patients suggesting that they are 
selectively homing to the inflamed joint90. However, the major source of tissue 
DCs are monocytes which infiltrate the site of inflammation while differentiating 
into distinct DC and macrophage phenotypes. Monocytes are found increased in 
the peripheral blood of RA patients, possibly in an attempt to keep up the numbers 
in the blood while a large proportion readily infiltrates the joints. Infiltrating CD68 
positive macrophages are found in large numbers in inflamed synovium of RA 
patients and the change in CD68 positive macrophages upon treatment correlates 
strongly with the change in disease activity score (DAS)91.
 Highlighting the importance of APCs in the disease process it is clear that 
APCs and their cytokines are effective therapeutic targets in the treatment of RA. 
Therapies often used now are biologicals directed against effector molecules like 
TNFα (adalimumab, etanercept, and infliximab), IL-6 (tocilizumab) or IL-1 (anakinra), 
cytokines readily produced by APCs upon activation. Another effective therapy 
directed against APCs, highlighting their crucial role in RA, is CTLA4-Ig (Abatacept), 
which binds to CD80/CD86 on the APC and prevents T cell activation. As Steinman 
and Banchereau recently stated, it appears that  “DCs are an early player in disease 
development and an unavoidable target in the design of treatments”92. 
Dendritic cells and macrophages in Psoriatic Arthritis
In psoriatic disease the role played by DCs and macrophages is apparent from 
studies ranging from mouse models to human in vitro studies and drug trials. 
While in normal human skin only DCs are present in both the epidermis 
(Langerhans cells) and the dermis (dermal DCs) in psoriatic skin macrophages 
are also found in considerable numbers93. In two different mouse psoriasis 
models the crucial role played by monocyte-derived cells was demonstrated by 
selective depletion. One study demonstrated that in mice with an epidermis-spe-
cific deletion of inhibitor of NF-kappaB (IkappaB) kinase 2 (IKK2), epidermal 
keratinocytes can initiate a hyperproliferative, inflammatory, psoriasis-like skin 
disease whose development requires skin DCs/macrophages but not granulocytes 
or T cells94. The CD18 hypomorphic psoriasis mouse model is characterized by 
the reduced expression of the common chain of beta2 integrins to only 2-16% of 
wild type levels. Activated APCs are significantly increased in lesional skin as well 
as in inflamed skin draining lymph nodes of affected CD18 hypomorphic mice 
and were identified as being an important source of TNFα. Both depletion of 
APCs and neutralization of TNF-α resulted in a significant alleviation of psoriasiform 
skin inflammation. Demonstrating that maintenance of psoriasiform skin inflammation 
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critically depends on the efficient recruitment and activation of DCs/macrophages95.
 The inflamed synovium from spondyloarthropathy patients, including PsA 
patients, is characterized by a higher vascularity and infiltration with “resident” 
CD163+ macrophages and polymorphonuclear leukocytes and by lower levels of 
lining-layer hyperplasia, lymphoid aggregates, infiltrating “proinflammatory” 
macrophages, CD1a+ cells and the number of CD83+ dendritic cells than RA 
synovitis. Global disease activity in spondyloarthropathy patients correlated 
significantly with lining-layer hyperplasia as well as with inflammatory infiltration 
with macrophages, especially the CD163+ subset, and with polymorphonuclear 
leukocytes96,97. 
 In lesional psoriatic skin immunoreactivity for IL-12 and IL-23 is significantly 
enhanced as compared to non-lesional and normal skin. Since recent trials using 
an antibody against IL-12p40, the common component of IL-12 and IL-23, have 
shown great efficacy in treating psoriatic disease and both IL-12 and IL-23 
 immunoreactivity were readily detected in CD68+ and some CD163+ cells and 
CD1a+ dendritic cells98 the crucial role played by myeloid APCs in human psoriatic 
disease is apparent. 
Fc gamma receptors
FcγR are expressed on the cell surface of various hematopoietic cell types. They 
recognize IgG and IgG containing IC and as a result constitute the link between 
humoral and cell-mediated immunity9. In man, the FcγR system comprises of two 
opposing families, the activating FcγRs I, IIa and III and the inhibitory FcγRIIb, the 
balance of which determines the outcome of IC mediated inflammation. Both 
activating as well inhibitory FcγRs are expressed on immature DC and full 
maturation of DC results in a down regulation of FcγR expression, highlighting the 
deprived capacity of antigen uptake of mature DC. Studies have demonstrated 
that the FcγR balance determines biological responses of macrophages and 
dendritic cells (DCs) upon IC mediated stimulation further identifying the pivotal 
role of FcγR in the immune response14-17. In fact, the balance between activating 
and inhibitory FcγR has been shown to be crucial in the susceptibility to and 
phenotype of various inflammatory conditions. The activating FcγR mediates its 
effect through an immunoreceptor tyrosine-based activation motif (ITAM). In contrast, 
the inhibitory FcγRIIb signals through an immunoreceptor tyrosine-based inhibitory 
motif (ITIM). It is the phosphorylation of the 5’-phosphoinositol phosphatase SHIP by 
ITIM which inhibits the ITAM regulated signaling pathways so that the balance 
between these FcγR systems determines cell fate.
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Fc gamma receptors in experimental arthritis
Thus far, accumulating evidence that illustrates the vital role of a balanced FcγR 
system in arthritis originates mainly from analyses of mouse models. For example, 
deletion of FcγRIIb can result in an aggravation of experimental arthritis, whereas 
deletion of activating FcγR subtypes has the opposite effect. Several studies have 
shown that the presence of activating FcγRs was associated with increased 
chondrocyte death and cartilage erosion and that FcγRIII knockout mice are 
protected from IC-induced arthritis. Inhibition of spleen tyrosine kinase (Syk), a 
key mediator of activating FcγRs and B cell receptor signaling, also shows 
suppression of inflammation and bone erosion, highlighting a possible role of 
activating FcγRs in arthritis models. On the other hand, deletion of the inhibitory 
FcγRII (mice lack FcγRIIa) induced arthritis even in non-susceptible mice. FcγRIIb 
not only inhibits activating FcγRs, but is also important for effective clearance of 
ICs. An important role for the inhibitory FcγRIIb in arthritis was further substantiated 
by the finding that arthritis can be induced with a single injection of IgG 
anti-collagen type II antibody in mice lacking this receptor99,100. Furthermore, 
FcγRIIa transgenic mice are hyper-responsive to pathogenic antibodies and 
blocking of this receptor in these mice inhibited development and stopped 
progression of collagen-induced arthritis.These data clearly show the importance 
of activating FcγRs on APCs in the initiation and progression of arthritis, which is 
in line with the in vitro data showing involvement of activating FcγRs in pro-inflam-
matory cytokine production and inhibition of this by FcγRIIb. 
Fc gamma receptors in Rheumatoid Arthritis
A role for FcγRs in RA synovial inflammation is less clear, but accumulating 
evidence suggests that these receptors are of considerable importance. Until 
recently a major problem in the study of FcγR on human myeloid cells was the 
inability to distinguish FcγRIIa from FcγRIIb on the cellular surface. In the synovial 
tissue macrophages and DC express significantly higher levels of FcγRII and III 
when compared with those present in synovium from healthy controls. Similarly, it 
was found that monocyte-derived macrophages and DCs obtained from patients 
with RA express FcγRII at significantly higher levels than those from their healthy 
counterparts101,102. Coherently, APCs from RA patients have been shown to 
produce more TNFα upon IC triggering than healthy control APCs. In addition, 
ICs derived from RA synovial fluid have been shown to trigger the production of 
TNFα by monocytes via FcγRIIa.
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 Variants of the activating Fc gamma receptors FcγRIIIa and FcγRIIIb have 
been associated with RA susceptibility in Europeans, but not in Asians. The 
FcγRIIIa variant is less effective in IC binding, implicating impaired clearance of 
ICs might play a role in the pathogenesis of RA. The functional polymorphism of 
the FcγRIIb (I232T) has been identified as the strongest prognostic factor for 
radiological joint damage in RA and was found to modulate DC function, further 
substantiating the role of FcγRs in RA103.
 Since Syk is involved in FcγR and B cell receptor signaling inhibition of this 
tyrosine kinase could reduce IC mediated inflammation and B cell responses, 
suggesting potential in RA treatment. In fact a randomized clinical trial has already 
demonstrated superior clinical efficacy of an oral Syk kinase inhibitor, R788 
compared to placebo104. 
Toll-like receptors 
Toll-like receptors (TLR) are pattern-recognition receptors capable of potently 
initiating DC activation and maturation. TLRs recognize both endogenous 
molecules, released upon cell activation/damage, and a wide range of conserved 
constituents from pathogens. At present, 10 TLR subtypes have been identified in 
humans, each having its specific ligands, cellular localization and expression 
profiles. TLR2 (as heterodimer in combination with TLR1 or TLR6) and TLR4 are 
extracellular receptors that are designed to recognize lipid-based structures both 
from gram-positive and gram-negative bacteria including lipopeptides and lipo-
polysaccharides (LPS)5. For TLR5, also expressed extracellular, the identified 
ligand is flagellin, a component of flagellated bacteria. TLR3, TLR7, TLR8 and 
TLR9 are generally addressed as intracellular receptors located in endosomal 
compartments and are involved in the recognition of nucleic acids derived from 
viruses, bacteria and the host105. For TLR10, which is believed to originate from 
the TLR1/TLR6 precursor no ligand has been described thus far. Downstream 
TLR signaling involves a family of five adaptor (MyD88, Mal, TRIF, TRAM and 
SARM) proteins that couple protein kinases ultimately leading to activation of 
transcription factors among which nuclear factor kB (NF-kB), the mitogen 
activated kinase-like proteins (e.g. p38, ERK1/2, JNK) and members of the 
interferon regulatory factor (IRF) family are the most thoroughly investigated 
nowadays (reviewed in5,105) In contrast with that what was expected in the first 
years after its discovery, the TLR system is highly specific in that distinct cellular 
responses are observed depending upon the activated TLR. Much of this 
specificity is likely to come forth from the use of various co-molecules and 
down-stream adaptor pathways by the various TLR.
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The ligation of TLRs results in a massive release of cytokines, creating an 
environment crucial for the appropriate adaptive immune response. However, 
TLRs are also highly suspected as conductors of autoimmunity. Most pathogens 
express several TLR ligands and numerous host-derived TLR ligands are 
generated in inflamed or degenerated tissue6,106,107. The activation of multiple 
TLRs leads to the abundant release of pro-inflammatory cytokines creating a 
volatile situation. In genetically predisposed individuals this might eventually lead 
to a breach in tolerance culminating in autoimmune disease108. In this context, the 
study of the control of TLR responses is of high relevance in diseases such as 
rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. 
However, it is essential to notice that an impaired release of pro-inflammatory 
mediators by innate immune cells might culminate in chronic inflammation due to 
the aberrant removal of pathogens or other inciting factors which might underlie 
diseases such as Crohn’s disease26,109.
 Activation of TLRs such as TLR4 and TLR7/8, and especially their simultaneous 
stimulation, results in DCs releasing copious amounts of IL-12p70, which favours 
the proliferation of Th1 cells while activation of TLR2 does not result in the release 
of IL-12p70 and is generally thought to induce a Th2 response110. While the 
function of TLR4 and TLR7/8 thus seems unambiguously aimed at the induction 
of a Th1 response, the precise function of TLR2 in immunity is less clear. To date, 
accumulating evidence points towards an, additional, regulatory role of TLR2 in 
inflammation111,112. Recently it was pointed out that there is interaction between 
TLR2 and other pattern recognition receptors demonstrating that TLR2 
co-activation inhibits the release of IL-12p70 induced by R848 in synergistic 
combination with LPS, b-glucan or zymosan113. However, Re and Strominger 
demonstrated already in 2004 that TLR2 activation induces the rapid production 
of IL-10 inhibiting IL-12p35 and IP-10 production induced by TLR4114. While a 
panoply of negative regulators of TLR responses are known, such as IL-10 and 
many endogenous signaling inhibitors (eg Tumor Necrosis Factor Alpha-Induced 
Protein 3 (TNFAIP3 (A20)), Single Immunoglobulin and Toll-interleukin 1 Receptor 
(TIR) Domain (SIGIRR), Toll Interacting Protein (TOLLIP), Suppressor Of Cytokine 
Signaling 1 and 3 (SOCS1, SOCS3)), the mechanisms that regulate these factors 
in macrophages and DCs infiltrating an inflammatory lesion are largely unknown115. 
Most studies have focused on their induction by TLRs themselves and have 
concluded that their generation mostly functions to restrict the production of pro-
inflammatory cytokines at later time points.   
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Toll-Like Receptors in experimental arthritis
Experimental arthritis models have contributed extensively to our understanding 
of the role of TLRs in arthritis. Classical animal models such as streptococcal cell 
wall (SCW) arthritis and autoimmune arthritis in IL-1 receptor antagonist-knockout 
(IL-1ra-/-) mice are dependent on activation of the innate immune system via TLRs. 
The acute phase of SCW induced arthritis is dependent on TLR2, while the TLR 
dependency shifts towards TLR4 in the chronic phase. This occurs simultaneously 
with the transition from a macrophage driven arthritis to a T cell dependent 
process116. Arthritis development in IL-1ra-/- mice is also regulated by TLRs, TLR2 
knockout mice develop a more severe arthritis while TLR4 knockouts are protected 
from severe arthritis. Selective blocking of TLR4 was also able to diminish the 
incidence and severity of experimental arthritis117,118. A role for TLRs is further 
supported by studies that show a self-limited form of arthritis in mice after synovial 
injection of TLR ligands, such as CpG DNA and dsRNA119,120.
Toll-Like Receptors in Rheumatoid Arthritis
The identification of TLRs as receptors for conserved pathogen associated 
molecular patterns as well as endogenous ligands started a whole new field of 
research. Data derived from those studies forms the basis of our current way of 
thinking regarding the role TLRs play in RA. First, various research groups have 
demonstrated that endogenous TLR ligands are abundant in RA patients, both in 
the circulation as well as in the synovial compartment. Ligands for TLR4 (heat 
shock protein B8) and TLR3 (host dsRNA) are, for example, highly expressed and 
potentially released upon an initiating event that might be as trivial as a small 
trauma or viral infection6,121. Second, the expression of various TLR subtypes is 
clearly increased in the synovial compartment of RA patients compared to their 
healthy counterparts and TLR ligands induce an augmented inflammatory 
response by macrophages and DCs from RA patients. DC from RA patients 
demonstrated a clearly potentiated response to purified ligands for TLR2 and 
TLR4 whereas TLR3 and TLR7 responses were comparable between patients and 
controls122,123. In addition, RA synovial fibroblasts produce increased amounts of 
chemokines upon stimulation with TLR2 ligands. TLR involvement is further 
suggested by a functional variant of the TLR4 gene that reduces the response to 
LPS and thereby decreases the susceptibility to RA, although not significant in 
another study124,125.
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 The intracellular localization of the nucleic acid sensing TLRs normally 
prevents aberrant activation of APCs by endogenous nucleic acids. In many 
autoimmune diseases however antibodies have been found aimed at nucleic 
acids or proteins bound to these, enabling endocytosis of these ICs resulting in 
TLR activation by normally harmless components of self. Recently, TLR8 has also 
been shown to be important for TNFα production in RA synovial tissue. Inhibition 
of TLR8 was able to inhibit spontaneous TNFα production by RA synovial 
membrane cultures126. Stimulation of TLR8 by an unknown ssRNA containing 
component present in the RA synovium appears to lead to pro-inflammatory 
cytokine production, including type I IFNs, and might support APC maturation 
and subsequent presentation of (self) peptides to (autoreactive) T cells, a crucial 
event in the pathogenesis of autoimmunity. It might be possible that the 
endocytosis pathway by which the ssRNA is delivered to the intracellular TLR8 is 
mediated via antibodies and FcγRs. A major candidate present in large amounts 
in the RA synovial cavity to which such antibodies might be aimed is hnRNP-A212. 
HnRNP-A2 forms a complex with heterogeneous nuclear RNA and in that form it 
might be a stimulus for TLR8 when delivered to the intracellular endosomes upon 
endocytosis via FcγRs. Immune complexes in joints might thus provide a direct 
link to cytokine dependent inflammation in RA, via APCs.
 Prove that TLRs play an important role in the pathogenesis of RA has to come 
from clinical trials aimed at dampening or modifying TLR responses. However, 
unknowingly, drugs directed against TLRs are already in use for decades. Hydroxy-
chloroquine, which prevents intracellular TLR activation, in combination with 
methotrexate shows increased effectiveness compared to methotrexate alone. 
The effectiveness of direct targeting of TLRs in RA is already somewhat supported 
by a phase II clinical trial with chaperonin 10, which inhibits TLR2 and TLR4 
signaling. No placebo was used in this trial, so confirmation of its potential is 
necessary, but it suggests quick and sustained improvement of symptoms during 
the 12 weeks follow up127. Long term controlled studies have to show if chaperonin 
10 could be used in the treatment of RA or not.
Toll-Like Receptors in Psoriatic Arthritis
The role played by TLRs in psoriatic disease is still less extensively studied than in 
RA. However, recent findings implicate that innate immunity might play a pivotal role 
in psoriatic disease. From genetic studies associations between inhibitors of Toll-like 
receptor (TLR) and nucleotide-binding oligomerization domain containing 2 (NOD2) 
signaling (TNFAIP3 (A20), TNIP1) and psoriasis are apparent20. In addition, it was 
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shown that mutations and polymorphisms in keratinocyte-expressed genes involved 
in physical barrier function or innate immunity, are risk factors for developing 
psoriasis18,19. Immunohistochemistry demonstrated the (intracellular) expression of 
TLR2, 3 and 4 in keratinocytes and psoriatic skin showed a strong over expression of 
TLR2 in the epidermis compared with normal skin. Furthermore dermal DCs were 
demonstrated to express TLR2 and TLR4 but no TLR9 while epidermal DC 
(Langerhans cells) expressed TLR4 but no TLR2 or TLR9. Heat shock proteins 27, 60 
and 70, endogenous ligands for TLRs, were present in psoriatic skin but not in healthy 
skin93. Activation via TLRs of infiltrating plasmacytoid DCs has been proposed to be 
an important pathogenic event in psoriasis/psoriatic disease. An aggravation and 
spreading of a psoriatic plaque was described upon the topical treatment with the 
TLR7 agonist imiquimod. This exacerbation was accompanied by a massive type I 
interferon production by infiltrating plasmacytoid DCs (pDCs)128. Especially 
pre-psoriatic skin was demonstrated to contain high numbers of pDCs and its 
chemotactic factor chemerin. Skin from chronic plaques showed low chemerin 
expression and few pDC in the dermis129. The role played by the activation of 
intracellular TLRs is also apparent from the use of chloroquine, hydroxychloroquine 
and quinacrine in the treatment of psoriatic disease for over 50 years130. These drugs, 
which were originally used as antimalarials, have an inhibitory effect on the signaling 
of the endocytic TLRs 3, 7, 8 and 9. A question that remained was how the shielded 
endocytic TLRs might be activated in psoriatic disease. Recently it was demonstrated 
that the antimicrobial peptide LL37 (cathelicidin), which is highly expressed in 
psoriatic skin, converts inert self-DNA and self-RNA released by dying cells into a 
potent trigger of type 1 interferon production by pDCs by binding the DNA/RNA to 
form complexes that are delivered to endocytic compartments in pDCs and myeloid 
DCs. In pDC, self-DNA-LL37 and self-RNA-LL37 complexes activate TLR9 and TLR7, 
respectively, and trigger the secretion of IFNα without inducing maturation or the 
production of IL-6 and TNFα. In addition, in contrast to self-DNA-LL37 complexes, 
self-RNA-LL37 complexes activate myeloid DCs via TLR8 which leads to the 
maturation of the DCs and the production of TNFα and IL-6. Self-RNA-LL37 complexes 
were demonstrated in psoriatic skin lesions and were associated with mature myeloid 
DCs in vivo131,132. 
Outline of this thesis
TLRs play an important role in the aetiology of many human diseases. They have 
been implicated in the resolution or induction and aggravation of infections, 
cancer and autoimmune and (auto)inflammatory diseases. Monocyte-derived 
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cells such as DCs and macrophages play a central role in the immune system. A 
better understanding of how TLR responses are regulated in these cells and what 
the consequences might be for the following adaptive immune response might 
open new opportunities for the treatment of some of the most debilitating and 
life-threatening diseases around. This thesis in general concerns the regulation of 
pro-inflammatory TLR responses in DCs and macrophages and specifically the 
role DCs and their TLRs might play in Psoriatic and Rheumatoid Arthritis. 
 Chapter 2 is a good example of the latter. In this chapter we aimed to delineate 
whether RA patients who were, in time, able to successfully discontinue their 
anti-rheumatic treatment had phenotypical and functionally different DCs 
compared to healthy controls or other RA patients. This chapter has a specific 
emphasis on the regulation of TLR4 responses by FcγRs. Chapter three further 
elucidates the role played by inhibitory and activating FcγRs on proinflammatory 
type 1 and anti-inflammatory type 2 macrophages and their regulation of Toll-like 
receptor responses. Much research has been focused on how immune reactions 
are ignited. How an immune reaction is terminated at a site of inflammation with a 
plethora of pro-inflammatory cytokines and endogenous danger signals present 
is much less extensively studied. In chapter 4 we describe a novel mechanism 
how the phenotype of proinflammatory type 1 macrophages and DCs might be 
forced into a more anti-inflammatory phenotype during the development of an 
inflammatory lesion, with grave impact on TLR responses. Proinflammatory 
responses induced by activation of TLR4 have been shown to be crucial in mouse 
models of arthritis while TLR2 appeared protective. During inflammation the 
presence of various endogenous ligands able to activate different TLRs appears 
inevitable. In chapter 5 and 6 we gained more insight in how the (simultaneous) 
activation of different TLRs influences the behaviour of DCs and other immune 
cells and we shed some light on the intracellular pathways involved. In addition, 
chapter 6 shines a new light on the decreased arthritis severity in TLR2-/- mice. 
Cytokine activated T cells and TLR ligands appear to play important roles in the 
imbalanced cytokine network in the arthritic joint. Chapter 7 describes the synergy 
of these two pathways in inducing cytokine production from type 1 macrophages 
and the effect Abatacept (CTLA4-Ig) has on these. Infectious agents have been 
implicated in the etiology of PsA and RA for decades. Chapter 8 focuses on the 
role the (dysfunctional) activation of PRRs/TLRs on monocyte-derived DCs by 
(myco)bacteria might play in PsA. Following chapter 8, chapter 8 focuses on why 
the immune response in PsA might derail with special emphasis on the “anti- 
inflammatory” type 2 macrophages. Chapter 10 elaborates on the implications 
the novel findings described in this thesis might have in the field of rheumatic 
diseases.  
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Abstract 
Rheumatoid arthritis (RA) is a common autoimmune disease leading to profound 
disability and premature death. Although a role for Fc gamma receptors (FcγRs) 
and Toll-like receptors (TLR) is accepted their precise involvement remains to be 
elucidated. FcγRIIb is an inhibitory Fc receptor important in the maintenance of 
tolerance. We hypothesized that the inhibitory FcγRIIb inhibits TLR responses on 
monocyte-derived DCs and serves as a counter-regulatory mechanism to 
dampen inflammation and we surmised that this mechanism might be defective 
in RA. The expression of the inhibitory FcγRIIb was found to be significantly higher 
on DCs from RA patients having low RA disease activity in the absence of 
treatment with anti-rheumatic drugs. Notably, the expression of activating FcγRs 
was similarly distributed among all RA patients and healthy controls. Intriguingly, 
only DCs with a high expression of FcγRIIb were able to inhibit TLR4 mediated 
secretion of pro-inflammatory cytokines when stimulated with immune complexes. 
In addition, when these DCs were co-incubated with the combination of a TLR4 
agonist and immune complexes a markedly inhibited T cell proliferation was 
apparent, regulatory T cell development was promoted and T cells were primed 
to produce high levels of IL-13 compared to stimulation of the DCs with the TLR4 
agonist alone. Blocking FcγRIIb with specific antibodies fully abrogated these 
effects demonstrating the full dependence on the inhibitory FcγRIIb in the induction 
of these phenomena. This TLR4-FcγRIIb interaction was shown to dependent 
upon the PI3K and Akt pathway. 
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Introduction
Rheumatoid arthritis (RA) is a characteristic autoimmune disease typified by 
polyclonal B cell stimulation and production of autoantibodies targeting the 
synovial membrane, cartilage and underlying bone. RA is a frequent disorder that 
affects 1% of the population worldwide thereby representing the most common 
inflammatory rheumatic condition. Despite a longstanding effort to understand 
and control the deranged immune process, the crucial events by which T-cell and 
B-cell tolerance is breached are poorly defined. To date still a substantial part of 
the patients suffer from severe disability and a decreased life expectancy1. 
Various cell types are recruited into the inflamed synovium where they are 
activated culminating in the secretion of a myriad of inflammatory mediators 
(reviewed in2). Numerous pathways could lead to the activation of immune cells in 
the synovium and accumulating evidence points towards the role of immune 
complexes (IC) binding to activating Fc gamma receptors (FcγR) and Toll-like 
receptor (TLR) ligands3-8. FcγR are expressed on the cell surface of various 
hematopoietic cell types. They recognize IgG and IgG containing IC and as a result 
constitute the link between humoral and cell-mediated immunity9. In man, the 
FcγR system comprises of two opposing families, the activating FcγRs I, IIa and 
III and the inhibitory FcγRIIb, the balance of which determines the outcome of IC 
mediated inflammation. Thus far, accumulating evidence that illustrates the vital 
role of a balanced FcγR system in arthritis originates mainly from analyses of 
mouse models. For example, deletion of FcγRIIb can result in an aggravation of 
experimental arthritis10,11 or lead to a fulminate lupus-like disease12, whereas 
deletion of activating FcγR subtypes has the opposite effect13. Subsequent studies 
have demonstrated that the FcγR balance determines biological responses of 
macrophages and dendritic cells (DCs) upon IC mediated stimulation further 
identifying the pivotal role of FcγR in the immune response14-17. 
A role of micro-organisms in RA pathogenesis has been advocated for a long 
time. The identification of TLRs as receptors for conserved pathogen associated 
molecular patterns as well as endogenous ligands sparked a revolution of 
research that constitutes the basis of our current way of thinking regarding the 
role for TLR in arthritis. First, various research groups have demonstrated that 
endogenous TLR ligands are abundant in RA patients, both in the circulation as 
well as in the synovial compartment18-20. Second, the expression of various TLR 
subtypes was clearly increased in the synovial compartment of RA patients3,4,21 
compared to their healthy counterparts and TLR ligands induce an augmented 
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inflammatory response by macrophages and DCs from RA patients3,22.  Finally, 
studies in mice revealed that the triggering of TLR aggravates arthritis whereas 
inhibition of the TLR4 pathways either by genetic knockdown23 or by addition of 
TLR antagonists drastically reduced the arthritis incidence and severity24. 
The ability of the immune system to distinguish self from non-self is central to its 
diametrically opposed functions; to protect against invading pathogens and, at 
the same time, maintain non-responsiveness to self.  Given the ubiquitous nature 
of endogenous TLR ligands during life highly regulated counter-regulatory 
responses must be in place to secure an adequate balance between immunity 
and tolerance25,26,27. Led by recent work from our group and others, we postulated 
that the inhibitory-activation FcγR paradigm might not be the full story in that 
FcγRIIb might also control TLR4 mediated cell activation17,28. This view on 
TLR4-FcγR cross talk can be carried over to DCs since these cells have been 
shown to be under tight control by both receptor systems and play a decisive role 
in the regulation of the balance between immunity and tolerance15,16,25,29. The 
pathways that underlie cross talk between TLR4 and FcγR are currently unknown. 
It has been reported that, at least some of the mediators implicated in FcγR 
mediated signaling, are involved in the TLR4 signaling cascade. For example, 
stimulation of TLR4 results in the recruitment of SHIP to lipid rafts where it is 
tyrosine phosphorylated and SHIP appears to be a positive regulator of TLR4 
activation by enhancing MAPK phosphorylation and decreasing Akt phosphory-
lation30. In turn, PI3K is known to reverse the effects of SHIP in both the TLR4 and 
FcγR pathways and in both pathways serine/threonine kinase Akt was shown to 
play a central role.
Here we demonstrate, for the first time, that the inhibitory FcγRIIb directly inhibits 
TLR4 mediated cell activation and functions as a counter regulatory mechanism 
designed to dampen TLR mediated responses. Strikingly, only DCs from RA 
patients who were able to discontinue their use of disease modifying anti-rheumatic 
drugs (DMARDs) without the occurrence of subsequent disease flares expressed 
remarkable high levels of FcγRIIb whereas the expression of activating FcγR was 
unaltered. Exclusively, DCs from those patients who were able to inhibit TLR4 
mediated DC activation and subsequent T cell proliferation but also restored the 
ability to induce T regulatory capacity by DCs. Collectively, here we show a unique 
counter-regulatory pathway for TLR4 mediated immune responses that is aberrant 
in RA underscoring the pivotal role for FcγRIIb in RA and opening novel avenues 
for therapeutic intervention.
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Materials and Methods
Study population
A total of thirty-two RA patients attending the Department of Rheumatology at the 
Radboud University Nijmegen Medical Centre and ten healthy controls were included. 
The patients were selected from our well-documented prospective cohort consisting 
of more than five hundred RA patients. All patients who were not on DMARD therapy 
for more than 2 years were selected, this resulted in a total population of 11 patients. 
By extensive screening outside of this cohort five additional RA patients not on 
DMARD therapy were found in our outpatient clinic. RA patients on DMARD therapy 
were all selected from our prospective cohort. All patients fulfilled the American 
College of Rheumatology criteria for RA at the time of disease diagnosis and gave 
their informed consent31. Patients using biological agents and/or prednisolone were 
excluded from the study. Before every vena puncture, in order to obtain monocytes 
for DCs culture, the disease activity of the RA patients was determined. To quantify 
the disease activity the DAS28 was used. The DAS28 incorporates the number of 
swollen and tender joints out of 28 joints, the erythrocyte sedimentation rate and a 
score on the visual analog scale on well-being. The presence of an erosive disease 
was scored as positive if on the last X-rays from the feet or hands at least one 
erosion was present scored by means of the modified Sharp/Van der Heyde 
method32. The local Medical Ethics Committee approved the study protocol. 
 
Culture of monocyte-derived Dendritic Cells
Peripheral Blood Mononuclear Cells (PBMCs) were isolated from heparinized 
venous blood by using density-gradient centrifugation over Ficoll-Paque 
(Amersham Bioscience). Monocytes were obtained using CD14 microbeads and 
MS columns (Miltenyi Biotec). This isolation method results in the isolation of 
untouched monocytes and circumvents artificial activation by FcγR ligation as 
occurs during the isolation of monocytes by means of adherence with human 
serum as used previously32. DCs were generated by culturing isolated monocytes 
in RPMI-1640 Dutch modification (Invitrogen Life Technologies) supplemented 
with 10% FCS and antibiotic-antimycotic (Invitrogen Life Technologies) in the 
presence of IL-4 (500 U/ml; Schering-Plough) and GM-CSF (800 U/ml; Schering-
Plough) for 6 days in a concentration of 10x106 cells per 10 ml culture medium in 
75-cm2 cell culture flasks (Corning). Fresh culture medium (5 ml) with the same 
supplements was added at day 3 where after the DCs were harvested at day 6. 
DCs were resuspended in fresh culture medium in a concentration of 0.5x106 
DCs/ml and either transferred to 24 well (1 ml) or 96 well (0.1 ml) culture plates 
and stimulated as described.
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Stimulation of peripheral blood lymphocytes 
The peripheral blood lymphocytes that remained after the extraction of the CD14+ 
cells, as described above, were washed with citrated PBS containing 5% FCS and 
resuspended in culture medium in a concentration of 1x106 cells/ ml. 1x105 cells 
were plated per well in a 96 well flat bottom plate in triplo and were stimulated 
overnight with PMA (50 ng/ml, Sigma) and Ionomycin (1 mg/ml, Sigma). The super- 
natants were collected for cytokine measurements.   
Phenotypical analysis of monocyte-derived DCs
Using standardized flow cytometry protocols as described previously the 
phenotypical analysis of monocytes and monocyte-derived DCs was performed33. 
The expression of FcγRs was determined on monocytes and monocyte- derived 
DCs using the antibodies for human FcγRI (CD64, clone 10.1, Dako) and FcγRIII 
(CD16, clone DJ130c, Dako), the FcγRIIb specific Fitc-labeled antibody 2B6 
(Macrogenics Inc) and clone IV.3 which preferentially binds to FcγRIIa (Medarex, 
kindly gifted by Dr. J. Ronnelid)15. Immature DCs were further characterized by 
staining with mAbs against human CD14 (Dakocytomation), CD80 (BD 
Biosciences), CD83 (Beckman Coulter), CD86 (BD Pharmingen), MHCII DR/DP 
(clone Q1514), ILT3 (R&D systems), ILT4 (R&D systems) and DCIR (BD 
Biosciences). As secondary antibody FITC-conjugated goat anti-mouse IgG 
(Zymed Laboratories) was used. DCs matured for 24 hours with LPS in the 
presence or absence of IC were analyzed for the expression of CD86 and MHCII 
as classical markers for DC activation. The level of apoptosis of the stimulated 
DCs was determined by annexin-V staining and with propidium iodide. Cells were 
analyzed with a fluorescence-activated cell sorter (FACSCalibur; BD Biosciences) 
for the proportion of positive cells and the mean fluorescence intensity relative to 
cells stained with the relevant IgG isotypes. 
Dendritic cell stimulation
Day 6 DCs were replated in a concentration of 0.5x106 DCs/ml and either transferred 
to 24 well (1 ml) or 96 well (100 ml) culture plates. DCs were then put in contact with 
medium, with heat-aggregated human immunoglobulins (IC, in all experiments 
used in a concentration of 50 mg/ml), prepared and used as previously described33, 
with immune complexes derived from the serum of healthy controls, RA patients or 
RA synovial fluid (Pegylated-IC, Peg-IC), double-purified LPS or with the 
combination of IC or Peg-IC and double-purified LPS. The Peg-IC precipitates were 
purified and washed in a single-step centrifugation procedure as described in34, 
briefly 1 ml of phosphate-buffered saline (PBS) containing 5% human serum 
albumin (HSA) and 2·5% PEG 6000 (PBS–HSA–PEG) was added to 1·5 ml 
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autoclaved Eppendorf tubes. Plastic cylinders made from 5 ml autoclaved pipette 
tips (by cutting off about 1·5 cm of the tips) were introduced into the Eppendorf 
tubes containing PBS–HSA–PEG. Hyaluronidase (Sigma-Aldrich, Stockholm, 
Sweden) treated synovial fluid or sera precipitated overnight were diluted 1 : 3 in 
RPMI-1640 containing 2·5% PEG 6000 and then placed on top of the PBS–HSA–
PEG in the pipette tips. An interface was formed with the less dense, red RMPI-1640 
solution on top. The tubes were then centrifuged at 2100 g, 4°C for 20 min, whereby 
the precipitates in the upper 2·5% PEG–RPMI solution were centrifuged down to the 
bottom of the Eppendorf tube. The remaining PBS–HSA–PEG solution was 
removed and the precipitated pellet was immediately resolubilized in ice-cold 
sterile PBS to the original serum volume. The precipitates were totally resolved in 
PBS leaving no insoluble aggregates. The dissolved PEG precipitates were then 
placed on ice until used in cell culture experiments.
The used Escherichia coli Lipopolysaccharide (100 ng/ml, Sigma-Aldrich) was 
double-purified at our lab using the phenol-water extraction method to remove 
any remaining protein contamination35. In experiments using intracellular signaling 
molecule inhibitors DCs were pre-treated with these inhibitors for 1h at 37°C 
before adding the stimulants. The following inhibitors were used in the mentioned 
concentrations: Wortmannin (PI3K inhibitor, 0.1 mM), Akt inhibitor IV (0.1 mM), Akt 
inhibitor X (0.5 and 5 mM), SB203580 (p38 inhibitor, 20 mM), Rottlerin (PKCd 
inhibitor, 10 mM), LFM-A13 (Btk inhibitor, 50 mM). All inhibitors were obtained from 
Calbiochem. Supernatants were collected after 24 hours for cytokine measurements, 
except for the experiments in which mentioned otherwise. In some experiments 
DCs were harvested after 24 hours of stimulation with LPS in the presence or 
absence of IC and subjected to FACS analysis for the determination of the level of 
CD86 and MHCII expression. To determine the level of intracellular retention of 
TNFα, DCs were subjected to 5 times repeated freeze (-80°C) -thaw cycles in their 
supernatants before TNFα measurements. To determine the role of the inhibitory 
FcγRIIb on the modulation of TLR4 responses by IC, selective ligation of the 
activating FcγR was performed by blocking FcγRIIb. Immature day 6 DCs were 
washed with PBS and incubated for 30 minutes at 4°C with the monoclonal 
antibody 2B6 (5 mg/ml) to selectively block FcγRIIb, DCs were washed with PBS 
three times, resuspended in culture medium and stimulated with LPS and LPS in 
combination with IC. IC were added to the DCs 5 minutes in advance of LPS. 
Preincubation with the mAb IV.3 (5 mg/ml) allowed for the absence of FcγRIIa 
stimulation upon IC stimulation, while preincubation in the absence of mAb 
allowed for the shared ligation of activating and inhibitory FcγRs. All solutions 
used in the experiments, except the LPS dilution, were checked for endotoxin 
contamination by Limulus Amebocyte Lysate assays. None were positive. 
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Mixed leucocyte reaction
At day 7 matured DCs were harvested from their 24 well plates, washed in PBS 
and resuspended in a concentration of 1x105 DCs/ml in culture medium. 5x103 
DCs were replated in 96 round bottom well plates. CD3+CD25- T cells from 
healthy controls were obtained by negative selection using microbeads against 
CD14 (M5E2), CD16 (3G8), CD19 (4G7), CD33 (P67.6), CD56 (B159), CD25 
(MA251) and CD235 (BD Biosciences, Erembodegem, Belgium) combined with 
sheep anti-mouse IgG coated magnetic beads (Dynal Biotech, Oslo, Norway) 
and MS columns (Miltenyi Biotec) after PBMC were isolated by density gradient 
centrifugation (Lymphoprep, Nycomed Pharma AS, Oslo, Norway) of buffy-coats 
obtained from normal healthy donors. This resulted in a CD3+CD25-CD127+ T cell 
purity of >95%. 5x104 CD3+ T cells were added to the DCs in the 96 round bottom 
well plates. T cell proliferation was monitored at day three during the mixed 
leucocyte reaction (MLR) by tritiated thymidine incorporation. The cells were 
pulsed overnight (day 3-day 4) with tritiated thymidine (0.5 mCi) and thymidine 
incorporation was analyzed by a gas scintillation counter. The tritiated thymidine 
incorporation is expressed as mean count per 5 minutes and SD of at least 
quadruplicate measurements. To determine the differentiation profile of the 
present T cells stimulation assays were performed. To this end, at day six at least 
quadruplicate wells were incubated with PMA (50 ng/ml, Sigma) and Ionomycin (1 
mg/ml, Sigma) for 12 hours before the collection of supernatants. 
Determination of the induction of regulatory T cells in MLR
T Cells from the MLR were phenotypically analyzed by five color flowcytometry as 
described previously36. Cells were washed twice with phosphate-buffered saline 
supplemented with 0.2% bovine serum albumin (Sigma). The following conjugated 
mAb were used: CD127 (hIL-7R-M21) PE, (BD Biosciences, Erembodegem, 
Belgium), FoxP3 (PCH101) FITC (Ebioscience, San Diego, CA), CD4(T4) PC7, 
CD8 (SFCI21Thy2D3) ECD and CD25 (B1.49.9) PC5 (Beckman Coulter). First the 
CD4+CD25+ T cells were gated by using anti-CD4 and anti-CD25 antibodies. This 
subset of CD4+CD25+ T cells was further characterized by determining the level 
of expression of FoxP3 and CD127 according to the indicated settings. Isotype 
matched antibodies were used to define marker settings. Intracellular analysis of 
FoxP3 was performed after fixation and permeabilization, using Fix and Perm 
reagent (Ebioscience, San Diego, CA).
Measurement of cytokines in culture supernatants
Levels of TNFα, IL-12p70, IL-17, IL-4, IFNγ and IL-13 were measured in the 
supernatants using commercially available kits (Bio-Rad) according to the 
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manufacturer’s instructions. Cytokine levels were measured and analyzed with 
the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay was < 5 pg/
ml for all cytokines measured. 
Statistical analysis 
Differences between groups were analyzed using paired Student’s t-tests or the 
Mann-Whitney U test. Correlations were analyzed using Spearman tests. P values 
less than 0.05 were considered significant.
Results
Monocyte-derived DCs from RA patients able to halt DMARD use express 
FcγRIIb at high levels.
RA is a tremendously heterogeneous disease in nature characterized by disease 
flares and remissions as measured by the disease activity score (DAS28) now 
generally accepted and used worldwide37. Next to this, the dependency on 
Disease Modifying Anti-Rheumatic Drugs (DMARDs) ranges from those 
perpetually in need of potent immunosuppressive drugs to a subset of patients 
who are able to discontinue its use. Based on these facts we divided RA patients 
into four categories using a well-documented prospective cohort of RA patients 
(38-40). Accordingly, at the time of study inclusion, RA patients were divided into 
those having moderate to high disease activity (DAS28 > 3.2) and those having 
a low disease activity (DAS28 < 3.2) with or without the use of DMARDs. All 
patients in the current study fulfilled the ACR criteria for rheumatoid arthritis at the 
time of inclusion in the inception cohort and suffered from a longstanding RA with 
a mean disease duration of 13 yrs (2-33 yrs) for RA patients not on DMARD 
therapy and 9 yrs (2-20) for those on DMARD therapy at the start of the current 
study. Notably, no significant differences were observed between both groups 
regarding rheumatoid factor, disease duration or the presence of erosions (Table 1). 
We examined the expression of FcγR subtypes in RA patients using the unique 
antibodies recently described to discriminate the FcγRIIa and FcγRIIb isoforms15,33. 
Compared with healthy controls, all patients having a moderate to high DAS28 
(regardless of DMARD use) or those having a low DAS28 using DMARDs 
(DMARD(+) RA) displayed a similar expression profile both of activating and 
inhibitory FcγRs (Figure 1a and b). Strikingly and in sharp contrast, all patients 
not on DMARD therapy and having a low disease activity (DAS28<3.2) (further 
designated as DMARD(-) RA) expressed a significantly higher level of FcγRIIb on 
their monocyte-derived DCs whereas the expression of activating FcγR was not 
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 Figure 1
FcγRIIb expression is markedly increased on DCs from RA patients having quiescent 
disease. (a) Whereas the expression of activating FcγR subtypes (FcγRI, IIa and IIIa) is 
comparable in all groups (one representative individual from each group is shown), the 
expression of the inhibitory FcγRIIb is increased only on immature DCs from RA patients 
having low disease activity who had stopped DMARD use at least 2 years ago. Mean 
fluorescence intensity is presented as measured by flowcytometry. (b) Expression of 
activating and inhibitory FcγR on DCs from the different RA subgroups (DMARD(+), 
DAS28>3.2, n=6; DMARD(+), DAS28<3.2, n=10; DMARD(-), DAS28>3.2, n=5; DMARD(-), 
DAS28<3.2, n=11) and healthy individuals (n=10). Mean and SEM are for combined data 
from 5-11 independent experiments. * indicates a p-value < 0.001, comparing the 
DMARD(-), DAS28<3.2 group to the four other groups (c) No correlation is present between 
FcγRIIb expression on DCs and disease activity in RA patients using DMARDs whereas 
there is a clear correlation in patients who halted DMARD use. The disease activity score 
DAS28 was measured at inclusion of the study. (d) Expression of FcγRIIb on monocytes 
from DMARD(+), DAS28<3.2 (n=5); DMARD(-), DAS28<3.2 (n=5) RA patients and healthy 
individuals (n=6). Mean and SEM are for combined data from 5 independent experiments.
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notably different (Figure 1a and b). With respect to various DC markers (CD14, 
CD80, CD83, CD86, MHCII) as well as the ITIM bearing molecules ILT3, ILT4 and 
DCIR, which are known to be expressed on “tolerogenic” DCs41,42 no differences 
were observed (data not shown). In patients on DMARD therapy no correlation 
between DAS28 and FcγRIIb expression could be observed whereas this 
correlation was clearly present in those individuals who did not use anti-rheumatic 
drugs (Figure 1c). These observations substantiate that the lack of DMARD use 
alone did not explain the high FcγRIIb expression in RA patients with a 
self-regulated low disease activity but rather indicates that they constitute a 
different class of RA patients. Of note, we also evaluated the expression of the 
FcγR on monocyte-derived DCs from patients suffering from other immune-related 
diseases such as systemic lupus erythematosus  and psoriatic arthritis. None of 
these patients DCs expressed FcγRIIb to such high levels as observed in RA 
patients having quiescent disease (data not shown). In order to determine 
whether the differences in FcγRIIb were already present on the progenitor cells of 
the DCs, monocytes from healthy controls, DMARD(+) and DMARD(-) RA patients 
were evaluated for their expression of FcγRIIb. No significant differences in the 
expression of FcγRIIb were found (Figure 1d).  
Immune complexes inhibit TLR4 mediated cytokine release on DCs from 
DMARD(-) RA patients.
We surmised that the high expression of FcγRIIb on DCs from DMARD(-) RA 
patients has clear functional consequences. To ascertain whether this idea holds 
true, we measured the production of the pro-inflammatory mediators TNF-α and 
IL-12p70 produced by DCs upon co-incubation of LPS (TLR4 agonist) compared 
with the combination of LPS and IC. In contrast with DCs from RA patients using 
DMARDs, which express low FcγRIIb levels (designated as DClow-FcγRIIb) (increase 
TNFα 2% ± 2 and IL-12p70 19% ± 4 (mean ± SEM)), DCs from DMARD(-) RA 
patients, which express high FcγRIIb levels (designated as DChigh-FcγRIIb), clearly 
inhibited the production of TNFα (-28% ± 2) and IL-12p70  (-43% ± 4) upon 
stimulation with the combination of LPS and IC compared with that seen upon 
stimulation with LPS alone (Figure 2a). Importantly, all DChigh-FcγRIIb were derived 
from DMARD(-) RA patients (untreated RA patients with a low DAS28) and all DCs 
from DMARD(-) RA patients were DChigh-FcγRIIb while all DClow-FcγRIIb were derived 
from DMARD(+) RA patients (RA patients on DMARD therapy with a low DAS28 
score). As expected, like DClow-FcγRIIb from DMARD(+) RA patients DCs from 
healthy controls were unable to suppress TLR4 responses by the ligation of IC 
(data not shown). Unstimulated or IC-stimulated DChigh-FcγRIIb and DClow-FcγRIIb did 
not release any detectable levels of TNFα or IL-12p70 demonstrable of their 
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immature nature. We next determined the inhibitory capacity of FcγRIIb over a 
range of LPS doses. The inhibitory effect of IC was potent since it was found to be 
effective in a wide range of LPS concentrations (10 pg/ml - 1mg/ml, data not 
shown). The use of heat aggregated human immunoglobulins in our experiments 
is well controlled but artificial. Therefore we repeated these experiments to ensure 
that naturally occurring immune complexes exert comparable effects with regard 
to FcγRIIb mediated TLR inhibition (34). Pegylated-immune complexes (Peg-IC) 
isolated from the serum from RA patients inhibited TLR4 responses to comparable 
levels as observed with IC attesting that circulating immune complexes can tune 
TLR mediated immune responses via FcγRIIb in vivo (Figure 2b). Peg-IC isolated 
from healthy individuals were able to inhibit TLR4 mediated DC activation to the 
Figure 2
 Only TLR4 mediated cytokine production by DCs from DMARD(-) RA patients is inhibited 
by co-stimulation with IC (a) Immature DCs from RA patients able to successfully 
discontinue DMARD therapy, of which all expressed high levels of FcγRIIb (further 
designated as DChigh-FcγRIIb), markedly inhibit TLR4 mediated secretion of TNFα and IL-12 
upon co-culture with IC compared to those stimulated with LPS only. In contrast, DCs from 
RA patients on DMARDs (DClow-FcγRIIb) were unable to inhibit TLR4 mediated cytokine 
production. The results displayed here originated from 10 independent experiments. (b) 
Immune complexes isolated by PEG precipitation from the serum of healthy controls (n=11) 
and RA patients (n=11) dampen the release of TNFα to the same extent as do artificial 
immune complexes. IC isolated from synovial fluid of RA patients (n=11) are less able to 
inhibit the production of TNFα. Results from DChigh-FcγRIIb from a representative DMARD(-) RA 
patient are shown.
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same extent as those Peg-IC from RA patients again underscoring the importance 
of FcγRIIb as a check point for tolerance. Interestingly, Peg-IC isolated from the 
synovial fluid of RA patients were less able to inhibit TLR4 responses. To exclude 
the possibility that intracellular retention of TNFα43 would explain our results we 
compared the release of TNF-α upon stimulation of DCs with the combination of 
IC and LPS before and after repeated freeze-thaw cycles. The inhibitory effect of 
IC was still clearly present suggesting that retention of TNFα was virtually 
neglectable (data not shown). To investigate whether the inhibition of TLR4 by 
FcγRIIb was prolonged or temporal, we stimulated DChigh-FcγRIIb with LPS in the 
presence or absence of IC at baseline and measured the amount of TNFα in the 
supernatants at several time points. TNF-α production was inhibited to the same 
extent at all time points (data not shown). Homo-aggregation of FcγRIIb on B 
cells induces apoptosis. The levels of Annexin V and Propidium Iodide were 
similar throughout the experiments, which refutes apoptosis as an explanation for 
our observations (data not shown). Notably, both IC and Peg-IC were found to 
be negative for LPS contamination using Limulus Amebocyte Lysate assays (data 
not shown).
FcγRIIb stimulation inhibits TLR4 mediated DC maturation which has clear 
effects on T cell responses. 
To further delineate whether the TLR4 dependent phenotypic maturation of DCs 
was affected by IC, DChigh-FcγRIIb were stimulated with the combination LPS and IC 
and compared to those stimulated with LPS alone. Subsequent analysis of CD86 
and MHCII demonstrated that the addition of IC to LPS halted the phenotypic 
maturation significantly (Figure 3a). In sharp contrast, IC had no significant effect 
on DClow-FcγRIIb. Since the expression of such maturation markers exerts direct 
effects on T cell instruction, we next examined their capacity to induce T-cell 
proliferation of allogeneic CD3+CD25-CD127+ T cells. The potency of DChigh-FcγRIIb 
to induce T-cell proliferation upon stimulation with the combination of LPS and IC 
was markedly diminished compared to stimulation with LPS alone (P < 0.05) 
(Figure 3b). As expected, on DClow-FcγRIIb the addition of IC to LPS had no inhibitory 
effect. Since the pathogenic role for Th1 cells in rheumatoid arthritis is evident 
from a wide range of clinical and experimental observations, we extended our 
result by analysis of T cell cytokines considered to reflect Th1 (IFN-γ) or Th2 (IL-13) 
status. Exposure of T cells to DChigh-FcγRIIb co-incubated with the combination of 
LPS and IC strongly increased the potential of T cells to secrete IL-13 compared 
to DChigh-FcγRIIb incubated with LPS alone, whereas this effect was absent on 
DClow-FcγRIIb (Figure 4a). IL-4 was also detectable in the MLR supernatants in a 
similar pattern as IL-13 however at much lower concentrations (data not shown). 
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Figure 3
 Co-stimulation of DChigh-FcγRIIb with IC inhibits TLR4 induced phenotypic maturation and has 
clear consequences for T cell priming. (a) DCs were cultured for 24 hrs with medium, with 
LPS alone or with LPS and IC. A decreased expression of cell surface makers CD86 and 
MHCII upon stimulation with combination of LPS and immune complexes by DC expressing 
high levels of FcγRIIb (n=5) is shown. In contrast, DCs that express low levels of FcγRIIb 
(n=5)  did not display an altered expression of these cell surface markers upon co-incubation 
with IC. Mean and SEM are for combined data from 5 independent experiments. (b) To 
determine the effect of IC mediated FcγR activation on the ability of DClow-FcγRIIb and 
DChigh-FcγRIIb to induce T cell proliferation CD3
+CD25- T cells were stimulated for 3 days with 
DCs. The DCs were activated before the MLR with the described ligands for 24 hours and 
were subsequently extensively washed. Incubation of DChigh-FcγRIIb with the combination of 
LPS and IC markedly inhibited T cell proliferation measured by 3H-Thymidine incorporation 
at day 3 compared to those stimulated with LPS alone. In sharp contrast, the addition of IC 
to LPS did not have any effect on T cell proliferation induced by DClow-FcγRIIb. For these 
experiments 5 RA patients of each group were tested in 4 independent experiments. 
* indicates a p-value < 0.05
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Strikingly, T cells directly isolated from the circulation from RA patients with high 
FcγRIIb levels produce significant higher levels of IL-4 and IL-13 compared to 
those from patients characterized by DCs with a low FcγRIIb (Figure 4b). Since T 
cells able to excrete IL-17, designated Th17, have recently been mentioned as 
mediators of inflammation in experimental arthritis models we measured the IL-17 
content in MLR with CD3+CD25-CD127+ T cells and DChigh-FcγRIIb activated by LPS 
alone or in combination with IC. No significant differences were observed (data 
not shown)44. These observations may suggest that FcγRIIb mediated TLR4 
inhibition has clear consequences on the Th1/Th2 axis but does not touch Th17 
development. To further explore the modulating effect of FcγRIIb signaling on the 
ability of DCs to influence T cell differentiation, we next studied the capacity of 
DChigh-FcγRIIb and DClow-FcγRIIb to induce regulatory T cells (Treg). To this end, 
CD3+CD25-CD127+ T cells were stimulated with DChigh-FcγRIIb or DClow-FcγRIIb 
activated with medium, IC, LPS or the combination of IC and LPS and were 
analyzed by flowcytometry after 6 days of co-culture. Newly induced 
CD4+CD25+FoxP3+CD127- T cells were present in all the cultures. However, the 
relative presence of CD4+CD25+FoxP3+CD127- T cells was significantly 
diminished by the prior activation of the DCs with LPS. Interestingly, the inhibitory 
effect of TLR4 on the relative presence of Treg observed by the addition of LPS 
was completely abolished by the addition of IC to DChigh-FcγRIIb. The addition of IC 
did not have any effect when looking at DClow-FcγRIIb (Figure 4c and d). Collectively, 
these data indicate that the FcγRIIb mediated inhibition of TLR4 responses has 
clear functional consequences for DC mediated T cell instruction and might 
explain the higher number of Th2 cells found in vivo in DMARD(-) RA patients45. 
The effect of IC on TLR4 signaling release is FcγRIIb dependent.
There is a remarkably clear correlation (R2 = 0.89, P = 0.001) between the level 
of FcγRIIb expression and the potential to inhibit TNF secretion upon LPS + IC 
stimulation by DCs in RA patients (Figure 5a). This strongly suggests that the 
level of FcγRIIb expression on DCs determines the level of inhibition of TLR4 
responses instrumented by the addition of IC. By using a blocking antibody 
against FcγRIIb we confirmed that the inhibitory effect of IC on TLR4 signaling in 
DChigh-FcγRIIb is fully dependent on FcγRIIb (Figure 5b)
15,16. In contrast, blocking 
FcγRIIa had no effect on IC mediated dampening of TLR4 dependent TNF-α 
secretion. The expression of co-stimulatory molecules (data not shown), 
inhibition of T cell proliferation (Figure 5c) and increased production of IL-13 by 
T-cells (Figure 5d) mediated by the addition of IC to DChigh-FcγRIIb were fully 
abrogated by blocking FcγRIIb implying that the inhibitory FcγRIIb was solely 
responsible for the inhibitory effect of IC on TLR4 immune responses.
2
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Figure 4
DChigh-FcγRIIb co-stimulated with IC promote the differentiation of Th2 cells and the 
CD4+CD25+FoxP3+CD127- T-cell population. (a) At day five during MLR T cells were 
exposed to PMA (50 ng/ml) and ionomycin (1 mg/ml), supernatants were collected after 12h 
for measurement of the released levels of IFNγ and IL-13. T cells incubated with DChigh-FcγRIIb 
that were stimulated with IC with or without LPS released increased levels of IL-13 compared 
to those cultured with DChigh-FcγRIIb stimulated with medium or LPS alone. In contrast, 
co-stimulation of DClow-FcγRIIb with IC did not sort an effect on IL-13 secretion. In both groups 
no effect could be observed by the addition of IC on the production of IFN-γ. Data are mean 
± SEM and represent 4 RA patients from each group in four independent experiments. (b) 
Peripheral blood lymphocytes (PBL) from healthy controls and RA patients without and 
with DMARD therapy were obtained and stimulated overnight with PMA and ionomycin. The 
cytokines released in the supernatants were measured by luminex. PBL from RA patients 
who had successfully stopped DMARD use secreted significantly more IL-13 and IL-4 
compared to those obtained from DMARD(+) RA patients while IL-10 demonstrated a 
similar trend. In line with our data originating from the MLR experiments, IFNγ levels were 
similar between groups. Bars are means ± SEM of 4 healthy controls and RA patients in 
each group. (c and d) CD3+CD25- CD127+ T cells were stimulated for 6 days with DCs from 
RA patients with a low DAS28 and either treated with DMARDs or not. After overnight 
incubation with medium alone, the presence of CD4+CD25+FoxP3+CD127- regulatory T 
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The inhibitory effect of FcγRIIb is mediated via the PI3K/Akt pathway. 
To further dissect the cross talk between FcγRIIb and TLR, we first explored the 
effect of inhibiting PI3K and Akt in our system since these are intricately involved 
in FcγR and TLR signaling. Inhibition of the PI3K/Akt pathway, with three separate 
PI3K or Akt inhibitors, led to an increased release of TNFα upon LPS stimulation 
of DCs (Figure 6a). Extensive dose-response curves were performed to obtain 
the levels at which the inhibitors had their optimal effect (data not shown). In 
addition we found that both the PI3K inhibitor as well as the Akt inhibitors fully 
abrogated the inhibitory effect of FcγRIIb on LPS mediated TNFα and IL-12p70 
production by DCs (Figure 6b and 6c). Inhibition of the MAP kinase p38, PKCd 
and Btk that also have been advocated to play a part in the signaling of either TLR 
or FcγR did not have any effect on the FcγRIIb inhibitory potential (Figure 6d and 
Figure 6e). 
2
cells was determined. The decreased relative presence of T regulatory cells due to the pre-
stimulation of DChigh-FcγRIIb with LPS was completely reversed by the addition of IC to the DC 
cultures. In clear contrast, the addition of IC to LPS had no effect on T regulatory cell 
development when DClow-FcγRIIb were used. The percentage of CD127
-FoxP3+ regulatory T 
cells as part of the CD4+CD25+ subgroup of T cells is shown from a representative MLR in 
panel c. The combined results from three independent experiments ± SEM are shown in 
panel d. First the CD4+CD25+ T cells were gated by using anti-CD4 and anti-CD25 
antibodies. This subset of CD4+CD25+ T cells was further characterized by determining the 
level of expression of FoxP3 and CD127. Isotype matched antibodies were used to define 
marker settings. * indicates a p-value < 0.05.
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Figure 5
 The modifi cation of the TLR4 response by IC is solely mediated by the inhibitory FcγRIIb. 
(a) The capacity of IC to inhibit TLR4 mediated TNFα secretion is highly correlated with the 
expression of the inhibitory FcγRIIb on DCs. Grey are patients on DMARDs (n=8) and black 
are patients who had stopped DMARD therapy (n=9). (b) The inhibitory effect on the 
LPS-induced release of TNFα by IC on DChigh-FcγRIIb could be completely reversed by the 
blockade of FcγRIIb. DCs with a high expression of FcγRIIb were cultured for 6 days, on day 
6 the DCs were washed and the activating FcγRIIa and the inhibitory FcγRIIb were blocked 
with their respective antibodies. The DCs were subsequently plated in 24 wells plates, 
exposed to IC and after 5 minutes LPS was added to the wells. Supernatants were obtained 
24 hours later. Data are representative of four individual experiments with in total fi ve RA 
patients with similar results. Bars represent mean and SD of triplicate wells (c) The inhibition 
of CD3+CD25- T cell proliferation induced by LPS-activated DChigh-FcγRIIb by the addition of 
IC (measured by 3H thymidine incorporation) was completely abolished by the prior 
blockade of FcγRIIb. Bars are mean ± SD representative of 3 independent experiments 
with DChigh-FcγRIIb from 3 RA patients. (d) As for T cell differentiation, the increased secretion 
of IL-13 by T cells in MLR with DChigh-FcγRIIb was abolished upon blockade of FcγRIIb. Mean 
and SD are representative for data from 3 independent experiments with DChigh-FcγRIIb from 3 
RA patients. For all fi gures * indicates a p-value < 0.05, ** indicates P –value <0.01.
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Figure 6
 The PI3K/Akt pathway is crucial in the inhibition of TLR4 signalling by FcγRIIb. (a) DC from 
a healthy control were stimulated with LPS in the presence of the PI3K inhibitor Wortmannin 
(0.1 mM) or in the presence of the Akt inhibitors IV (0.1 mM) or X (0.5 mM). Data are mean and 
SD of duplicate wells representative for data from 3 independent experiments. (b, c and d) 
LPS-induced TNFα secretion with and without co-stimulation of DChigh-FcγRIIb by IC in the 
absence or presence of inhibitors for PI3K (Wortmannin, 0.1 mM), Akt (Akt inhibitor X, 5 mM), 
PKCd (Rottlerin, 10 mM) and p38 MAP kinase (SB203580, 20 mM). Results are from separate 
DChigh-FcγRIIb from 5-6 DMARD(-) RA patients in each figure. (e) The percentage change in 
LPS-induced TNFα secretion with and without co-stimulation of DChigh-FcγRIIb by IC was 
measured by luminex technology in the absence or presence of inhibitors for PI3K, Akt, 
PKCd, p38 and Btk (LFM-A13, 50 mM). Results are the mean and SEM of 3-6 separate 
experiments with DChigh-FcγRIIb of 3-6 DMARD(-) RA patients. * indicates a p-value < 0.05 
compared to DChigh-FcγRIIb stimulated in the absence of an inhibitor.
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Discussion
The present study establishes a novel role of the inhibitory FcγRIIb providing a 
general checkpoint of our immune system tuning TLR4 mediated immune 
activation. The ability of the immune system to distinguish self from non-self is 
seminal to the ability to protect the host from the detrimental effects of invading 
pathogens. The mechanisms that orchestrate these properties operate at discrete 
checkpoints involving central and peripheral tolerance. Given the complexity of 
these processes it is not surprising that central tolerance is frequently incomplete. 
Therefore, inhibitory signaling has emerged as a critical feature of peripheral 
tolerance. The role of TLR in the initiation of immunity is extensively shown. 
However, the counter-regulatory mechanisms that control this inflammation and 
thus should prohibit chronic inflammation and uphold tolerance are not yet 
identified. The FcγRIIb mediated inhibitory capacity on TLR signaling that we 
show here provides a novel mechanism on how the immune system exploits 
FcγRIIb as a counter-regulatory mechanism to limit inflammation in order to 
prohibit exaggerated damage to host tissues. 
In arthritis, it has been irrefutably shown that the balance between activating and 
inhibitory FcγR is seminal in controlling both susceptibility to and the severity of the 
disease5,10,11,17,34,46-49. Here we demonstrate that the expression of FcγRIIb was 
insufficient to inhibit TLR4 mediated immune activation in all but RA patients able to 
suppress disease activity in the absence of anti-rheumatic drugs, suggesting that the 
high FcγRIIb expression observed in these latter patients might underlie their state of 
disease “remission”. Further evidence for the existence of such deranged FcγRIIb 
system in RA comes from the use of intravenous immunoglobulins (IVIG) that have 
been applied successfully to treat a variety of immune-related diseases such as 
immune thrombocytopenic purpura, SLE, Kawasaki disease and Guillain-Barre 
syndrome. Whereas the mechanisms that exert the effects of IVIG remain enigmatic, 
binding to and up regulation of the inhibitory FcγRIIb is advocated (50 reviewed in 51). 
In this line it is remarkable that the administration of IVIG to RA patients has been 
disappointing52,53. Recently, Kaneko et al. provided evidence for the role of sialylation 
of IC as another mechanism underlying the distinct effect of IC observed during 
inflammation and health54. Our data underscores the existence of such mechanism 
since pegylated IC obtained from the synovial fluid, thus originating from a more 
inflammatory environment, exerted significant less inhibitory capacity compared to 
pegylated IC obtained from the peripheral blood of RA patients. However, the fact 
that these former IC are still able to inhibit TLR4 responses indicates that the inhibitory 
capacity of the FcγRIIb system is superior over the level of sialylation. 
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The precise pathways underlying FcγRIIb mediated inhibition of ITAM are 
extremely complex and not completely elucidated let alone the mechanisms by 
which it might inhibit other immune receptors such as TLR4. Prime suspects are 
PI3K and it’s counteracting opponent SHIP. Whereas PI3K is known to increase 
PIP3 levels and thereby the level of phosphorylated Akt SHIP degrades PIP3 and 
reduces the level of Akt phosphorylation. Inhibiting Akt or PI3K led to an increase 
in TLR4 induced cytokine production by DCs in our experimental set-up. Based 
on our observations we propose a mechanism centered on the PI3K/Akt-SHIP 
balance by which FcγRIIb might inhibit TLR4 signaling. In our conceptual 
framework FcγRIIb activation leads to the recruitment and phosphorylation of 
SHIP to the cell membrane decreasing the level of SHIP available for enhancement 
of the TLR4 pathway. Increased levels of phosphorylated Akt might thus arise due 
to a shifted balance towards PI3K, instead of SHIP, closely associated with the 
TLR4 signaling cascade, leading to decreased LPS mediated DC activation. The 
likely massive presence of phosphorylated SHIP near FcγRIIb in DChigh-FcγRIIb 
activated by IC thus potentially increases the PI3K/Akt inhibitory signal leading to 
a decrease in TLR4 mediated cytokine production. Most likely however, this 
proposition is still an oversimplified scheme of the signaling events taking place. 
SHIP for example has been found to bind to adaptor molecules belonging to the 
family of Dok proteins which were first identified as substrates for the p210(bcr/
abl) oncoprotein and are implicated in inhibitory signaling (55-57). The function of 
the Dok proteins, which are phosphorylated by Lyn, has been linked to the 
facilitation or sustainment of the activation of SHIP and the inhibition of the ras 
pathway58,59. In addition, ligation of TLR4 by LPS has been shown to rapidly 
induce the phosphorylation and adaptor function of Dok proteins and the absence 
of Dok proteins resulted in the elevated activation of Erk and hyperproduction of 
TNFα60. Whether this inhibitory effect of the Dok proteins on TLR4 signalling is 
linked to their role as adaptor molecules needs further investigation. It does 
however demonstrate that the events taking place intracellularly in our experiments 
are far more intricate than we have tried to contemplate. The changes in 
intracellular TLR4 signaling induced by FcγRIIb leads to a decreased release of 
the pro-inflammatory cytokines TNFα, IL-6 and IL-12p70 as well as an increased 
capability of the DCs to induce Tregs and Th2 cells. These changes are seen as 
important events in the resolution of Th1 mediated inflammation. Intriguingly, the 
absence of SHIP in mice results in the increased presence of alternatively 
activated macrophages as well as a spontaneous allergic inflammation in the 
lungs characterized by elevated levels of the Th2 cytokines IL-13 and IL-461. These 
findings make it even more tempting to speculate that FcγRIIb signaling is 
designed to induce alternatively activated DCs capable of dampening inflammation. 
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DCs from patients having quiescent disease display a more tolerogenic phenotype 
as compared to those from RA patients having active disease, which is witnessed 
by the lower level of cytokine secretion, higher levels of Foxp3 expressing T cells 
and higher production of Th2 cytokines by T cells primed by these DCs. These 
observations are in keeping with that of Dhodapkar et al. demonstrating that 
FcγRIIb is crucial to keep DCs in immature state in steady state conditions16,62. As 
we show that healthy individuals had circulating IC, which exerted an inhibitory 
capacity comparable to that seen by RA IC, these findings suggest that circulating 
immune complexes orchestrate the DChigh-FcγRIIb tolerogenic phenotype by a 
constant down tuning of TLR mediated immune activation. As anticipated, healthy 
individuals did not express FcγRIIb at high levels potentially mirroring their steady 
state situation. These data further substantiate that FcγRIIb is designed to tune 
immune responses, restoring steady state conditions. Presumably, at some stage 
of immune activation, pathways must be turned on that lead to a clear shift in 
FcγR expression toward the inhibitory subtype. The pathways that regulate the 
expression of FcγR remain obscure. Although, IL-13/IL-4 with and without the 
combination of IL-10 has been demonstrated to skew the FcγR balance toward the 
inhibitory subtype, whereas IFN-γ strongly shifts this balance toward activating 
FcγR. Although, we have previously shown that the regulatory capacity of IL-13 is 
lost in RA patients, the high levels of FcγRIIb observed in DMARD (-) RA patients 
could not be explained by IL-13 or IL-10 since blocking these mediators during 
culture of DCs from RA patients with quiescent disease did not show any effect 
(63 data not shown). In addition, the expression of FcγRIIb seen in these patients 
reached such extra-ordinary high levels that they could not be reached by the 
addition of these mediators to DCs from healthy controls. Thus, these data 
indicate that other mechanisms must be responsible for the regulation of FcγRIIb 
expression. The identification of such pathways is likely to result in the delineation 
of the processes underlying the deranged up-regulation of FcγRIIb that was found 
to be specific for RA patients. This, in turn, would significantly contribute to the 
development of therapeutic targets that are specifically designed to act on the 
defective pathway that underlies the chronic course of RA, a current unmet need 
in the treatment of this condition.
Taken together, here we show for the first time, that most RA patients have a 
deranged expression of the inhibitory FcγRIIb rendering them incapable of controlling 
TLR mediated immune activation. Our data strongly suggest that the up regulation 
of FcγRIIb expression opens novel therapeutic avenues for the treatment of RA 
and other autoimmune conditions where TLR signaling is implicated.
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Abstract
Macrophages are a very heterogeneous subset of myeloid cells with both anti- and 
pro-inflammatory functions. In autoimmune diseases like rheumatoid arthritis they 
play a major role in amplifying local inflammation and their activation occurs in the 
presence of abundant amounts of immune complexes. Depending on the balance 
between activating Fc gamma receptors (FcγR) and the inhibitory FcγRIIb, immune 
complexes can further activate or inhibit cell activation. The purpose of this study 
was to determine FcγR expression on pro- and anti-inflammatory macrophages 
and identify the functional consequences this has on immune complex uptake 
and macrophage activation via toll-like receptors (TLRs) and activated T cells. 
Human monocytes were isolated and differentiated into pro-inflammatory type-1 
(mf-1) and anti-inflammatory type-2 (mf-2) macrophages in the presence of GM-
CSF and M-CSF, respectively. FcγR expression on mf-1 and mf-2 was measured 
by flow cytometry and functional consequences were evaluated by stimulating 
the macrophages with either TLR ligands or activated T cells in the presence or 
absence of immune complexes. TNFα and IL-10 production were determined. 
Anti-inflammatory mf-2 express high levels of the activating FcγRIIa and FcγRIII 
and low levels of the inhibitory FcγRIIb. Contrastingly, pro-inflammatory mf-1 
have much higher FcγRIIb levels and lower levels of the activating FcγRs. Immune 
complexes can inhibit TNFα production by mf-1 after TLR stimulation, while mf-2 
are unaffected. This inhibition is dependent on FcγRIIb and subsequent PI3K 
activation. Mf-1, but not mf-2, produce high levels of TNFα upon co-culture with 
cytokine activated T cells, which can be inhibited by the presence of immune 
complexes. Immune complex uptake by mf-2 is increased compared to mf-1, 
corresponding with higher expression of activating FcγRs. In conclusion, immune 
complexes can inhibit TLR responses and T cell mediated activation of mf-1 and 
thereby control its pro-inflammatory phenotype, while no inhibition is seen in 
mf-2 which express very low levels of the inhibitory FcγRIIb.
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Introduction
Macrophages are a very heterogeneous subset of immune cells with functions 
ranging from maintaining tissue homeostasis to fighting infections. Depending 
on micro environmental signals present in a tissue, monocytes that exit the 
bloodstream will differentiate into different types of macrophages. Two important 
survival and differentiation factors for macrophages are macrophage colony-
stimulating factor (M-CSF) and granulocyte-macrophage colony-stimulating 
factor (GM-CSF). M-CSF is ubiquitously expressed during steady-state conditions 
and induces anti-inflammatory macrophages that promote tissue repair and 
remodeling1. GM-CSF, on the other hand, is barely present in steady state 
conditions but is clearly detectable at sites of inflammation, such as an arthritic 
joint2. GM-CSF is produced by both immune cells and non immune cells such 
as fibroblasts and endothelial cells upon activation by various stimuli including 
the pro-inflammatory cytokines TNFα and IL-1b3,4. Corresponding with this in vivo 
distribution, human monocyte derived macrophages cultured in the presence 
of GM-CSF (type 1 macrophages, mf-1) have a pro-inflammatory phenotype, 
while macrophages cultured in the presence of M-CSF (type 2 macrophages, 
mf-2) have a more anti-inflammatory phenotype, marked by high levels of IL-10 
production upon stimulation5. Recently, these macrophage subtypes have been 
extensively phenotyped; however specific knowledge of Fc gamma receptors on 
these macrophage subsets is still missing5,6. 
Macrophages play an important role in autoimmune diseases like rheumatoid 
arthritis (RA). In an inflamed joint macrophages are one of the main effector cells 
present and their levels correlate with disease activity and joint destruction (7,8). 
Macrophages are the main producers of pro-inflammatory cytokines, including 
TNFα and IL-6. The importance of these cytokines is exemplified by the efficacy 
of current therapeutics neutralizing these cytokines in the treatment of RA. In an 
arthritic joint, macrophages can be activated by TLR ligands (both endogenous 
and exogenous) and activated T cells, but also by the presence of immune 
complexes that are present in most RA patients. Immune complexes are recognized 
by Fc gamma receptors present on the membrane of antigen presenting cells. 
The Fc gamma receptor (FcγR) system consists of the activating FcγRI, FcγRIIa 
and FcγRIII that trigger cell activation via an immunoreceptor tyrosine-based 
activation motif (ITAM) in their cytoplasmic domain and the inhibitory FcγRIIb that 
signals via an immunoreceptor tyrosine-based inhibition motif (ITIM). FcγRIIa, 
FcγRIIb and FcγRIII are involved in the recognition of immune complexes and IgG 
coated particles/bacteria, while FcγRI mainly recognizes monomeric IgG. The 
balance between the activating and the inhibitory FcγRs on the cell membrane 
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determines the response of macrophages to immune complexes. Therefore, it is 
important to know the exact FcγR expression on different macrophage subtypes 
to understand their role in (auto) immunity and their behavior in the presence 
of immune complexes. Major factors hindering the extensive examination of 
different FcγR expression on myeloid cells, was the lack of specific antibodies 
to discriminate between the activating FcγRIIa and the inhibitory FcγRIIb. The 
development of the FcγRIIb specific antibody 2B6 gives us the opportunity to look 
specifically at FcγRIIa and FcγRIIb, which have very different functions9. Signaling 
via FcγRIIb can inhibit phagocytosis and cell activation mediated by the activating 
FcγRs, but FcγRIIb recently has been shown to have a more broad function in 
regulating immune function. Immune complex binding to FcγRIIb can modulate 
DC maturation and cytokine production upon TLR4 triggering10,11. This direct 
link between the Toll like receptor signaling and FcγR receptor signaling puts 
FcγRIIb at a central location in the pathogenesis of autoimmune diseases like 
RA and systemic lupus erythematosus (SLE), since TLR signaling and immune 
complexes have been shown to play important roles in these diseases. The broad 
immune regulatory function of FcγRIIb made us wonder if it could also influence 
the T cell mediated activation of macrophages. 
Therefore, we determined the FcγR expression on type 1 and type 2 macrophages, 
two extremes in the whole range of anti- and pro-inflammatory macrophage 
subtypes. We further looked at the functional consequences of differential FcγR 
expression by evaluating the effect on immune complex uptake, but also on the 
modulation of macrophage activation via both TLRs and activated T cells in the 
presence of immune complexes.  
Materials and Methods
Culture of monocyte-derived type 1 and type 2 macrophages and Tck cells
Peripheral blood mononuclear cells were isolated from heparinized venous blood 
of healthy volunteers using density-gradient centrifugation over Ficoll-Paque 
(Amersham Bioscience). The local Medical Ethics Committee approved the study 
protocol. Monocytes and CD4+ T cells were obtained using CD14 and CD4 
microbeads respectively, and MS columns (Miltenyi Biotec). Monocyte-derived 
type 1 macrophages (mf-1) and type 2 macrophages (mf-2) were generated 
by culturing isolated monocytes in the presence of GM-CSF (800 U/ml; R&D) or 
M-CSF (25 ng/ml; R&D) for 6 days, respectively. Macrophages were cultured in 6 
well plates (Corning) with 0,5x106 cells per well in 2 ml of culture medium (RPMI-
1640 Dutch modification (Invitrogen) supplemented with 10% FCS, antibiotic-
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antimycotic and L-glutamine (Invitrogen)). New culture medium with the same 
supplements (1 ml) was added at day 3 after which the cells were harvested at 
day 6. In parallel, CD4+ T cells from the same donor were cultured in complete 
medium with recombinant human IL-2 (25 ng/ml), IL-6 (100 ng/ml) and TNFα (25 
ng/ml) at a density of 5x106 cells/ml for 6 days. 
For the western blot experiments monocyte derived DCs have been cultured from 
CD14+ monocytes by culturing them for 6 days in the presence of GM-CSF (800 
U/ml; R&D) and IL-4 (500 U/ml; R&D).
Phenotypical analysis
Using standardized flow cytometry protocols as described previously12, 
phenotypical analysis of mf-1 and mf-2 was performed. Mf-1 and mf-2 were 
characterized for their FcγR expression using antibodies against FcγRI (CD64, 
clone 10.1; Dako) and FcγRIII (CD16, clone DJ130c; Dako), clone IV.3 which 
preferentially binds to FcγRIIa (Medarex) and the FcγRIIb specific antibody 2B6 
(Macrogenics). Furthermore the expression of CD14, CD163 (both BD Biosciences) 
and MHC-II DR/DP (clone Q1514) was determined. Cells were analyzed using Cell 
Quest software for the proportion of positive cells and the mean fluorescence 
intensity relative to cells stained with the appropriate IgG isotypes. 
Stimulation of monocyte-derived type 1 and type 2 macrophages
At day 6 mf-1 and mf-2 were harvested, washed, counted and replated in a 
concentration of 0.5x106 cells/ml in 96 well (100 ml) culture plates. Cells were 
stimulated with TLR agonists for 20-24 hours in the presence or absence of heat-
aggregated human immunoglobulins (IC, used in a concentration of 50µg/ml), 
prepared as previously described13. The concentration in which the TLR agonists 
were used was as follows: LPS (100 ng/ml, E. coli 0111:B4, Sigma-Aldrich), R848 
(2 mg/ml, InvivoGen) and Pam3CSK4 (P3C; 5 mg/ml, EMC Microcollections). The 
used E. coli Lipopolysaccharide was double-purified at our laboratory according 
to the two-step phenol-water extraction method to remove any contaminating 
proteins resulting in purified LPS (14). Mf-1 and mf-2 were also co-cultured with 
cytokine-activated T cells for 24 hrs in a 1:5 ratio. This was performed in the 
presence or absence of IC prestimulation (50µg/ml) of macrophages for 1 h. 
To determine the role of the inhibitory FcγRIIb in response to IC stimulation, FcγRIIb 
was specifically blocked before IC addition. FcγRIIb blocking was performed by 
30 min pre-incubation of macrophages with 30 µg/ml 2B6 antibody at 4°C before 
stimulation with IC and TLR agonists. To determine the involvement of PI3K in 
the FcγRIIb mediated interference with TLR signaling, macrophages were also 
stimulated with IC and LPS in the presence of PI3K inhibitors. Macrophages were 
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pre-treated with the PI3K specific inhibitors Wortmannin (0.1 µM; Calbiochem) or 
LY294002 (10 µM; Calbiochem) for 1 h at 37°C before stimulation with IC and LPS. 
Measurement of cytokines in culture supernatants
Levels of IL-6, IL-10 and TNFα were measured in the supernatants using 
commercially available kits (Bio-Rad) according to the manufacturer’s instructions. 
Cytokine levels were measured and analyzed with the Bio-Plex system (Bio-Rad). 
The sensitivity of the cytokine assay was < 5 pg/ml for all cytokines measured. 
Phagocytosis assays 
Phagocytosis assays were performed with fluorescently labeled ICs, prepared as 
previously described (15). Mf-1 and mf-2 were incubated with FITC-labeled ICs 
(50 mg/ml) for 30 min at 37°C. The amount of IC uptake was determined by flow 
cytometry.
Western blot
moDCs were harvested 30 min after stimulation, washed in PBS and lysed in 
lysisbuffer. Protein concentrations were measured and equal amounts (50 
mg) of protein were loaded on an 8% polyacrylamide gel and transferred to a 
nitrocellulose membrane. Membranes were then blocked with 5% nonfat dried 
milk in TBST (15 mM Tris-HCL (pH 7.4), 150 mM NaCl, 0.1% Tween 20). Blots were 
probed overnight with a mouse antibody specific for phosphorylated SHIP and 
AKT (Cell signaling technologies) or with a mouse antibody specific for IkBα, 
according to the manufacturers protocol. The membranes were subsequently 
treated with the appropriate secondary antibodies and visualized by the ECL 
Western blotting detection kit (Pierce).     
Statistical analysis 
Differences were analyzed using paired Student’s t-tests. P values less than 0.05 
were considered significant.
Results
Mf-1 express high levels of the inhibitory FcγRIIb, while mf-2 express higher 
levels of the activating FcγRIIa and FcγRIII
To date, mounting evidence suggests pivotal differences in macrophage subsets 
and supports a central role of Fc gamma receptor expression in part explaining 
the specific function of these subsets. Therefore, we evaluated the expression of 
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activating and inhibitory FcγRs on pro- and anti-inflammatory mf-1 en mf-2. To 
confirm the phenotype of our mf-1 en mf-2 we first analyzed their expression of 
CD14, CD163 and MHC-II. According to literature the expression of CD14 and 
CD163 was higher on mf-2, while the expression of MHC-II was slightly increased 
on mf-1 (Figure 1A)5,6. The monomeric IgG receptor FcγRI was similarly expressed 
in mf-1 and mf-2, while FcγRIII mean fluorescence intensity (MFI, reflects 
expression per cell) was highly increased on mf-2 compared to mf-1 (Figure 
1B). Investigating the activating and inhibiting subtype of FcγRII separately, we 
observed a marked difference between the mf-1 en mf-2. Whereas the activating 
FcγRIIa is expressed higher on mf-2, the inhibitory FcγRIIb expression was 
markedly higher on mf-1. More specifically, the FcγRIIb/FcγRIIa ratio was 1.17 
for mf-1 and 0.36 for mf-2. Thus, mf-2 have a skewed FcγR balance toward 
the activating FcγRs whereas FcγR expression on mf-1 is skewed towards the 
inhibitory FcγRIIb. In contrast with MFI, the percentage of positive cells was 
similarly distributed between mf-1 and mf-2 for all FcγR subtypes (Figure 1B).
The capacity to take up immune complexes is an important function of macro-
phages and dendritic cells. To evaluate the functionality of this altered activating/
inhibitory FcγR balance, we investigated whether the mf-1 and mf-2 display a 
different uptake of ICs. By adding fluorescently labeled ICs to both macrophage 
subtypes, we determined that mf-2 show a significantly increased potential for IC 
uptake compared to mf-1 (Figure 1C), likely caused by their enhanced expression 
of FcγRIIa and FcγRIII. 
Immune complexes inhibit TLR induced cytokine production by mf-1 but 
not by mf-2.
It has been shown previously that DCs from RA patients having quiescent 
disease express high levels of FcγRIIb and are able to inhibit TLR4 responses 
when co-stimulated with immune complexes10. To further evaluate the functional 
consequences of the differential expression of inhibitory and activating FcγRs 
on mf-1 and mf-2 we studied the role of immune complexes on TLR induced 
cytokine production. We found that mf-1 produce high levels of TNFα and low 
levels of IL-10 upon TLR stimulation, while mf-2 are marked by their relatively 
high IL-10 production and low production of pro-inflammatory cytokines which 
corroborates the literature (Figure 2A)5. After co stimulation with LPS and ICs, 
mf-1 were able to significantly attenuate TNF production compared to those 
stimulated with LPS alone, while IL-10 production is relatively unaffected (Figure 
2A). In contrast, but in line with our observations on FcγR expression, the addition 
of ICs to LPS did not result in inhibition of TLR4 mediated cytokine production on 
mf-2. In fact, mf-2 show a trend towards increased production of TNFα. Following 
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experiments learned that the inhibitory effect of IC on TLR signaling by mf-1 is 
not limited to TLR4, but also extends to TLR2 and TLR7/8 (Figure 2B). Again, IL-
10 production was not clearly affected by the presence of ICs and this effect on 
TNFα production was not present in mf-2 (Figure 2B and data not shown). 
Immune complexes can inhibit mf-1 activation by activated T cells
It has been advocated that macrophages that enter an arthritic joint do not only get 
activated by the presence of (endogenous) TLR ligands, but also by the presence 
Figure 1
 Mf-1 express high levels of the inhibitory FcγRIIb, while mf-2 express higher levels of the 
activating FcγRIIa and FcγRIII. Monocytes were cultured for 6 days with GM-CSF or M-CSF into 
mf-1 and mf-2. (A) CD14, CD163 and MHC-II expression (mean fluorescence intensity (MFI) ) 
were determined by flow cytometry. Bars are mean and SEM from 6 donors. (B) The FcγR 
expression of the mf-1 and mf-2 was measured by flow cytometry. The upper panel shows the 
MFI and the lower panel the percentage positive cells from the same experiments. Bars are 
mean and SEM from 11 donors from 5 independent experiments. (C) Mf-1 and mf-2 were 
incubated with fluorescent labelled ICs (50 µg/ml) for 30 min at 37°C. IC uptake was determined 
by flow cytometry. Figure shows mean and SEM of 4 independent experiments. * p < 0.05 
compared to mf-1, ** p < 0.001 compared to mf-1.
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of already activated T cells. T cells from RA synovial tissue or synovial fluid have 
been shown to mainly induce TNFα expression by monocytes/macrophages in 
a cell-cell contact dependent manner16,17. The phenotype of RA synovial fluid or 
synovial tissue T cells is comparable to T cells cultured in the presence of TNFα, 
IL-2 and IL-616,18. To be able to mimic the in vivo RA situation more closely, we 
studied whether the difference in FcγR expression between mf-1 and mf-2 would 
affect the interaction of mf with these so-called cytokine activated T cells (Tck). 
Tck induced significant levels of TNFα production by the mf-1, while they hardly 
induce any cytokine production by the more anti-inflammatory mf-2 (data not 
shown). More importantly, pre-stimulation of mf-1 with ICs dramatically reduced 
the TNFα release by these cells with more than 50% upon TCK stimulation (Figure 3). 
3
Figure 2
 Immune complexes can inhibit TLR2, 4 and 7/8 induced cytokine production in mf-1. Monocytes 
were cultured for 6 days into mf-1 and mf-2, after which they were harvested, washed and 
replated in 96 well plates. (A) 5x104 macrophages per well were stimulated with LPS (100 ng/
ml) in the presence or absence of ICs (50 µg/ml). After 24 hours, supernatants were collected 
and analyzed for TNFα and IL-10 levels. (B) Mf-1 were stimulated with P3C (5 µg/ml) or R848 
(2 µg/ml) in the presence or absence of ICs. After 24 hours, supernatants were collected and 
analyzed for TNFα and IL-10 levels. * p < 0.05 difference with and without IC.
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The inhibitory effect of immune complexes is mediated via FcγRIIb and the 
PI3K/AKT pathway, preventing IkBα degradation
To determine whether the high FcγRIIb expression on mf-1 was responsible for 
the inhibitory effect of ICs on TLR signaling in these cells, we used a blocking 
antibody against FcγRIIb. Blocking of FcγRIIb fully abrogated the inhibitory effect of 
ICs on TLR induced TNFα production (Figure 4A). In dendritic cells our group has 
previously shown that the PI3K/Akt pathway is involved in the crosstalk between 
FcγRIIb and TLR410. To test if this pathway is also involved in macrophages, we 
blocked PI3K with two different inhibitors before stimulation of mf-1 with ICs and 
LPS. The IC mediated inhibition of LPS induced TNFα production was clearly 
abrogated in the presence of either Wortmannin or LY294002, confirming the role 
of the PI3K pathway in FcγRIIb signaling in mf-1 (Figure 4B). The different effects 
of Wortmannin and LY294002 on TNF production upon TLR stimulation alone 
have been previously described and are caused by inhibitory effects of LY294002 
on mRNA synthesis unrelated to PI3K function19. 
To further understand the mechanism involved in FcγRIIb-TLR4 crosstalk, we 
used DCs from RA patients with high and low FcγRIIb expression as described 
in our previous report10. Using this system we were able to investigate potential 
differences in FcγRIIb expression without the interference of other FcγRs, since 
these were similar in the FcγRIIb high and the FcγRIIb low DCs. Western Blot 
analysis demonstrated that the presence of ICs during the stimulation by LPS 
Figure 3
IC can inhibit T cell mediated macrophage activation in mf-1. Monocytes were cultured for 6 
days into mf-1. From the same donor, CD4+ T cells were simultaneously cultured with IL-2 (25 
ng/ml), IL-6 (100 ng/ml) and TNFα (25 ng/ml). At day 6 the macrophages and cytokine activated 
T cells (Tck) were harvested, washed and cultured together in a ratio of 1:5  in the presence or 
absence of ICs for 24 hours before collecting the supernatant. Bars are mean and SEM from 
three independent experiments.
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resulted in markedly increased levels of phosphorylated SHIP in DChigh-FcγRIIb 
whereas the addition of ICs had no effect on phosphorylated SHIP in DClow-
FcγRIIb (Figure 4C). In addition, DChigh-FcγRIIb displayed slightly increased levels of 
phosphorylated Akt upon the addition of ICs and LPS demonstrating that the 
increased phosphorylation of SHIP was not inhibiting the activation of Akt. 
Furthermore, the degradation of IkBα induced by LPS was abrogated by the 
addition of ICs to DChigh-FcγRIIb, while IkBα degradation was unaffected in DClow-
FcγRIIb (Figure 4C). These results suggest that the activation of FcγRIIb inhibits the 
release of the p65 subunit of NFk-B upon the stimulation of DChigh-FcγRIIb with LPS 
culminating in a decreased release of pro-inflammatory cytokines.
3
Figure 4
TLR inhibition by IC binding to FcγRIIb is mediated via PI3K. Monocytes were cultured for 6 days 
into mf-1 after which they were harvested, washed and replated in 96 well plates. (A) Mf-1 were 
stimulated with P3C and IC with and without blockade of FcγRIIb by the specific 2B6 antibody 
(30 µg/ml). After 24 hours, supernatants were collected and TNFα levels were analyzed. Bars 
show a representative experiment which was replicated three times. (B) Mf-1 were treated for 
1 hour with PI3K inhibitor wortmannin (100 nM) or LY294002 (10 µM), prior to stimulation with 
LPS and ICs. After 24 hours, supernatants were collected and analyzed for TNFα levels. Bars 
are mean and SD of duplicate wells representative of 3 experiments. (C) DChigh-FcγRIIb derived 
from RA patients who had successfully discontinued anti-rheumatics and DClow-FcγRIIb obtained 
from RA patients on DMARDs were stimulated for 30 minutes with medium, ICs, LPS or with the 
combination of LPS and ICs before protein isolation for Western Blot. The protein content of all 
cell lysates was measured to ascertain equal loading. Analysis was done on the protein content 
of the DCs derived from the same RA patient on phosphorylated SHIP, phosphorylated AKT 
and IkBα. Blots are representative for the results from 3 RA patients in each group.                  
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Discussion 
Mf-1 and mf-2 have been extensively characterized in the past few years5,20. 
Here we focused on FcγR expression on these macrophage subsets with special 
emphasis on the balance between activating and inhibitory FcγR subtypes. 
The increased FcγRIII expression on mf-2 and similar levels of FcγRI between 
mf-1 and mf-2 are confirming previous reports (5,21). Specifically determining 
the expression of FcγRIIa and FcγRIIb provided novel information regarding 
the inhibitory versus activating balance of FcγRs on these macrophages. Mf-1 
have an increased expression of the inhibitory FcγRIIb, whereas mf-2 have a 
low expression of FcγRIIb and a high expression level of FcγRIIa (and FcγRIII), 
which most importantly, had clear consequences for multiple cell functions. TNFα 
production upon TLR and T cell mediated activation of mf-1 was inhibited by the 
presence of immune complexes, which was not the case for mf-2. Mf-2 were 
more efficient in immune complex uptake compared to  mf-1, seemingly in line 
with the increased expression of the activating FcγRs. 
So far, two studies have shown the capacity of FcγRIIb to inhibit TLR4 signaling10,11. 
Here, we demonstrate that the inhibitory effect of immune complex binding 
to FcγRIIb on TLR signaling is not specific for TLR4, but also applies to TLR2 
and TLR7/8 on mf-1 further substantiating the pivotal role of the FcγR balance 
in regulation of the immune response. Our group previously described the 
involvement of the PI3K/Akt pathway in FcγRIIb-TLR4 crosstalk in human DCs10. 
Here we show that the PI3K pathway is also critically involved in immune complex 
mediated suppression of mf-1 TLR responses. In addition, we demonstrated that 
FcγRIIb activation leads to a clear and immediate inhibition of LPS induced IkBα 
degradation, implicating direct inhibition of the TLR4 signaling pathway. This 
indicates that de novo production of inhibitory mediators such as prostaglandin 
E2, as was suggested by Zhang et al, might not play a crucial role in the inhibition 
of TLR responses by FcγRIIb (Zhang et al, 2009). It has been described that 
signaling via ITAM containing FcγRs can interfere with TLR signaling22; however 
in our study we clearly show a selective effect in cells that express high levels of 
the ITIM containing FcγRIIb while cells with low FcγRIIb expression do not show 
inhibition. Even more, the inhibitory effect was completely prevented by blocking 
immune complex binding to FcγRIIb using a specific blocking antibody. More 
research is needed to determine the exact mechanisms of IC interference with 
TLR signaling.
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In arthritis the pivotal role for FcγR has been often addressed. Two recent studies 
regarding macrophage responses to ICs in RA have been done on mf-2. They 
show that ICs formed by citrullinated fibrinogen and ACPA IgG can trigger 
activation of mf-2 mainly via FcγRIIa in combination with TLR423,24. However, it 
would be interesting to further investigate the response not only by mf-2 but 
also by mf-1 under these circumstances. Since the ratio of FcγRIIb /FcγRIIa is 
clearly different on mf-1, these cells might show a quite different response to 
these TLR ligand containing ICs. This might help to explain better why some 
patients have high and some have low disease activity despite the presence of 
these antibody complexes in both groups. Moreover, not many CD163 positive 
macrophages (mf-2) are found in RA synovial tissue and joint inflammation in 
RA is better correlated with mf-1 derived cytokines25. Mf-1 would thus be an 
interesting macrophage subtype to look at in the context of RA.  
T cell mediated macrophage activation seen in RA synovial tissue is dependent 
on cell-cell contact between memory CD4+CD45RO+ T cells and macrophages 
involving CD69, CD18 and CD49d18. Cytokine activated T cells resemble the 
functional properties of synovial T cells16 and we show that ICs can inhibit Tck 
induced TNFα production by mf-1. Thus far, no direct interactions are known 
between FcγR signaling and CD69, CD18 or CD49d signaling. Hence, our work 
justifies more research focused at deciphering potential mechanisms involved in 
FcγRIIb inhibition on T cell mediated macrophage activation. 
Next to regulating cell activation, FcγRs are also involved in endocytosis of 
small immune complexes and phagocytosis of IgG coated particles. The role for 
FcγRIIb in these two processes has been extensively investigated and appeared 
to be different in endocytosis compared to phagocytosis. While FcγRIIb has 
been demonstrated to inhibit phagocytosis induced via activating FcγRs, it does 
not inhibit endocytosis and it even actively participates in this process26. The 
increase of immune complex endocytosis in mf-2 is therefore most likely not 
a direct effect of lower FcγRIIb expression but merely an increased expression 
of the other FcγRs. Leidi et al. looked at phagocytosis of rituximab-coated B 
cells and found a two to three times increased rituximab-coated B cell uptake 
by mf-2 compared to mf-121. Although FcγRIIb is more likely to actively inhibit 
phagocytosis in these settings, the difference is quite similar to what we see 
with fluorescent immune complexes. These findings support an important role 
for FcγR bearing macrophages not only in disease pathogenesis, but also in the 
treatment of RA. 
FcγR expression is also closely linked to the pathogenesis of SLE and although 
macrophages were not originally considered a major contributor to SLE, recent 
studies have demonstrated a prominent role for macrophages in the pathogenesis 
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of SLE. In biopsies of kidney tissue from SLE patients activated macrophages are 
abundantly present, while they are not found in healthy kidneys27. Animal models 
demonstrate that mice with elevated numbers of circulating bone marrow-derived 
macrophage progenitor cells spontaneously develop an SLE phenotype, while 
the removal of macrophages prevents this28,29. Bergtold et al show that FcγRs 
on circulating hematopoietic cells are necessary for development of nephritis 
in (NZBxNZW)F1 mice. Even more, in the absence of activating FcγRs on 
hematopoietic cells, restoration of FcγR expression on monocytes/macrophages 
only is enough to induce development of glomerulonephritis in these mice30. In 
SLE there is also a strong interplay between the FcγR system and TLRs. The 
immune complexes present in SLE patients mostly consist of autoantibodies 
directed against DNA or RNA binding proteins, which can function as triggers 
for TLR7, 8 or 9. The findings that in both RA and SLE immune complexes are 
present which contain TLR ligands even further substantiates the importance 
of the interplay between these receptors. Further research would be necessary 
to determine the role of FcγR expression on multiple macrophage and dendritic 
cell subtypes regarding responses to these disease related immune complexes. 
Targeting FcγRIIb, especially on mf-1 since these are capable of reacting 
vigorously to TLR stimulation, might thus be a valuable new target in SLE.  
In conclusion, we demonstrate that mf-1 and mf-2 display a different FcγR balance 
with high FcγRIIb expression on mf-1 and high FcγRIIa and FcγRIII expression on 
mf-2. This results in quite different responses to immune complexes, with an 
inhibitory function for immune complexes in combination with TLRs or cytokine 
activated T cells in mf-1 but not in mf-2. These differences in FcγR balance might 
be used for therapeutic targeting of specific macrophage subsets covering a 
wide spectrum of clinical conditions depending on what type immune reaction 
is desired.
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Abstract
Macrophages perform dichotomous tasks; they are mediators of inflammation yet 
are capable of suppressing immune responses and mediate tissue homeostasis. 
The exact mechanisms by which macrophages shift their phenotype is unknown. 
We hypothesized that accumulation of macrophages during inflammation induces 
a shift from a pro-inflammatory to an anti-inflammatory phenotype, aimed at 
dampening the immune response. Pro-inflammatory type-1 (mf-1) but not anti-
inflammatory type-2 macrophages were highly sensitive to homotypic cell-cell 
contact. Cell-cell contact led to mf-1 producing dramatically lower levels of TNFα, 
IL-1b and IL-6, while the IL-10 production was increased upon stimulation with TLR 
ligands or M. tuberculosis. This phenotypical shift depended on Mac-1, signaling 
via p38, the activation of COX2 and the subsequent up regulation of SOCS-3. 
Correspondingly, the pro-inflammatory cytokine production by dendritic cells as 
well as their ability to induce T cell differentiation into pro-inflammatory Th1 cells 
was restricted by cell-cell contact. Concluding, Mac-1 activation during 
macrophage and dendritic cell differentiation serves as a natural inhibitory 
mechanism designed to dampen chronic inflammation. This places signaling via 
Mac-1 at a centre stage in the regulation of macrophage and dendritic cell 
behavior in a wide range of diseases including autoimmune diseases as well as 
cancer, elucidating novel therapeutic avenues.   
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Introduction
Upon entering tissues or sites of inflammation monocytes differentiate into 
effector cells, such as macrophages and dendritic cells (DCs), with distinct 
phenotypes and roles in inflammation and immunity. Through the production of a 
vast array of mediators the resulting subsets of immune cells are able to control 
the progression or resolution of inflammatory processes 1. Activated macrophages 
and their inflammatory products play a key role in innate immunity and in the 
pathogenesis of autoimmune and inflammatory diseases. GM-CSF and M-CSF 
are two cytokines important in the control of the differentiation and function of 
macrophage lineage populations in steady state as well as in inflammatory 
conditions 2-4. Human monocyte-derived macrophages have been divided in 
pro-inflammatory type-1, GM-CSF cultured macrophages (mf-1) and anti-inflam-
matory type 2, M-CSF cultured macrophages (mf-2). Mf-1 produce high levels of 
the pro-inflammatory cytokines TNFα, IL-6 and IL-1b whereas mf-2 mainly 
produce IL-10 and trophic factors such as TGFb and VEGF 1;5. With regard to 
inflammation M-CSF and GM-CSF seem to play different and even competing 
roles. 
GM-CSF has been depicted as a crucial mediator in various diseases 6;7. Whereas 
under steady-state conditions GM-CSF is barely present, locally at sites of 
inflammation GM-CSF is clearly detectable 8. GM-CSF is produced by a wide 
array of cells (e.g. monocytes, fibroblasts, endothelial cells) upon activation with 
various stimuli such as the pro-inflammatory cytokines IL-1b and TNFα 9-11. In its 
turn GM-CSF primes cells from the myeloid lineage for the release of pro-inflam-
matory cytokines and the differentiation of monocytes into proinflammatory 
macrophages 12. Neutralization of GM-CSF inhibited lipopolysaccharide (LPS) 
induced lung-inflammation and repressed the occurrence of inflammation and 
destruction in arthritis models while Rheumatoid Arthritis disease severity flares 
during GM-CSF treatment of neutropenia 13;13;14;14-17. Regarding its role in infection 
GM-CSF was found invaluable for the formation of granulomas and the 
containment of M. tuberculosis 18. In contrast to GM-CSF, M-CSF is constitutively 
expressed during steady state conditions and is found in high levels in serum. 
M-CSF is thought to regulate the development and maintenance of tissue 
macrophage subpopulations that have important trophic and scavenger roles in 
tissue morphogenesis and function 19. In addition to this, it has been suggested 
that mf-2 might have a role in the suppression of tissue inflammation due to their 
preferential secretion of IL-10, their suppressive effect on the development of IFNγ 
producing T cells and their ability to induce regulatory T cells 5;20.
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Macrophage activation needs to be tightly controlled to enable them to rapidly 
mount responses to inciting pathogens but avoid excessive tissue damage by an 
over activate immune reaction. The activation of macrophages occurs for a large 
part via the activation of Toll-like receptors (TLRs). TLRs are essential pattern 
recognition receptors of the immune system widely expressed on a large variety 
of cells 21;22. Most pathogens express several microbial TLR ligands and numerous 
host-derived TLR ligands are generated in inflamed or degenerated tissue 23-25. In 
this context, the study of the control of TLR responses is of high relevance in 
inflammatory/autoimmune diseases including inflammatory bowel disease, ath-
erosclerosis and rheumatoid arthritis as well as infectious diseases such as 
tuberculosis. While a panoply of negative regulators of TLR responses are known, 
such as IL-10 and many endogenous signaling inhibitors (e.g. Tumor Necrosis 
Factor Alpha-Induced Protein 3 (TNFAIP3 (A20)) and Suppressor Of Cytokine 
Signaling 1 and 3 (SOCS1, SOCS3)), the mechanisms that regulate these factors 
in macrophages and DCs infiltrating an inflammatory lesion are largely unknown 
26. Different receptors have been shown to be able to inhibit TLR responses in 
macrophages and DCs. FcγRIIb activation by immune complexes inhibits TLR4 
responses by monocyte-derived DCs while the activation of b2-integrins by 
fibrinogen inhibits TLR and interferon signalling in macrophages. Interestingly, 
b2-integrins are known to play a role in cell-cell contact and homotypic aggregation 
of macrophages. This suggests that they might play a role in modulating the pro-
inflammatory phenotype of macrophages without the presence of other external 
stimuli  27.  
Since monocytes that enter a site of inflammation become highly pro-inflammato-
ry macrophages under the influence of GM-CSF we hypothesized that there 
should be a negative feedback mechanism restricting the pro-inflammatory 
phenotype of mf-1 when at a site of inflammation sufficient amounts of 
macrophages have infiltrated. This might be an explanation for the ability of 
macrophages to perform such dichotomous tasks in an inflammatory microenvi-
ronment such as the clearance of pathogens and in time the removal of cellular 
debris and the restoration of tissue homeostasis. The current article supports this 
hypothesis by demonstrating that homotypic cell-cell contact via Mac-1 is a 
potent modulator of their pro-inflammatory phenotype. This phenotypical change, 
occurring when large and sufficient amounts of macrophages have infiltrated, 
appears to be aimed at dampening inflammation and restoring tissue integrity by 
the production of IL-10 and VEGF. This feedback mechanism was found to depend 
on signalling via the MAPK p38, the production of prostaglandins and the 
subsequent up regulation of SOCS-3. It thus appears that this pathway might play 
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an important regulatory role in shaping the extra-(and intra)cellular  environment 
during inflammation. In diseases like Rheumatoid Arthritis, in which there is a 
skewed balance towards proinflammatory cytokines, this pathway might be 
exploited to reduce the production of these, while in cancer, the inhibition of this 
pathway might reduce the presence of suppressive tumor-associated macro phages 
leading to better anti-tumor responses.   
Materials and Methods
Culture of monocyte-derived mf-1, mf-2 and DCs
PBMCs were isolated from heparinized venous blood of healthy volunteers by 
using density-gradient centrifugation over Ficoll-Paque (Amersham Bioscience). 
The local Medical Ethics Committee approved the study protocol. Monocytes 
were obtained using CD14 microbeads and MS columns (Miltenyi Biotec). Monocyte- 
derived mf-1, mf-2 or DCs were generated by culturing isolated monocytes in the 
presence of GM-CSF (800 U/ml; R&D), M-CSF (50 ng/ml, R&D) or IL-4 (500 U/ml; 
R&D) in combination with GM-CSF (800 U/ml), respectively, for 6 days. Mf/DCs 
were cultured in 6 or 24 wells plates (Corning) with the number of cells per well as 
indicated in 2 ml of culture medium (RPMI-1640 Dutch modification (Invitrogen Life 
Technologies) supplemented with 10% FCS, antibiotic-antimycotic and L-glutamine 
(Invitrogen Life Technologies). Fresh culture medium (1 ml) with the same 
supplements was added at day 3 after which the mf/DCs were harvested at day 6. 
Experiments performed in 12 well transwell plates (Corning) were carried out as 
follows: none or 0.5x106 mf-1 were cultured for 6 days in the insert with or without 
none, 0.5x106 or 2x106 cells in the bottom well and after 6 days of differentiation 
the mf-1 were harvested. In some experiments we collected the media at day 6 
from mf-1 cultured in a low (0.5x106 / well) and a high density (2x106 / well) and 
cultured newly isolated monocytes in this medium in a low concentration (0.5x106 
/ well) for 6 days with 1:1 fresh medium containing GM-CSF (800 U/ml). 
In blocking experiments antibodies against LFA-1 (clone L15, 5 mg/ml), Mac-1 
(clone Bear-1, 5 mg/ml) or CD18 (clone or L19, 5 mg/ml) or against IL-6 receptor (10 
mg/ml, R&D), IL-10 receptor (10 mg/ml, R&D) and TGFb (10 mg/ml, kindly gifted by 
Dr. R. Lafyatis, Boston University, Boston, USA)  were added to the wells at the 
beginning of the culture. As a control antibody a mouse IgG1 isotype control was 
used (10 mg/ml, eBioscience). 
In experiments with intracellular signalling molecule/enzyme inhibition the 
following inhibitors were added at the beginning of culture and at day three: p38 
(SB203850, 10 mM), Akt inhibitor X (0.5 mM), PI3K (Wortmannin, 10 nM), Erk 
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(PD98059, 2 mM ), JNK inhibitor III (0.1 mM, with appropriate negative control in 
same concentration), Syk inhibitor II (0.1 mM), PP2 (0.5 mM), COX-2 inhibitor I (10 
mM) (all purchased from Calbiochem).  
In experiments determining the role of IFNb and TGFb in the differentiation of 
mf-1, monocytes were cultured into mf-1 in 6 well plates in a density of 0.5x106 / 
well or 2x106 / well for 6 days with or without IFNb (5 ng/ml, Invitrogen) or TGFb 
(5 ng/ml, Invitrogen) and subsequently harvested and stimulated.
Phenotypical analysis
Using standardized flow cytometry protocols as described previously 28, 
phenotypical analysis of mf-1, mf-2 and monocyte-derived DCs was performed. 
Mf-1 and mf-2 were characterized for their expression of CD163, TLR2, TLR4, 
CD14, CD86 (all BD Biosciences) and MHC-II DR/DP (clone Q1514). DCs were 
characterized by staining with mAbs against human CD80 (BD Biosciences), 
CD86 and MHC-II DR/DP. Cells were analyzed for the proportion of positive cells 
and the mean fluorescence intensity relative to cells stained with the appropriate 
IgG isotypes. 
Phagocytosis assays 
Phagocytosis assays were performed with labeled beads (2 mM carboxylate 
modified FluoSpheres, nile red 535/575nm, Invitrogen) or with labeled Escherichia 
coli (K-12 strain, Alexa Fluor 488 BioParticles, Invitrogen). Macrophages were 
harvested at days six, washed and replated in 96 wells plates in a concentration 
of 5x104/100 ml/well. The labeled beads or E. coli were added to reach a final 
concentration of 10 beads per cell or 50 mg/ml. The macrophages were left on ice 
or were incubated at 37°C for 15, 30 or 60 minutes. Hereafter the cells were 
harvested and analyzed by flow cytometry for the amount of E. coli or beads 
bound and taken up.  
Stimulation of monocyte-derived mf-1, mf-2 and DCs 
Harvested day 6 monocyte-derived mf-1, mf-2 and DCs were washed, counted 
and plated in a concentration of 0.5x106 DCs/ml and transferred to 24 well (1 ml) 
or 96 well (100 ml) culture plates. Cells were then stimulated with TLR agonists for 
16-24 hours. For experiments in which mRNA levels were determined, TRIzol was 
added to monocyte-derived mf-1 immediately upon harvesting at day six. The 
concentration in which the TLR agonists were used was as follows: LPS (100 ng/
ml, E. coli 0111:B4, Sigma-Aldrich), R848 (2 mg/ml, InvivoGen), Pam3CSK4 (5 mg/
ml, EMC Microcollections). The used E. coli LPS was double-purified at our 
laboratory according to the two-step phenol-water extraction method to remove 
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any contaminating proteins resulting in purified LPS 29. The dessicated Myco - 
bacterium tuberculosis (H37Ra) was obtained from Difco and used in a concentration 
of 100 mg/ml. As a dectin-1 ligand Curdlan (50 mg/ml, Wako) was used. 
Autologous mixed leukocyte reaction (MLR)
At day 6 DC were harvested, washed and resuspended in a concentration of 
100x103 DC/ml in culture medium. 5x103 DC were replated in 96 round bottom 
well plates and were left unstimulated or were stimulated with R848 (2 mg/ml). 
CD4+ T cells from PBMCs from the same healthy controls were obtained by 
negative selection using microbeads and MS columns (Miltenyi Biotec). 
CD4+CD45RA+ naïve T cells were separated from the CD4+ population by the 
use of microbeads aimed at CD45RO. 50x103 CD4+CD45RA+ T cells were added 
to the DCs in 96 round bottom well plates. At day six of the MLR cells were 
incubated with PMA (50 ng/ml, Sigma) and Ionomycin (1 mg/ml, Sigma) 12 hours 
before the collection of supernatants. 
Measurement of cytokines in culture supernatants
Levels of IL-10, TNFα, IL-12p70, IL-6, IL-1b, VEGF, IFNγ, IL-13 and IL-17A were 
measured in the supernatants using commercially available kits (Bio-Rad) 
according to the manufacturer’s instructions. Cytokine levels were measured and 
analyzed with the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay 
was < 5 pg/ml for all cytokines measured. 
RNA isolation and real-time PCR 
Total RNA was extracted in 1 ml of TRIzol reagent. Quantitative real-time PCR was 
performed using the ABI/Prism 7000 sequence detection system (Applied 
Biosystems). All PCRs were performed with SYBR Green Master mix (Applied 
Biosystems), 10 ng cDNA, and a primer concentration of 300 nmol/L in a total 
volume of 20 ml. Quantification of the PCR signals was performed by comparing 
the cycle threshold value (Ct) of the gene of interest of each sample with the Ct 
values of the reference genes GAPDH (DCt) and were deployed as relative 
expression (2-DCt). Software package Primer Express Version 2.0 (Applied 
Biosystems) was used to identify appropriate primer sets for TLR2, TLR4, TLR7, 
TLR8, IFNb, IRF7, TGFb, SOCS1, SOCS3, TOLLIP, SIGIRR and A20. 
Statistical analysis 
Differences between groups were analyzed using the Mann-Whitney U test, when 
appropriate a paired students T test was used. P values less than 0.05 were 
considered significant.
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Results
Culture density affects the pro-inflammatory phenotype and function of 
mf-1 which resembles that of alternatively activated macrophages 
In order to test our hypothesis that the phenotype of macrophages is influenced 
by the accumulation of monocytes during inflammation, resulting in a shift towards 
macrophages aimed at suppressing inflammation and restoring tissue homeo - 
stasis, we started by culturing monocytes for 6 days in the presence of GM-CSF 
or M-CSF to yield type 1 and type 2 mf, respectively, and analysed their 
phenotype. According to the literature the expression of CD163, CD14 and TLR2 
was higher on mf-2 while the expression of CD86 and MHCII was higher on mf-1 30. 
The expression of TLR4 and Dectin-1 did not differ between the two mf subtypes 
(Figure 1A). Next we cultured the monocytes in increasing concentrations with 
either GM-CSF or M-CSF. On day 6 the macrophages were harvested, counted 
and replated in 96 wells plates at a fixed concentration of 5x104/100 ml per well 
before stimulation with LPS. In line with literature type 1 mf were capable of 
producing much higher levels of TNFα, IL-1b and IL-6 compared to type 2 mf. 
Strikingly, culturing monocytes into type 1 mf in high concentrations, mimicking 
an inflammatory setting with a high influx of monocytes/macrophages, resulted in 
a markedly reduced production of TNFα, IL-1b and IL-6 while the contrary was 
observed for IL-10 and VEGF after stimulation with LPS (Figure 1B). This effect 
was greatly dependent on cell concentration and not significantly present in type 
2 mf. Although there was a trend towards even less TNFα and IL-6 production by 
type 2 mf cultured at higher concentrations. As with TLR4 activation similar 
effects were noted upon stimulation with a TLR2 or TLR7/8 ligand as well as with 
M. tuberculosis (Figure 1C). These observations indicate that high cell density 
orchestrates a significant chance in cell behaviour that is unique for type I mf.
Based upon our early observations, we evaluated whether mf-1 cultured in higher 
densities would also gain an increased capacity to phagocytose particles 
mirroring so-called alternatively activated mf. Indeed, increasing cell densities in 
mf-1 boosted their ability to phagocytose labelled beads as well as labelled 
Escherichia coli considerably, whilst the expression of pivotal antigen uptake 
receptor was untouched (Figure 2A, B, C). As described for “alternatively 
activated” macrophages 31 mf-1 cultured at high density, in contrast to those 
cultured at a low density, responded vigorously to Dectin-1 ligation, a pattern 
recognition receptor important in the recognition of Candida spp. 32, by releasing 
massive amounts of TNFα and IL-6 as well as IL-10 (Figure 2D and data not shown). 
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The shift towards a more anti-inflammatory mf-1 is dependent on cell-cell 
contact controlled by the b2-integrin Mac-1
As with a higher amount of monocytes in a 6 wells plate, culturing mf-1 in 24 wells 
plates induced increased IL-10 secretion upon TLR stimulation, while the release 
of TNFα was decreased (Figure 3A and data not shown). This latter effect was 
not explained by higher amounts of GM-CSF since the addition of increasing 
amounts of GM-CSF had no effect (data not shown). Also, cell survival was 
unaffected underscoring the idea that this effect is solely explained by an 
increased cell density (Figure 3B). b2-integrins are known to play a role in cell-cell 
contact and homotypic aggregation of macrophages 27. Blocking of the common 
b chain CD18, which associates with CD11a, CD11b, CD11c and CD11d to form 
distinct functional heterodimers (LFA-1, Mac-1, gp150,95 and CD11d/CD18, 
respectively), during mf-1 differentiation under high-density circumstances 
completely prevented the aggregation of the monocytes/macrophages while 
blocking of CD11a alone did not (Figure 3C). Blocking of CD18 on high density 
cultured mf-1 led to macrophages producing significantly less IL-10 and more 
TNFα upon LPS stimulation. In contrast, blocking of CD11a did not affect the 
release of these cytokines (Figure 3D). Specific blockade of Mac-1 (CD11b/
CD18) resulted in the same effect as blockade of CD18 and was similar upon the 
stimulation with other TLR ligands and M. tuberculosis (Figure 3D and data not 
shown). When GM-CSF macrophages were cultured in low concentrations the 
addition of CD18 blocking antibodies did not have an effect on the release of IL-10 
or TNFα upon TLR4 activation (Figure 3E and data not shown). Blockade of 
CD18 or CD11b of high density mf-1 at the time of stimulation with LPS did not 
Figure 1
Differentiation of monocytes into type 1 mf in increasing concentrations shifts their 
behaviour from a highly pro-inflammatory to an anti-inflammatory phenotype. (A) Monocytes 
were cultured with GM-CSF or M-CSF after which they were analysed for their expression 
of various markers. Bars represent means and SEM of 5 independent experiments. * 
p<0.05 compared to type 1 mf. (B) Mf-1 and mf-2 were cultured in increasing 
concentrations, were harvested at day 6 and stimulated with LPS (100 ng/ml) for 24 hours 
before cytokine measurement of the supernatants. Results are presented as mean and SD 
of three replicates representative of three independent experiments. N.D. is not detectable. 
(C) Monocytes were cultured at a density of 0.5x106 (low density) or 2.0x106 (high density) 
per well in 6 wells plates for 6 days with GM-CSF in equal amounts of culture medium. At 
day 6 the mf-1 were harvested, washed, replated in 96 wells plates with 5x104 macrophages 
per well and stimulated with Pam3CSK4, R848 or desiccated M. Tuberculosis (C). 
Supernatants were collected after 24 hours and analysed for their TNFα and IL-10 content. 
Data are presented as means and SEM of four independent experiments. * p<0.05 
compared to mf-1 cultured in low density.
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influence their release of IL-10, TNFα and IL-6 (data not shown). Taken together, 
our observations show the pivotal role of Mac-1 in the control of cell function in 
inflammatory conditions where high cell densities are likely.
4
Figure 2
Type 1 macrophages cultured at high density display characteristics of alternatively 
activated macrophages. Monocytes were cultured in a low (0.5x106 per well in 6 wells 
plates) or a high density (2x106 per well in 6 wells plates) into Mf-1 after which they were 
analysed for their ability to phagocytose labelled beads (A) or labelled E. coli (B) by 
flowcytometry. Numbers are percentage positive cells (A) and mean fluorescence intensity 
(B). Data are representative for three independent experiments. (C) Mf-1 and mf-2 were 
cultured at low and high density and the expression of CD14, TLR2 and TLR4 was 
determined at day 6. Bars are mean and SEM of four independent experiments (D) Mf-1 
were cultured at low and high density for 6 days and subsequently stimulated with curdlan 
for 24 hours. Levels of TNFα and IL-6 were measured in the supernatants. Bars are mean 
and SEM of four independent experiments, * p<0.05 compared to low density mf-1.
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Figure 3
Blocking CD18 inhibits the differentiation of mf-1 towards more anti-inflammatory 
macrophages. (A) 0.5x106 monocytes were cultured into mf-1 in either a 6 wells plate well 
(low density) or a 24 wells plate well (high density) and subsequently stimulated with LPS, 
Pam3CSK4 or R848. After 24 hours the supernatants were analysed for their IL-10 content. 
Bars represent mean and SEM of 5 independent experiments. * p<0.05 (B) Monocytes 
were cultured into mf-1 with 0.5x106 in a 6 or a 24 wells plate or with 2x106 in a 6 wells plate. 
At day 6 the mf-1 were harvested and counted. The amount of counted cells was related to 
the amount of monocytes that were added to the wells at the start of the culture (% survival). 
Data are presented as means and SEM of three independent experiments. (C) Monocytes 
were cultured into mf-1 at high density in the presence of blocking antibodies against 
CD18 or CD11a or mouse IgG1 control antibodies (all 5 mg/ml). At day 3 photographs were 
taken at an original magnification of 100x. (D) Low density mf-1 (low), high density mf-1 
(high) and high density mf-1 cultured in the presence of an isotype control antibody or 
blocking antibodies against CD18, CD11b or CD11a were stimulated with LPS for 24 hours. 
The IL-10 and TNFα levels were measured in the supernatants. Bars are mean and SD of 
triplicate wells representative of three experiments. (E) 0.5x106 monocytes were cultured 
into mf-1 in a 6 wells plate (low density) or a 24 wells plate (high density) in the presence 
of blocking antibodies against CD18, a control antibody or medium.  At day 6 the 
macrophages were stimulated with LPS after which the IL-10 levels in the supernatants 
were determined. Bars are mean and SD of triplicate wells representative of three 
independent experiments. 
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The shift towards a more anti-inflammatory mf-1 is mediated by a soluble 
factor
Fuelled by our observations we sought evidence for the possibility that these 
effects were caused by soluble factors. In this light it was interesting to take note 
that increasing the concentration of macrophages in the bottom well of a trans-well 
system induced a more anti-inflammatory phenotype of the macrophages in the 
upper well (Figure 4A). In addition, culturing mf-1 at a low concentration in day 6 
medium from mf-1 cultured at a high concentration produced markedly elevated 
levels of IL-10 and decreased levels of TNFα compared to macrophages cultured 
in medium from mf-1 cultured at low density (data not shown). We set to 
determine whether cytokines known to be able to dampen the pro-inflammatory 
phenotype of myeloid cells would play a role in the b2 integrin mediated 
phenotypical shift. We determined the basal mRNA expression of TGFb and IFNb 
as well as the basal secretion of IL-6 and IL-10, since these have been implicated 
in the induction of anti-inflammatory macrophage cell types and found that the 
level of TGFb was up regulated while IFNb and IRF7 expression was unaffected 
(Figure 4B). Mf-1 were found to spontaneously produce slightly higher levels of 
IL-6 when cultured in high concentrations while IL-10 was not produced (data not 
shown). We determined whether the inhibition of IL-6 or TGFb would mimic the 
effect of blocking CD18. Blocking IL-6 receptor or neutralising TGFb during the 
differentiation of mf-1 had no significant effect on the production of IL-10 so 
neither appeared to be involved in the effect caused by b2 integrin activation via 
cell-cell contact (Figure 4C). In contrast, specific and dose-dependent inhibition 
of COX2 led to the complete reversal of the Mac-1 activation induced anti-inflam-
matory phenotype of mf-1 cultured at high density (Figure 4D, E). These 
observations thus identified prostaglandins as key mediators orchestrating the 
anti-inflammatory mf-1 phenotype upon increasing cell densities.  
Signalling through MAPK p38 underlies the shift towards a more anti- 
inflammatory mf-1 phenotype and increases the expression of SOCS-3 
To further delineate the signalling pathways involved in the Mac-1 mediated induction 
of an anti-inflammatory phenotype in mf-1 we cultured mf-1 at a high density in 
the presence of various inhibitors of intracellular signalling molecules. In addition 
to COX2 the inhibition of p38 MAPkinase resulted in a reduction of the release of 
IL-10 to levels produced by mf-1 cultured at low density (Figure 5A). To determine 
whether this effect was not due to a direct inhibitory effect on TLR signalling we 
measured the release of TNFα. The release of TNFα was increased upon TLR 
stimulation when signalling via p38 was blocked during culture (Figure 5B), 
stressing the role played by p38 in Mac-1 signalling as was previously proposed 33.    
4
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Figure 4
The anti-inflammatory mf-1 phenotype induced by cell-cell contact is carried over by a 
soluble factor and can be halted by inhibiting COX2. (A) Monocytes were cultured in a 
transwell system with no cells (none / ), 0.5x106 (low / ) or 2x106 (high / ) cells in the lower 
well and no cells ( / none) or 0.5x106 ( / low) in the insert. At day 6 the mf-1 were stimulated 
with LPS and after 24 hours the supernatants were analysed for their IL-10 (left panel) or 
TNFα (right panel) content. (B) Mf-1 cultured in a low or high density were analysed for 
their mRNA expression of TGFb, IFNb, IRF7 by real-time PCR. Expression is relative to 
GAPDH expression. Data are presented as the mean ± SEM of three independent 
experiments. * p<0.05 compared to mf-1 cultured in low density. (C) Mf-1 were cultured at 
high density in the presence of medium, control antibody, a TGFb neutralising antibody or 
blocking antibodies against IL-6 receptor or CD18. After their differentiation they were 
stimulated with LPS and the released IL-10 levels were measured. Bars are mean and SD of 
triplicate wells representative of three experiments. Low density mf-1 and high density 
mf-1 were cultured either in the absence or presence of increasing amounts of COX2 
inhibitor after which they were harvested and stimulated with LPS for 24 hours before 
collection of the supernatants. The levels of IL-10 (D) and TNFα (E) were measured in the 
supernatants. Bars are mean and SD of duplicate wells representative of three experiments. 
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Next we evaluated the expression of intracellular inhibitors of TLR signalling 
pathways SOCS-1, SOCS-3, TOLLIP, SIGIRR and A20 and observed that SOCS3 
was up regulated significantly when mf-1 were cultured in high concentrations, 
an effect which was modulated by Mac-1 signalling (Figure 5C, D). Moreover, 
functional p38 and COX2 were necessary for the induction of SOCS3 (Figure 5E). 
These results clarify a new potent anti-inflammatory feedback mechanism in the 
innate immune response. Accumulation of macrophages in inflammation appears 
to invoke an anti-inflammatory phenotype in macrophages through cell-cell 
contact by Mac-1, leading to signalling via p38, thereby inducing the production 
of COX2 dependent prostaglandins which modulate macrophage phenotype by 
increasing the expression of SOCS3 and enabling the marked production of IL-10. 
The inflammatory phenotype of monocyte-derived dendritic cells is strictly 
controlled by cell-cell contact
We next sought evidence for a similar role for integrin biology in the regulation of 
monocyte-derived DC behaviour. As with mf-1, DCs cultured in high concentrations 
produced increased level of IL-10 and decreased levels of IL-12p70 and TNFα 
(Figure 6A, B and C). No significant differences were found in the expression 
levels of MHCII, CD80 or CD86 on DCs cultured at a low or high density on a 
basal level or upon stimulation with R848 (data not shown). Since DCs are the 
professional antigen-presenting cells of the immune system we wondered whether 
the induction of T cell proliferation and differentiation would also be affected when 
DCs were cultured in higher concentrations. DCs cultured at low density induced 
a polarization of autologous naive T cells into T cells capable of releasing strikingly 
higher levels of IFNγ and they induced an increased proliferation of  autologous 
naive T cells (Figure 6D and 6E). This demonstrates that the phenotype of DCs 
shifts towards a phenotype less capable of inducing strong Th1 responses when 
differentiated in the close presence of homotypic neigh bouring cells.   
TGFb plays a restricting role in the development of a more anti-inflammatory 
mf-1 phenotype
Since TGFb is found in high levels during chronic inflammatory processes we 
wondered what the effect of TGFb would be on the differentiation of high and low 
density mf-1. We found that TGFb had no effect on the differentiation of low 
density mf-1. However, when mf-1 were cultured at high concentrations in the 
presence of TGFb, increased TNFα production but suppressed IL-10 secretion upon 
TLR stimulation was observed, as well as decreased basal SOCS-3 expression 
(Figure 7A and B). In line with the increased TNFα (and IL-10) production upon 
Dectin-1 stimulation when mf-1 were cultured at high cellular numbers, addition 
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Figure 5
The anti-inflammatory mf-1 phenotype induced by Mac-1 activation is dependent on the 
MAPkinase p38. (A) Mf-1 were cultured in a low concentration (low) or a high concentration 
(high) or at a high concentration in the presence of inhibitors for p38, COX2, SRC family 
kinases, Syk, Erk, Akt, PI3K or JNK. At day 6 the resulting mf-1 were harvested and 
stimulated with LPS. After 24 hours the supernatants were harvested and analyzed for their 
IL-10 content. Data are mean and SD of duplicate wells. Data are representative of 3 
independent experiments. (B) Similar experiments as described for panel A were performed 
with low and high density mf-1 and high density mf-1 in the presence of inhibitors for p38 
or COX2. The production of TNFα after 24 hours of stimulation with LPS was determined. 
Data are mean of duplicate wells and SD. Data are representative of 3 independent 
experiments. (C) Mf-1 cultured in a low or high density were analysed for their mRNA 
expression of SOCS-1, SOCS-3, SIGIRR, TOLLIP and A20. Expression is relative to GAPDH 
expression (x100).  Data are presented as the mean ± SEM of four independent experiments. 
* p<0.05 compared to mf-1 cultured in low density. (D) Mf-1 cultured at high density in the 
presence of an isotype control antibody (control) or blocking antibodies against CD18 or 
CD11b were analysed for their mRNA expression of SOCS-3. Expression is relative to 
GAPDH expression (x100). Data are presented as mean ± SD of triplicate wells. Data are 
representative of 3 independent experiments. (E) Mf-1 cultured at low density or high 
density in the absence or presence of an inhibitor for COX2 or p38 were analysed for their 
mRNA expression of SOCS-3. Expression is relative to GAPDH expression (x100). Data are 
presented as mean ± SD of duplicate wells. Data are representative of 3 independent 
experiments. 
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of TGFb prevented this increased response and reduced it to levels found with 
mf-1 cultured at low densities (Figure 7C and data not shown). 
 This shows that TGFb can have clear proinflammatory effects on mf-1 increasing 
their responsiveness towards TLR ligands. This indicates that the presence of 
TGFb during chronic inflammation might support the continuation of inflammatory 
processes.    
4
Figure 6
DCs are subject to down modulation of their pro-inflammatory phenotype when cultured at 
a higher density. DCs cultured in 6 wells plates with either 0.5x106 (low density) or 2x106 
(high density) cells per well were harvested at days 6 and stimulated with R848 for 24 
hours. The levels of IL-10 (A), IL-12p70 (B) and TNFα (C) in the supernatants were measured 
by Bio-plex technology. Data are presented as means and SEM of 5 independent 
experiments. DCs cultured in 6 wells plates with either 0.5x106 (low density) or 2x106 cells 
(high density) per well were harvested at days 6, washed and added 1:10 to autologous 
CD4+CD45RA+ T cells. R848 was added to the wells in a concentration of 2 mg/ml and the 
DCs and T cells were subsequently cultured for 6 days before stimulation with PMA and 
Ionomycin (D) or for 3 days before the addition of EDU to determine proliferation rates (E). 
After 24 hours the supernatants were harvested and the levels of IFNγ, IL-13, IL-17 and TNFα 
were measured or the T cells were harvested and analysed by flowcytometry for their 
incorporation of EDU. Data are presented as means and SEM of 4 independent experiments. 
* p<0.05 compared to DCs cultured in low density. 
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Discussion
In an inflammatory lesion monocytes are one of the first cells to appear. The 
infiltrating monocytes differentiate into macrophages, a phenomenon that is 
under strict control of factors produced locally upon activation by pathogen or 
damage associated molecular patterns or inflammatory mediators. The resulting 
macrophages are highly capable of producing proinflammatory cytokines when 
Figure 7
The Mac-1 mediated anti-inflammatory mf-1 phenotype is inhibited by TGFb. 0.5x106 (low 
density) or 2x106 (high density) monocytes were cultured in a 6 well plate into mf-1, in 
addition monocytes were cultured in a concentration of 2x106/well with GM-CSF in the 
presence of TGFb (5 ng/ml) for 6 days. At day 6 the mf-1 were harvested, washed and 
stimulated with LPS, R848 (A) or curdlan (C) before the measurement of IL-10 and TNFα 
Bars are mean of duplicate wells and SD. Data are representative of four independent 
experiments. (B) In similar experiments the expression of SOCS3 was determined by 
RT-PCR. Expression is relative to GAPDH expression (x100). Data are representative of 
three independent experiments.
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they encounter pro-inflammatory stimuli. The invoked immune response will lead 
to tissue damage culminating in the release of endogenous ligands recognized 
by TLRs, which in turn will activate macrophages and DCs to produce high levels 
of proinflammatory cytokines starting a vicious cycle of damage and inflammatory 
mediator release. So far,  no clear mechanism explains the restoration of tolerance 
once a vicious cycle has been incited. This manuscript provides compelling 
evidence for a model in which cell-cell contact caused by the influx of inflammatory 
cells itself is able to dampen this self-perpetuating loop. Cell-cell contact potently 
reduces the release of pro-inflammatory cytokines by type 1 macrophages while 
increasing the release of the anti-inflammatory cytokine IL-10. This change in 
phenotype was dependent on signalling through the b2 integrin Mac-1 resulting in 
the up regulation of SOCS3. The increased release of IL-10 and up regulated 
expression of SOCS3 was dependent on the MAPkinase p38 and COX2. Our 
results extend on findings described in a recent study in which b2 integrin 
stimulation with fibrinogen interfered with TLR signalling resulting in increased 
IL-10 and decreased TNF and IL-6 mRNA levels 33. We excluded IL-6, IL-10 and 
IFNb as playing prominent roles in the described phenomenon. In contrast, TGFb 
which is highly present in many chronic inflammatory conditions can inhibit the 
anti-inflammatory phenotype induced by b2 integrin mediated cell-cell contact, 
thereby possibly contributing to chronic inflammation. These findings highlight 
the importance of Mac-1 in the control of the inflammatory response by, among 
others, enabling mf-1 to produce high levels of IL-10, thereby preventing 
exaggerated tissue damage and restoring immune homeostasis and possibly 
even prevent tolerance breakthrough.   
Upon infection, deficiencies in IL-10 production were shown to lead to exacerbated 
tissue damage and increased mortality resulting from excessive immune 
activation 34. Nevertheless aberrant IL-10 production can inhibit the proinflamma-
tory response to pathogens to the extent that they escape immune control 35. It 
was recently demonstrated that overexpression of IL-10 in CD68+ mf highly 
increases the susceptibility of mice to M. tuberculosis 36. The production of IL-10 
by macrophages thus needs to be tightly controlled explaining why its production 
is only initiated in mf-1 later in the inflammatory response when substantial 
numbers have infiltrated. Earlier production of ample amounts of IL-10 would most 
likely undermine the capability of the immune system to contain the inciting 
pathogen. An insufficient production of IL-10, on the other hand, allows the initial 
proinflammatory mechanisms to culminate, leading to massive immunopatholo-
gy. Next to infections the capability of macrophages to produce IL-10 appears 
important in the suppression of atherosclerosis and arthritis 37;38. In contrast the 
4
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presence of macrophages in tumors which produce IL-10 is correlated with 
progression of tumor growth and metastasis 39. The regulation of the production 
of IL-10 by macrophages and DCs is thus a crucial point in immunity in various 
diseases and appears to be regulated by Mac-1 signalling.
 
b2 integrins are heterodimers consisting of the common b chain CD18 and either 
CD11a, CD11b, CD11c or CD11d forming LFA-1, Mac-1/CR3, p150,95/CR4 or 
CD11d/CD18, respectively. b2 integrins mediate adhesion of leucocytes to the 
endothelium facilitating the extravasation of immune cells into tissues 40. Next to 
this b2 integrins have been shown to be important in monocyte/macrophage 
homotypic aggregation and their formation into multinucleated cells such as 
osteoclasts and foreign body giant cells 27. Recently, a new role for b2 integrins in 
the resolution of inflammation has been described. It was found that CD18 
hypomorph mice infected with Borrelia burgdorferi developed an aggravated 
carditis and demonstrated a tendency towards an increased arthritis severity. 
This significant increase in carditis disease severity was not due to an increased 
B. burgdorferi burden but was marked by a massively increased infiltration of 
macrophages into the heart and an increased production of MCP-1 41. It thus 
appears that in mice with low levels of b2 integrins the resolution phase of the 
immune response, by shifting the phenotype of the infiltrating macrophages into 
a more anti-inflammatory one, is most likely not induced to a sufficient extent 
resulting in the observed aggravated innate immune response. The intricate 
involvement of b2 integrins in the immune system was also demonstrated by the 
increased severity of a psoriasis model in CD18 hypomorph mice previously 
demonstrated to crucially depend on activated macrophages 42. The diminished 
expression of CD18 impaired the contact between regulatory T cells and DCs and 
the regulatory T cells additionally displayed decreased levels of membrane bound 
TGFb resulting in dysfunctional regulatory T cells 43. The increased disease 
severity could only partly be restored by adoptive transfer of wild type regulatory 
T cells indicating that other mechanisms might play additional roles in the 
increased severity, such as the mechanism described in the current manuscript. 
In cancer CD18 positive macrophages have been shown to promote metastasis 
and outgrowth of breast cancer and tumors in CD18 hypomorphic mice are much 
more sensitive to radiotherapy 44;45. Together with the data demonstrating that 
COX2 inhibition increases the effect of immunotherapy and reduces the presence 
of tumor-associated suppressive macrophages 46 these findings underscore the 
importance of the described inhibitory pathway and the therapeutic possibilities 
of abrogating this pathway in cancer. 
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Furthermore, a recent report demonstrated that the phenotype of wound 
macrophages changes over time. In the beginning the macrophages have a pro-
inflammatory phenotype which develops into a more anti-inflammatory 
macrophage phenotype after 7 days when the amount of monocytes in the wound 
has increased 40 fold. This was independent of both IL-4 or IL-13, but might be 
fully dependent on b2 mediated cell-cell contact 47. We thus established a new 
mechanism independent of the known polarizing agents GM-CSF and M-CSF by 
which the phenotype of macrophages is regulated likely playing a major role in 
immune regulation.
TGFb appears to have dual roles in inflammation. While its anti-inflammatory 
functions are apparent from literature 48, its pro-inflammatory effects are less 
clear although it was demonstrated that the inhibition of ALK5 led to a decreased 
production of TNFα by type 1 macrophages 49. This is in line with our results 
showing that TGFb can prevent the phenotype shift towards more anti-inflamma-
tory type 1 macrophages when cultured at high density, resulting in high levels of 
TNFα and IL-6 after stimulation with TLR ligands. Thereby the presence of TGFb 
could prevent the dampening of inflammation when large amounts of monocytes 
have entered a site of inflammation, promoting chronic inflammation. Animal 
models of arthritis also support this dual role of TGFb, since systemic administration 
of TGFb to mice prevents collagen induced arthritis, while its local administration 
to the joints induces synovitis and aggravates disease 50. The beneficial systemic 
effects of TGFb are most likely caused by its effects on T cell tolerance, while the 
detrimental effects of local TGFb administration could at least partially be 
explained by preventing the anti-inflammatory phenotype shift of macrophages at 
the site of inflammation. 
Altogether, we demonstrate that the pro-inflammatory phenotype of mf-1 is tightly 
controlled by cell-cell contact via the b2 integrin Mac-1. This phenotypic shift was 
dependent on p38 and COX2 and was transferable by a soluble factor, implicating 
the release of prostaglandins as major players. This feedback mechanism 
ultimately results in the resolution of inflammation and the restoration of tissue 
homeostasis. Our observations suggest an important role for the inhibition of 
TGFb at the site of inflammation in the treatment in chronic inflammatory 
conditions. Local efforts to restore the naturally existing capacity to limit 
inflammatory responses would be an important step towards patient tailored 
medicine.
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Abstract
Rheumatoid arthritis (RA) has been associated with an increased risk of infections, 
but the underlying pathways have not yet been identified. Toll-like receptors (TLR) 
probably play a role in synovial inflammation and may also contribute to the 
understanding of the role of infections in RA. The objective of this study was to 
investigate if the synovial expression of TLR3 and TLR7 in RA correlates with that 
of inflammatory cytokines, and to assess whether this has functional consequences 
for local cytokine production and to study potential links between the TLR3/7 axis 
and TLR4 in RA synovium. Immunohistochemistry was used to study the 
expression of TLR3, TLR7, interferon α (IFNα), tumour necrosis factor α (TNFα) 
and interleukins IL1b, IL12, IL17 and IL18 in RA synovium obtained by arthroscopy 
from 34 patients with RA. Monocytes, monocyte-derived dendritic cells (MoDCs) 
and RA synovial fibroblasts were stimulated via TLR3 (poly-IC) and TLR7 
(loxorubin), after which IL1b, IL6 and TNFα were measured by Luminex bead array 
technology. Following preincubation with IFNα, IL1b and IL18, TLR3 and TLR7 
mRNA expression was assessed using real-time PCR. Cytokine production after 
preincubation with IFNα and subsequent TLR stimulation was measured. Synovial 
TLR3/7 expression was co-expressed with IFNα, IL1b and IL18, but not with TNFα, 
IL12 and IL17. Stimulation of TLR3/TLR7 on monocytes, MoDCs or synovial 
fibroblasts led to secretion of type I IFN but no biologically active IL1b or IL18 
could be detected. Type I IFNa increased TLR3/7 mRNA expression whereas IL1b 
and IL18 did not. In spite of the fact that the mRNA level of TLR4 remained 
unchanged, IFNa enhanced the response to TLR4 agonists, a phenomenon that 
was clearly more marked in patients with RA. 
Type I interferons are highly co-expressed with TLR3/TLR7 in RA synovium. They 
enhance TLR3/TLR7-mediated cytokine production and also TLR4-mediated 
responses.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune disease which is characterised 
by chronic inflammation of the synovial joints. Although the cause of RA is still 
unidentified, a role for both genetic and environmental factors has repeatedly 
been advocated. As environmental factors, it has been suggested that bacteria 
and/or viruses may trigger autoimmunity in the host, and evidence for the presence 
of at least some viruses – including cytomegalovirus,1,2 Epstein-Barr virus3 and 
parvovirus B194 – has been demonstrated. In line with these observations, it has 
been shown that dsRNA, which is a common feature of viruses, exerts clear 
arthrogenic properties,5 further substantiating the potential role of viruses in RA. 
Although recent studies have indicated a type I interferon (IFN) signature in the 
RA synovium, the underlying pathway for the role of type I IFN remains unknown.6
Accumulating evidence points to a role for the Toll-like receptor (TLR) family in the 
type I IFN-mediated response. TLR belong to the family of pattern recognition 
receptors, which were first identified to recognise microbial components known 
as pathogen-associated patterns. TLR are constitutively expressed by numerous 
immune cells and designed to detect and eliminate invading pathogens by 
activation of both innate as well as adaptive immune responses. TLR3/7 and 9 
serve as receptors for viral nucleic acids, by which means they have a key role in 
antiviral immunity by inducing type I IFN production.7,8,9 In contrast, TLR2 and 
TLR4 elicit immune responses on binding of antigens from bacteria and 
host-derived molecules (so-called endogenous ligands or alarmins), leading to 
the production of inflammatory mediators including tumour necrosis factor α 
(TNFα) and interleukin 1b (IL1b).10,11,12,13 The increased expression of various TLR 
subtypes in the synovial tissue of patients with RA further substantiates the 
potential role of TLR in RA. 
Recently, the role of TLR in arthritis was highlighted in experimental models.14,15 
Although TLR and its ligands are abundant in the synovial compartment of 
patients with RA, it is hard to conceive that any trigger of a single TLR subtype 
would be sufficient to convert tolerance to immunity. If this is the case, then 
autoimmunity should regularly follow from infections. It is therefore more likely 
that more then one TLR ligand is needed for the initiation of a chronic and 
persisting inflammatory response as is seen in RA. Accordingly, recent research 
suggested that simultaneous or sequential triggering of different pathways is 
perhaps needed to set off autoimmunity.16 It is thus tantalising to speculate that 
simultaneous triggering of different TLR pathways might initiate a series of events 
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that form the basis of the breakthrough of tolerance. Previous evidence from our 
group demonstrated a high expression of TLR2, 3, 4 and 7 in the synovial tissue 
from patients with RA and a synergistic effect with regard to cytokine production 
after stimulation of dendritic cells (DC) with two (or more) TLR subtypes. Here we 
sought evidence for a potential link between TLR2/4 and TLR3/7 pathways in RA 
inflammation. 
Our study showed that IL1b, IL18 and IFNα (the classic type I interferon) are 
co-expressed with TLR3/7 in RA synovium. In addition, we provide evidence that 
type I IFN increases the expression of TLR3 and TLR7 which, on stimulation, lead 
to an increased production of cytokines. Interestingly, type I IFN also induced a 
clear augmentation of TLR4-mediated production of pro-inflammatory mediators 
including TNFα, IL1b and IL18, which was clearly more potent in RA. These data 
show that TLR3/7-mediated stimulation indirectly lowers the threshold for 
TLR4-mediated immune activation, setting the stage for the vicious circle of 
inflammation observed in RA. Together, these observations underscore the 
potential role of viruses in RA and provide a rationale for interference with TLR 
signalling in this condition. 
Methods
Study population
For immunohistochemistry, synovial biopsy specimens were obtained from the 
medial and lateral suprapatellar pouch of 24 patients with RA by small needle 
arthroscopy. A mean of 30 samples were obtained at each biopsy. For in vitro 
experiments, heparinised venous blood was collected from 10 patients with RA, 11 
healthy volunteers and 3 patients with systemic sclerosis (SSc) of a diffuse 
cutaneous subtype. All the patients with RA were attending the Department of 
Rheumatology of the Radboud University Nijmegen Medical Centre; they fulfilled 
the American College of Rheumatology criteria for RA, gave informed consent and 
had a disease activity score (DAS) of >3.2, reflecting moderate to high disease 
activity.17 All the patients with SSc fulfilled the preliminary criteria of the American 
College of Rheumatology for SSc.18 SSc was classified as either a limited subtype 
or a diffuse subtype according to the extent of skin involved, as proposed by Leroy 
et al.19 Patients using high-dose prednisolone (>10 mg/day) and those receiving 
intra-articular steroids or anti-cytokine therapies (anti-TNFα and/or IL1Ra) were 
excluded from the study. For the arthroscopy, patients who had a history of 
bleeding, infectious disorders or were currently pregnant or lactating were excluded. 
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Immunohistochemical staining of synovial biopsies
Tissue samples were immediately fixed with 4% formaldehyde and embedded in 
paraffin. Staining of IL1b, IL12, IL17, IL18 and TNFα was performed as described 
previously.20,21,22 For TLR3, TLR7 and IFNα staining, sections were incubated for 
60 min with monoclonal antibodies against human TLR3 (T-17), human TLR7 
(V-20) or IFNα (FL-198), which were all obtained from Santa Cruz, California, USA. 
After this, endogenous peroxidase was blocked with 3% hydrogen peroxide in 
methanol for 15 min and subsequently the appropriate biotinylated secondary 
antibody (mouse anti-goat (Jackson ImmunoResearch, West Grove, Pennsylvania, 
USA)/swine anti-rabbit (DakoCytomation, Glostrup, Denmark)) was incubated for 
30 min. For TLR3 and TLR7 staining, Vectastain ABC (Vector Laboratories, Burlingame, 
California, USA) reagent was incubated for 30 min, developed with diaminobenzidine 
(Sigma, St Louis, Missouri, USA) and counterstained with haematoxylin for 30 s. 
For IFNα staining, sections were incubated with streptavidin peroxidase 
(DakoCytomation), developed with diaminobenzidine and counterstained with 
haematoxylin for 30 s. Staining was semi-quantitatively scored on a 5-point scale 
(scores 0–4) at 200× magnification where a score of 0 represents no or minimal 
staining, 1 represents 10–20% positive cells, 2 represents 30–40%, 3 represents 
50–60% and 4 represents staining of >60% of the cells. 
Isolation and culturing of monocytes and monocyte-derived dendritic cells 
(MoDCs)
Peripheral blood mononuclear cells (PBMC) were isolated from heparinised 
venous blood using density gradient centrifugation over Ficoll-Paque (Amersham 
Biosciences, Roosendaal, The Netherlands). Low-density cells were collected 
and washed with citrated phosphate buffered saline/5% fetal calf serum (FCS). 
For monocytes, the CD14+ cell fraction was isolated using MACS cell separation 
according to the manufacturer’s instructions. Briefly, PBMC were incubated with 
anti-human CD14 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany) for 
30 min, cells washed and the CD14+ fraction was separated from the CD14− 
fraction over a MACS MS separation column (Miltenyi Biotec). The CD14+ cell 
fraction was eluted from the column, washed again and resuspended in a 
concentration of 0.5×106 cells/ml in RPMI 1640 Dutch modification (Invitrogen 
Corporation, Carlsbad, California, USA) supplemented with 10% FCS, plated in 
6-well plates and cultured overnight at 37°C and 5% carbon dioxide. 
For MoDCs, PBMC were allowed to adhere for 1 h at 37°C in RPMI 1640 Dutch 
modification supplemented with 2% human serum (PAA Laboratories, Pasching, 
Austria) in 25 cm2 cell culture flasks (Corning, New York, USA). Adherent 
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monocytes were cultured in RPMI-1640 Dutch modification supplemented with 
10% FCS and antibiotic-antimycotic (Life Technologies) in the presence of IL4 
(500 U/ml, Schering-Plough, Amstelveen, The Netherlands) and granulocyte-
macrophage colony stimulating factor (800 U/ml, Schering-Plough) for 6 days. 
Fresh culture medium with the same supplements was added on day 3. Immature 
DCs were harvested at day 6, resuspended in fresh cytokine-containing culture 
medium, transferred to 6-well culture plates (Corning) in a concentration of 
0.5×106 cells/ml and cultured for 16 h at 37°C and 5% carbon dioxide. 
Isolation and culturing of RA synovial fibroblasts
Immediately after surgery the synovial tissue was minced and digested with 
dispase at 37°C for 60 min. After washing, the cells were grown in Dulbecco’s 
minimum essential medium (Gibco Invitrogen, Basel, Switzerland) supplemented 
with 10% FCS, 50 IU/ml penicillin/streptomycin, 2 mM L-glutamine, 10 mM HEPES 
and 0.2% Fungizone (all from Gibco Invitrogen). Cell cultures were maintained at 
37°C in a humidified incubator in an atmosphere of 5% carbon dioxide. For the 
experiments, cultured synovial fibroblasts between passages 4 and 8 were grown 
in 12-well culture plates (6×104 synovial fibroblasts/well) and cultured for 16 h at 
37°C and 5% carbon dioxide. 
Stimulation of monocytes, MoDCs and RA synovial fibroblasts
To study TLR mRNA expression on cytokine stimulation, after a resting period of 
16 h monocytes (which express TLR7), MoDCs and synovial fibroblasts (which 
both express TLR3) were stimulated for 8 h with TNFα, IL1b, IFNα, IL12, IL17, IL18 
(all R&D Systems, Minneapolis, Minnesota, USA). Culture supernatants were 
removed and 1 ml TRIzol reagent (Sigma) was added to the cells and stored at 
−20°C until RNA isolation was performed.
To study functional upregulation of TLR, after a resting period of 16 h monocytes, 
MoDCs and RA synovial fibroblasts were stimulated with IFNα (R&D Systems) for 
24 h and subsequently stimulated with the TLR3 and TLR7 agonists poly(I:C) and 
loxoribin, respectively (both Invivogen, San Diego, USA) or medium. All non-TLR4 
ligands were tested for lipopolysaccharide (LPS) contamination using the Lumilus 
assay and all were negative. After a further 24 h the culture supernatants were 
collected and stored at −20°C until cytokine measurement was performed. In 
addition, to investigate the role of type I IFN, various cell types were preincubated 
with 100 U/ml IFNα for 16 h.
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RNA isolation and real-time PCR
Total RNA was extracted in 1 ml TRIzol reagent, an improved single-step RNA 
isolation method based on the method described by Chomczynski et al.23 
Quantitative real-time PCR was performed using the ABI/Prism 7000 sequence 
detection system (Applied Biosystems, Foster City, California, USA). PCR 
conditions were as follows: 2 min at 50°C and 10 min at 95°C followed by 40 
cycles of 15 s at 95°C and 1 min at 60°C, with data collection in the last 30 s. All 
PCR were performed with SYBR Green Master mix (Applied Biosystems), 10 ng 
cDNA and a primer concentration of 300 nmol/l in a total volume of 25 µl. 
Quantification of the PCR signals was performed by comparing the cycle threshold 
value (Ct) of the gene of interest of each sample with the Ct values of the reference 
gene GAPDH (glyceraldehyde 3-phosphate dehydrogenase). Primer sequences 
for gene expression analysis for hGAPDH, hTLR3, hTLR7 and IL1b are shown in 
table 1. 
Measurement of cytokines in culture supernatant
TNFα, IL1b, IL6, IL10 and IL12p70 levels were measured in the supernatant of the 
cell cultures using commercially available kits (Bio-Rad Laboratories, Hercules, 
California, USA) according to the manufacturer’s instructions.24 Cytokine levels 
were measured and analysed using the Bio-Plex system (Bio-Rad Laboratories) 
and data analysis was performed with Bio-Plex Manager software (Bio-Rad 
Laboratories). The secretion of IL18 was measured using an ELISA (Invitrogen, 
Biosource, USA) carried out using the manufacturer’s instructions. For the 
measurement of IFNα and IFNb, ELISA kits were used and the ELISAs were 
performed according to the manufacturers’ protocols (Cell Science, Canton, 
Massachusetts, USA). 
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Table 1  Oligonucleotide primers for quantitative PCR analysis
cDNA Forward primer Reverse primer
hGAPDH ATC TTC TTT TGC GTC GCC AG TTC CCC ATG GTG TCT GAG C
hTLR3 AGA GTT GTC ATC GAA TCA AAT TAA AGA G CAT TGT TCA GAA AGA GGC CAA AT
hTLR7 TGC CAT CAA GAA AGT TGA TGC T GGA ATG TAG AGG TCT GGT TGA AGA G
hIL1b AAT CTG TAC CTG TCC TGC GTG TT TGG GTA ATT TTT GGG ATC TAC ACT CT
Software package Primer Express Version 2.0 (Applied Biosystems) was used to identify appropriate 
primer sets. All sequences are presented in the 5′→3′ direction.
GAPDH, glyceraldehyde 3-phosphate dehydrogenase; IL, interleukin; TLR, Toll-like receptor.
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Statistical analysis
Correlations of the expression of TLR and cytokines in human synovial biopsies 
were calculated using the Pearson correlation test. Differences in mRNA 
expression and cytokine production on cell stimulation with cytokines and TLR 
agonists were calculated using the Mann-Whitney U test. p Values were two-sided 
and the level of significance was set at p<0.05. 
Results
Clinical features
The clinical and demographic features of the patients included in the immunohisto-
chemistry studies are presented in table 2. All patients had active disease as 
defined by the inclusion criteria (DAS >3.2). Not surprisingly, patients with severe 
knee joint arthritis tended also to have more active disease. The patients with RA 
included in the in vitro studies on DCs (n = 10) also had active disease with a 
mean (SD) DAS of 3.8 (0.4) and were comparable with the patients included in the 
studies on synovial tissues. 
Table 2   Clinical and demographic data of patients with rheumatoid arthritis 
according to clinical status of biopsied joint
Moderate arthritis
(n = 12)
Severe arthritis
(n = 12)
Median (range) age (years) 61 (41–75) 59 (45–83)
Gender (F/M) 5/7 8/4
Rheumatoid factor positivity (%) 92 100
Mean (range) disease duration (years) 10 (3–29) 11 (3–26)
Mean (SD) DAS 5.0 (1.0) 5.5 (1.5)
Median (range) number of previous DMARDs 4 (2–8) 5 (2–7)
Knee joint examination
    Pain at rest (n) 2 9
    Pain at inspection (n) 6 12
    Median (range) score* 1 (0–2) 2 (1–3)
    Swelling (n) 9 12
    Median (range) score† 1 (0–1) 2.5 (2–3)
    Effusion (n) 5 12
*Pain score: 0 = none, 1 = pain reported on asking, 2 = patient winces, 3 = patient withdraws.
†Swelling score: 0 = absent, 1 = mild, 2 = moderate, loss of bony loss or bony contour, 3 = severe bulging.
DAS, disease activity score; DMARDs, disease-modifying antirheumatic drugs.
119
Ty
p
e 
1 
IF
N
 a
nd
 T
LR
s 
in
 s
yn
ov
ia
l i
nf
la
m
m
at
io
n
Correlation of TLR3/7 expression with IL1b, IL18 and IFNα in RA synovium
Synovial biopsy specimens from 24 patients with active RA (DAS >3.2) stained 
for TLR subtypes (TLR2, 3, 4 and 7) and inflammatory cytokines IL12, IL17, IL18 
and IL1b were used to study the association between TLRs and inflammatory 
mediators.20,21,22 Sequential slides from those used for the aforementioned 
markers were then stained for IFNα (fig 1A). TLR3/7 expression was correlated 
with the levels of expression of IFNα, IL1b and IL18 but not with IL12, IL17 and 
TNFα. Not unexpectedly, IFNα was clearly correlated with TLR3 and TLR7 
expression in the lining and sublining of synovial biopsies (fig 1B, table 3). 
Moreover, both IL1b and IL18 were correlated with the expression of TLR in the 
lining, although these correlations were weaker than that observed between TLR 
and type I IFN. In contrast, neither IL1b nor IL18 was associated with either TLR3 
or TLR7 expression in the sublining. Neither TNFα, IL12 nor IL-17 were correlated 
with the TLR expression levels in RA synovium. 
5
Table 3   Correlation between TRL3/7 expression and type I IFN, IL1 and IL18 in 
RA synovium
Correlation (r) p Value
Correlation TLR–type I IFN expression
TLR3–type I IFN
    Lining 0.76 0.02
    Sublining 0.77 0.01
TLR7–type I IFN
    Lining 0.70 0.04
    Sublining 0.84 0.01
Correlation TLR–IL1 expression
TLR3–IL1
    Lining 0.54 0.02
    Sublining 0.22 NS
TLR7–IL1
    Lining 0.32 NS
    Sublining 0.17 NS
Correlation TLR–IL18 expression
TLR3–IL18
    Lining 0.48 0.04
    Sublining 0.11 NS
TLR7–IL18
    Lining 0.48 0.04
    Sublining 0.16 NS
IFN, interferon; IL, interleukin; NS, not significant; RA, rheumatoid arthritis; TLR, Toll-like receptor.
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Figure 1
Increased expression of type I interferon (IFN) in rheumatoid arthritis (RA) synovium and 
association of Toll-like receptor (TLR) 3/7 with IFNα, interleukin (IL)1b and IL18. (A) 
Expression of IFNα in RA synovium (right panel) and isotype control staining (left panel). 
Magnification 200×. (B) Staining of RA synovial tissue with a specific antibody against 
IFNα showing the association between TLR3/7 and IFNα, IL1b and IL18 in RA synovial 
tissue. Synovial tissue sections were counterstained with haematoxylin.
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TLR3/7-mediated stimulation of monocytes, MoDCs or synovial fibroblasts 
could not explain its correlation with IL1b/IL18
Since we found a correlation between TLR3/7 expression and the presence of IFNα, 
IL1b and IL18, we further investigated the functional relation between these mediators 
and TLR3/7. It is generally accepted that stimulation of TLR3/7 leads to the production 
of type I IFN DCs. In line with this, we found that TLR3/7-mediated stimulation of 
MoDCs resulted in clearly enhanced protein levels of both IFNα and IFNb that 
reached similar levels in healthy donors and patients with RA (fig 2A). To investigate 
the potential relation between TLR3/7 and IL1b, TLR3-expressing MoDCs and 
synovial fibroblasts were stimulated with poly(IC) and TLR7-expressing monocytes 
were stimulated with loxoribine. All cell types investigated showed markedly increased 
expression of IL1b mRNA upon stimulation of either TLR3 or TLR7; however, IL1b 
protein could not be detected. The stimulation of monocytes, MoDCs or synovial 
fibroblasts with TLR3/7 did not lead to the secretion of IL18 proteins. 
Regulation of TLR3/7 expression by IL1b, IL18 and type I IFN
Since TLR3/7 stimulation leads to the production of IFNα but not to IL1b or IL18, 
we investigated whether the correlation between TLR3/7 and IL1b/IL18 could be 
explained by IL1b/IL18-induced upregulation of these receptors. Monocytes 
(TLR7-expressing cells), MoDCs (TLR3-expressing cells) and RA synovial 
fibroblasts (TLR3-expressing cells) were cultured in the presence of IFNα, IL1b 
and IL18. IFNα significantly enhanced TLR3 mRNA expression on RA synovial 
fibroblasts and MoDCs and TLR7 mRNA expression on monocytes (fig 2B). This 
increase in TLR expression was similar in patients with RA (n = 5) and in healthy 
volunteers (n = 5), and was specific for TLR3 and TLR7 since the expression of 
TLR2 and TLR4 was not altered. In contrast, IL1b and IL18 had no effect on the 
expression of TLR3/7, excluding a direct role in their co-expression with TLR3/7. 
Functionality of IFNα-mediated upregulation of TLR3/7
As we found that the expression of TLR3 and TLR7 was strongly upregulated by 
IFNα, we examined whether this enhanced TLR expression was functional in 
terms of increased TLR-mediated cytokine production. TLR7-expressing monocytes 
and TLR3-expressing MoDCs and RA synovial fibroblasts (n = 8) were incubated 
with IFNα or medium and TLR3 or TLR7 were stimulated with poly(IC) and 
loxoribine as appropriate. As anticipated, TLR7 stimulation on monocytes and 
TLR3 stimulation on MoDCs and RA synovial fibroblasts led to production of IL6 
and TNFα, which was significantly enhanced when the cells were preincubated 
with IFNα compared with cells stimulated with TLR3/7 ligands alone (fig 3). These 
data show that the upregulation of TLR3/7 by type I IFN is functional. 
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Augmentation of TLR4-mediated cytokine production by type I IFN provides 
the missing link explaining the correlation between TLR3/7 and IL1/IL18 
expression 
Since TLR4 triggering is recognised as a potent inducer of inflammatory mediators 
including IL1b and IL18, we postulated that stimulation of TLR3/7 leading to the 
production of type I IFN perhaps augments the TLR4 response ending up in the 
production of IL1b and IL18. To test this we prestimulated MoDCs with IFNα and 
then stimulated them with the TLR4 agonist LPS. Surprisingly, prestimulation with 
Figure 2
Effects of type I interferon (IFN), interleukin (IL)1b and IL18 on Toll-like receptor (TLR) 3/7 
expression. (A) IFNα and IFNb protein levels were measured using ELISA techniques. Both 
TLR3 and TLR7 agonists increased the production of IFNα and IFNb by monocyte-derived 
dendritic cells (DCs). No differences in IFN type I secretion were observed between DCs 
from healthy controls (open bars) and patients with rheumatoid arthritis (RA) (solid bars). 
(B) IL1b, IL18 and IFNα induced TLR3/7 mRNA expression by monocytes, monocyte-de-
rived DC and RA synovial fibroblasts from patients with RA (n = 5) and healthy controls 
(n = 5). Cells were incubated with 20 ng IL1b, IL18 and 100 IU/ml IFNα for 8 h and TLR mRNA 
expression was determined by real-time PCR. Data shown as mean (SD).
123
Ty
p
e 
1 
IF
N
 a
nd
 T
LR
s 
in
 s
yn
ov
ia
l i
nf
la
m
m
at
io
n
5
Figure 3
Functionality of increased Toll-like receptor (TLR) 3/7 expression by type I interferon (IFN). 
(A) Monocytes, (B) monocyte-derived dendritic cells (DCs) and (C) rheumatoid arthritis 
(RA) synovial fibroblasts from patients with RA (n = 5) were stimulated with TLR3/7-specific 
ligands after incubation with medium only or medium containing IFNα 100 U/ml for 10 h. 
Data shown as mean (SD). TNFα, tumour necrosis factor α.
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Figure 4
Augmentation of Toll-like receptor (TLR) 4 responses by preincubation with type I interferon 
(IFN). Secretion of tumour necrosis factor α (TNFα, upper panel) and interleukin 18 (IL18, 
lower panel) by monocyte-derived dendritic cells (DCs) co-incubated for 24 h with agonists 
for TLR3 (TLR3), TLR4 (purified LPS) or the combination of both. TNFα and IL18 secretion 
was compared between DCs prestimulated with 100 U/ml IFNα for 10 h and those not 
prestimulated. DCs from healthy individuals (n = 5), patients with rheumatoid arthritis (RA, 
n = 4) and patients with systemic sclerosis (SSc, n = 3) were compared. Data shown as 
mean (SD).
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IFNα resulted in a marked potentiation (threefold) of TLR4-mediated secretion of 
TNFα by DC from healthy controls (3044 pg/ml vs 1000 pg/ml, p = 0.01, n = 5; fig 4). 
In addition, preincubation with type I IFN augmented TNF production by the 
combination of TLR3/4 ligands by almost threefold (1880 pg/ml vs 5010 pg/ml, 
p<0.01). Compared with DC from healthy controls, stimulation of DC from patients 
with RA with TLR4 led to significantly greater production of TNF, as previously 
described.22 Notably, DC from patients with RA (n = 4) produced a fourfold higher 
level of TNFα on stimulation with IFNα/LPS (12344 pg/ml vs 3044 pg/ml, p = 0.001) 
and IFNα/LPS/Poly-IC (28477 pg/ml vs 8484 pg/ml), p = 0.01) than DC from 
healthy individuals. To investigate whether the augmented TLR4-mediated 
stimulation by type I IFN could underlie the association between TLR3/7 and IL18, 
we measured the production of this crucial mediator. In corroboration with TNFα, 
the secretion of IL18 was markedly increased following prestimulation with type I 
IFN and stimulation with LPS (2155 pg/ml vs 4855 pg/ml, p = 0.02). The addition 
of a TLR3 agonist, however, did not amplify IL18 production as is seen with TNF 
secretion, which is in line with our observation that TLR3/7 stimulation does not 
result in IL18/IL1b production. The secretion of IL1b showed the same trend, but 
the absolute levels by MoDCs was low (data not shown). Together these data 
imply that the TLR4 response is potentiated by prestimulation with type I IFN, and 
this is even more pronounced in patients with RA. To investigate whether the 
IFN-mediated augmentation of the TLR4 response is RA-specific, we included 
DC from patients with SSc (n = 3) in the analysis. Although the absolute production 
of pro-inflammatory mediators tends to be higher than that seen in healthy 
controls, the magnitude of potentiation of the TLR4 response is similar to that 
observed in healthy controls and thus smaller than that in RA.
Discussion
In this study we have shown that TLR3 and TLR7 in synovial tissue from patients 
with RA is associated with the presence of IL1b, IL18 and type I IFN. Since TLR3/7-
mediated cell activation did not result in IL1b/IL18 secretion and TLR3/7 expression 
was not regulated by these mediators, we sought evidence for the underlying 
mechanism to explain the relationship between these mediators in the synovium. 
Preincubation of DCs with IFNα led to clear augmentation of TLR4-mediated 
responses. It is therefore tempting to speculate that TLR3/TLR7 triggering leads 
to the production of type I IFN which, in turn, augments TLR4-mediated triggering 
leading to the production of pro-inflammatory mediators, explaining the observed 
correlation between TLR3/7 and IL1b/IL18 expression. Since ligands for the 
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TLR3/7 axis and TLR4 axis are abundantly present in the synovial compartment 
of patients with RA, this chain of events is likely to contribute to the inflammatory 
cascade in this condition. 
IFN type I is the key cytokine that regulates the innate immune response against 
viruses.25 Type I IFN is released upon transcription of interferon regulating factor 
(IRF)-3 or IRF-7, which can be induced following TLR3- or TLR7-mediated cell 
activation. TLR3 and TLR7 are highly expressed in synovial tissue from patients 
with RA,22 and TLR3/7 ligands such as cytomegalovirus, Epstein-Barr virus and 
parvovirus B19 have also been demonstrated in the joints of patients with RA.1,3,26 
The observation that a type I IFN signature is present in the synovium in a 
substantial proportion of patients with RA supports the notion that TLR3 and/or 
TLR7 triggering is likely to occur in RA synovium. In view of this, it is tempting to 
speculate that exposure to TLR3/TLR7 agonists might sensitise the synovial 
milieu for TLR4 ligands via IFNα production which, in turn, acts as a key regulator 
in the sustained inflammation in RA. For several reasons, IFNb therapy has been 
expected to have a beneficial effect in RA comparable to that seen in multiple 
sclerosis.27 However, IFNb therapy was shown to be effective in animal models of 
collagen-induced arthritis but ineffective in several clinical trials in RA.28,29,30 The 
fact that IFN type I strongly upregulates TLR3/TLR7 expression and tunes TLR4 
responses which, in turn, are continuously stimulated by ligands present in the 
synovial joints might, in fact, maintain the inflammatory processes and therefore 
lead to failure of IFN therapy. Identification of endogenous TLR agonists is of 
great interest in terms of autoimmune disorders. In particular for TLR4, several 
endogenous agonists have been described to date—for example, hyaluronan 
fragments, heparan sulfate, fibronectin and (small) heat shock proteins—which 
can all be released in RA joints as a result of inflammation-induced tissue injury 
and cell stress.11,12,13,31 For instance, Brentano et al described an endogenous 
ligand for TLR3, as endogenous RNA released from necrotic synovial fluid cells 
was able to activate RA synovial fibroblasts in a TLR3-dependent fashion.10 
Highly conserved RNA sequences within small nuclear ribonucleoprotein particles 
are able to activate immune cells via TLR7 and could act as an endogenous 
autoantigen in systemic lupus erythematosus.32,33 Thus, triggering of the TLR3/7 
pathways does not necessarily result from viruses but might well originate from 
the host itself. TLR-mediated immune responses in the synovial joints might lead 
to the release of endogenous TLR ligands originating from cells under stress or 
tissue damage. It is therefore not unlikely that a self-sustaining loop of TLR 
activation and generation of new endogenous TLR ligands might lead to a chronic 
inflammatory process as occurs during RA. 
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It has recently been demonstrated that stimulation of several different TLRs at the 
same time leads to synergistically induced levels of pro-inflammatory mediators.22,34 
Our data indicate that cytokine levels induced in a synergistic fashion by 
co-stimulation of TLR3 and TLR4 were even more enhanced when cells were 
preincubated with type I IFN. The exact mechanisms underpinning the augmented 
TLR4 response after preincubation with type I IFN is not yet understood. From our 
data, we can conclude that this phenomenon is not explained by an increased 
expression of TLR4 itself since preincubation with type I IFN does not affect its 
mRNA expression. Perhaps the explanation for this lies in the upregulation of 
adaptor molecules or downregulation of intracellular inhibitors that are part of the 
TLR4 pathways.35 Since the augmentation of TLR4 responses by type I IFN was 
significantly more potent in patients with RA, further investigation into the 
causative pathways is highly desirable because it might open novel insights into 
treating this condition selectively. 
In conclusion, this study has shown that the expression of TLR3 and TLR7 is 
associated with IFNα, IL1b and IL18 in synovial tissue from patients with RA. 
Furthermore, we have demonstrated the involvement of IFNα in the regulation of 
TLR3/7 expression and function and also in an augmented TLR4-mediated 
response. These observations might, at least partly, explain the role of type I IFN 
in the inflammatory cascade of RA.
5
128
References
1.  Einsele H, Steidle M, Muller CA, Fritz P, Zacher J, Schmidt H, et al. Demonstration of cytomegalovirus 
(CMV) DNA and anti-CMV response in the synovial membrane and serum of patients with rheumatoid 
arthritis. J Rheum 1992;19:677–81.
2.  Muller CA, Einsele H. Influence of human cytomegalovirus on immune reconstitution after bone 
marrow transplantation. Ann Hematol 1992;64(Suppl):A140–2.
3.  Saal JG, Krimmel M, Steidle M, Gerneth F, Wagner S, Fritz P, et al. Synovial Epstein-Barr virus infection 
increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis 
Rheum 1999;42:1485–96.
4.  Saal JG, Steidle M, Einsele H, Muller CA, Fritz P, Zacher J. Persistence of B19 parvovirus in synovial 
membranes of patients with rheumatoid arthritis. Rheumatol Int 1992;12:147–51.
5.  Zare F, Bokarewa M, Nenonen N, Bergstrom T, Alexopoulou L, Flavell RA, et al. Arthritogenic properties 
of double-stranded (viral) RNA. J Immunol 2004;172:5656–63.
6.  van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, Voskuyl AE, Rustenburg F, Baggen JM, et al. 
Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of 
a type I interferon signature in a subpopulation of patients. Ann Rheum Dis 2007;66:1008–14.
7.  Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation 
of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732–8.
8.  Hoshino K, Sugiyama T, Matsumoto M, Tanaka T, Saito M, Hemmi H, et al. IkappaB kinase-alpha is 
critical for interferon-alpha production induced by Toll-like receptors 7 and 9. Nature 2006;440:949–
53.
9.  Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, et al. Recognition of single-stranded 
RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci U S A 2004;101:5598–603.
10.  Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells 
activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 2005;52:2656–
65.
11.  Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous 
ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558–61.
12.  Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin 
activates Toll-like receptor 4. J Biol Chem 2001;276:10229–33.
13.  Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of hyaluronan 
activate dendritic cells via toll-like receptor 4. J Exp Med 2002;195:99–111.
14.  Abdollahi-Roodsaz S, Joosten LA, Koenders MI, Devesa I, Roelofs MF, Radstake TR, et al. Stimulation 
of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J Clin Invest 
2008;118:205–16.
15.  Abdollahi-Roodsaz S, Joosten LA, Roelofs MF, Radstake TR, Matera G, Popa C, et al. Inhibition of 
Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis. Arthritis Rheum 
2007;56:2957–67.
16.  Hamilton-Williams EE, Lang A, Benke D, Davey GM, Wiesmuller KH, Kurts C. Cutting edge: TLR 
ligands are not sufficient to break cross-tolerance to self-antigens. J Immunol 2005;174:1159–63.
17.  Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism 
Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 
1988;31:315–24.
18.  Anon. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for 
scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria 
Committee. Arthritis Rheum 1980;23:581–90.
19.  LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic 
sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
20.  Joosten LA, Radstake TR, Lubberts E, van den Bersselaar LA, van Riel PL, van Lent PL, et al. 
Association of interleukin-18 expression with enhanced levels of both interleukin-1beta and tumor 
necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum 
2003;48:339–47.
129
Ty
p
e 
1 
IF
N
 a
nd
 T
LR
s 
in
 s
yn
ov
ia
l i
nf
la
m
m
at
io
n
21.  Radstake TR, Roelofs MF, Jenniskens YM, Oppers-Walgreen B, van Riel PL, Barrera P, et al. Expression 
of toll-like receptors 2 and 4 in rheumatoid synovial tissue and regulation by proinflammatory cytokines 
interleukin-12 and interleukin-18 via interferon-gamma. Arthritis Rheum 2004;50:3856–65.
22.  Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. 
The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and 
costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic 
cells. Arthritis Rheum 2005;52:2313–22.
23.  Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-
phenol-chloroform extraction. Anal Biochem 1987;162:156–9.
24.  de Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human 
cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 
2003;10:133–9.
25.  Biron CA. Interferons alpha and beta as immune regulators—a new look. Immunity 2001;14:661–4.
26.  Takahashi Y, Murai C, Shibata S, Munakata Y, Ishii T, Ishii K, et al. Human parvovirus B19 as a causative 
agent for rheumatoid arthritis. Proc Natl Acad Sci U S A 1998;95:8227–32.
27.  Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007;68(24 Suppl 
4):S8–11.
28.  Genovese MC, Chakravarty EF, Krishnan E, Moreland LW. A randomized, controlled trial of interferon-
beta-1a (Avonex) in patients with rheumatoid arthritis: a pilot study. Arthritis Res Ther 2004;6:R73–7.
29.  van Holten J, Pavelka K, Vencovsky J, Stahl H, Rozman B, Genovese M, et al. A multicentre, 
randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the 
treatment of patients with active rheumatoid arthritis. Ann Rheum Dis 2005;64:64–9.
30.  van Holten J, Reedquist K, Sattonet-Roche P, Smeets TJ, Plater-Zyberk C, Vervoordeldonk MJ, et al. 
Treatment with recombinant interferon-beta reduces inflammation and slows cartilage destruction in 
the collagen-induced arthritis model of rheumatoid arthritis. Arthritis Res Ther 2004;6:R239–49.
31.  Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al. Identification 
of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the 
pathogenesis of rheumatoid arthritis. J Immunol 2006;176:7021–7.
32.  Savarese E, Chae OW, Trowitzsch S, Weber G, Kastner B, Akira S, et al. U1 small nuclear ribonucleo-
protein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. 
Blood 2006;107:3229–34.
33.  Vollmer J, Tluk S, Schmitz C, Hamm S, Jurk M, Forsbach A, et al. Immune stimulation mediated by 
autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J Exp Med 
2005;202:1575–85.
34.  Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist 
combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat 
Immunol 2005;6:769–76.
35.  Roelofs MF, Abdollahi-Roodsaz S, Joosten LA, van de Berg WB, Radstake TR. The orchestra of 
Toll-like receptors (TLR) and their potential role in frequently occurring rheumatic conditions. Arthritis 
Rheum 2008;58:338–48. Extended report
5

TLR2 promotes Th2/Th17 responses 
via TLR4 and TLR7/8 by abrogating 
the type I IFN amplification loop
Mark H. Wenink1
Kim C.M. Santegoets1
Jacobus C.A. Broen1
Lenny van Bon1
Shahla Abdollahi-Roodsaz1
Calin Popa1
Richard Huijbens1
Thijs Remijn1
Erik Lubberts2
Piet L.C.M. van Riel1
Wim B. van den Berg1
Timothy R.D.J. Radstake1
Affiliation
1   Department of Rheumatology, Radboud University Nijmegen Medical Center, Nijmegen, 
The Netherlands.
2  Department of Rheumatology, Erasmus Medical Center, Rotterdam, The Netherlands.
6
132
Abstract
Toll Like Receptor (TLR) 2 plays an important role in the removal of gram-positive 
bacteria, contrastingly it also appears to have important protective effects against 
unrestrained inflammation and subsequent organ injury during infection and 
autoimmunity. We hypothesized that TLR2 tunes the phenotype of dendritic cells 
(DCs) activated through other TLRs thereby fulfilling a crucial role in the modulation 
of the immune response. TLR2 potently inhibited TLR4 and TLR8 induced cytokine 
production by human DCs. The inhibitory effect of TLR2 on the release of TNFα 
but not of IL-12p70 was mediated by PI3K. TLR2 inhibits the production of IL-12p70 
by dampening the type 1 interferon (IFN) amplification loop. When DCs were 
triggered with the potent synergistic combination of LPS (TLR4) and R848 (TLR8) 
in conjunction with a TLR2 ligand a clear shift from Th1 to more Th2 and Th17 
prone responses in the naïve and memory T cell subpopulations was observed. 
This shift in T cell responses was inherent to the inability of TLR2 stimulated DCs 
to produce IL-12p70 and was dependent on the production of IL-1 and IL-6. 
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Introduction
Dendritic cells (DCs) are professional antigen-presenting cells which continuously 
probe their environment for invading microbes and are crucial for upholding 
tolerance or inducing immune responses1. Upon activation DCs elicit T cell 
responses crucial for the protection against invading microbes. The adaptive 
immune response evoked is specifically aimed at the pathogen sensed by the 
DCs. To accurately restrain this threat a balanced appearance of Th1, Th2 and 
Th17 cells at the compromised site is of paramount importance. However, next to 
their profitable role in the immunity against pathogens, Th1 as well as Th17 cells 
have been described as mediators of autoimmune pathology. It was recently 
suggested that the conditions during the initial exposure to antigens primes anti-
gen-presenting cells thereby determining whether the resulting effector phase is 
either a Th1 or a Th17 response, placing DCs in the centre of (auto)immunity2-4.     
Toll like receptors (TLRs) are essential pattern recognition receptors of the 
immune system widely expressed on a large variety of cells5. An important role 
for TLRs involves their expression on DCs which enables them to sense invading 
pathogens and mount an appropriate immune response. As most pathogens 
express several microbial TLR ligands and numerous host-derived TLR ligands 
are generated in inflamed or degenerated tissue, simultaneous activation of 
multiple TLRs in vivo during chronic inflammatory diseases is conceivable. In this 
context, the study of the interaction and crosstalk between TLRs is of high 
relevance in chronic inflammatory diseases including inflammatory bowel disease, 
atherosclerosis and rheumatoid arthritis (RA). Recently, the presence of TLR 
ligands was addressed in RA patients6-8 and enhanced expression of various 
TLRs in RA synovium further substantiates their role in RA9,10. 
The ligation of TLRs results in a massive release of cytokines, creating an 
environment crucial for the appropriate adaptive immune response. Activation of 
TLRs such as TLR4 and TLR7/8 results in DCs releasing IL-12p70, consisting of 
IL-12p35 and IL-12p40 subunits, which favours the proliferation of Th1 cells while 
activation of TLR2 does not result in the release of IL-12p70 and is generally 
thought to induce a Th2 response11. The production of IL-12p70 depends on the 
type 1 interferon (IFN) amplification loop in which an initial small production of 
IFN leads to the additional transcription of IFN genes and IL-12p35. Interferon 
Regulatory Factors (IRF) 1, 7 and 8 have been demonstrated to be intricately 
involved in this process leading to IL-12p70 production and Th1 responses12-14. In 
addition to Th1 and Th2 cells DCs have also been implicated in the promotion of 
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Th17 cells, although the bacterial components and the type of pattern recognition 
receptors involved are not evidently recognized15,16. Recently the activation of the 
intracellular bacterial sensor nucleotide oligomerization domain 2 (NOD2) was 
found to be implicated in the differentiation of Th17 cells by the enhanced 
production of TLR induced IL-1 and IL-2317. In addition, whereas type 1 interferon 
signalling was found to be pivotal for the induction of Th1 responses it also 
constrains Th17 development18,19. Interestingly, it was recently demonstrated that 
adoptive transfer of both IL-12p70 (Th1) as well as IL-23-polarized (Th17) T cells 
resulted in a clinically indistinguishable experimental autoimmune encephalitis. 
The histopathological features, however, were very distinct with myeloid cell rich 
infiltrates in IL-12p70-driven disease whereas IL-23-driven lesions were prominently 
populated by neutrophils20. 
While the function of TLR4 and TLR7/8 thus seems unambiguously aimed at the 
induction of a Th1 response, the precise function of TLR2 in immunity is less clear. In 
experimental autoimmune arthritis, TLR2 deficiency results in more severe arthritis, 
whereas TLR4 deficiency leads to protection against severe destructive disease21. To 
date, accumulating evidence points towards an inhibitory role of TLR2 in inflammation. 
For instance, TLR2 mediates the intracellular survival of certain bacteria, such as 
Porphyromonas gingivalis, in macrophages22 and the absence of TLR2 during 
experimental Mycobacterium tuberculosis infection led to increased mortality due to 
uncontrolled inflammation and injury of the lungs23. These studies demonstrate that 
TLR2 signals might have important protective effects against unrestrained 
inflammation and subsequent organ injury. Similarly, Gerosa et al. pointed out that 
there is interaction between TLR2 and other pattern recognition receptors 
demonstrating that TLR2 co-activation inhibits the release of IL-12p70 induced by 
R848 in synergistic combination with LPS, b-glucan or zymosan24. Fuelled by these 
observations, we aimed to further explore the role of TLR2 co-stimulation in controlling 
TLR mediated responses and to delineate the underlying pathways. Here, we report 
that TLR2 was able to specifically restrain the TLR4 and/or TLR7/8 induced production 
of a wide array of cytokines while leaving the cytokine production induced by TLR3 or 
TLR5 untouched. Importantly we disclose the mechanisms by which TLR2 exerts its 
suppressive function and demonstrate that co-activation of TLR2 leads to a clear shift 
in the DC mediated T cell differentiation from a Th1 response to a Th2 and Th17 prone 
response. This shift was inherent to the inability of TLR2 stimulated DCs to produce 
IL-12p70 via the abrogation of the type 1 IFN amplification loop and was dependent 
on IL-1 and IL-6. Collectively, this points towards a prominent role for TLR2 mediated 
signalling in (auto)immunity by coordinating the effector phase of an immune 
response towards a predominant Th1 or Th17 mediated process. 
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Materials and Methods
Isolation and culture of monocyte-derived Dendritic Cells and BDCA-1 
(CD1c)+ myeloid DCs
PBMCs were isolated from heparinized venous blood of healthy volunteers by 
using density-gradient centrifugation over Ficoll-Paque (Amersham Bioscience). 
Monocytes were obtained using CD14 microbeads and MS columns (Miltenyi 
Biotec). The positive selection kit for BDCA-1 (CD1c)+ from Miltenyi Biotec was 
used to isolate myeloid DCs. Monocyte-derived DCs were generated by culturing 
isolated monocytes in the presence of IL-4 (500 U/ml; Schering-Plough) and 
GM-CSF (800 U/ml; Schering-Plough) for 6 days. Fresh culture medium was 
added at day 3. The local Medical Ethics Committee approved the study protocol.
Phenotypical analysis of monocyte-derived DCs
Using standardized flow cytometry protocols as described previously25 
phenotypical analysis of monocyte-derived DCs was performed. DCs were 
characterized by staining with mAbs against human CD80 (BD Biosciences), 
CD83 (Beckman Coulter), CD86 (BD Pharmingen) and MHC-II DR/DP (clone 
Q1514). Cells were analyzed for the proportion of positive cells and the mean 
fluorescence intensity relative to cells stained with the appropriate IgG isotypes. 
Stimulation of monocyte-derived DCs and myeloid DCs 
Freshly isolated myeloid DCs and day 6 monocyte-derived DCs were plated in a 
concentration of 0.5x106 DCs/ml and transferred to 24 well (1 ml) or 96 well (100 
ml) culture plates. Cells were then stimulated with TLR agonists for 16-24 hours. 
For experiments in which mRNA levels were determined monocyte-derived DCs 
were stimulated for 4 hours before they were put in TRIzol. The concentration in 
which the TLR agonists were used is as follows unless otherwise described: LPS 
(LPS, 100 ng/ml, E. coli 0111:B4, Sigma-Aldrich), R848 (2 mg/ml, InvivoGen), 
Pam3CSK4 (5 mg/ml, EMC microcollections), Poly(I:C) (25 mg/ml, InvivoGen), S. 
Typhimurium Flagellin (1 mg/ml, InvivoGen), FSL-1 (Pam2Cys, 1 mg/ml, EMC mi-
crocollections). The used E. coli Lipopolysaccharide was double-purified at our 
laboratory according to the two-step phenol-water extraction method to remove 
any contaminating proteins resulting in purified LPS (pLPS)26. Blocking of TLR2 
was accomplished by using antibodies specific for TLR2 (clone TL2.1, isotype 
IgG2a, 30mg/ml, eBioscience). As a control antibody clone eBM2a was used 
(isotype IgG2a, 30 mg/ml, eBioscience). In certain experiments DCs were 
pre-treated with the following for 1h at 37°C before adding TLR ligands: 
Wortmannin (PI3K inhibitor, 100 nM, Calbiochem), PD98059 (Erk inhibitor, 20 mM, 
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Calbiochem), antibody against IL-10 (3 mg/ml, R&D systems), IFNα and IFNb1 
(both 100 IU/ml, R&D systems), blocking antibodies specific for IFNαR2  (Interfer-
onsource.com, 30 mg/ml). Supernatants were collected after 24 hours for cytokine 
measurements. 
Mixed leukocyte reaction (MLR)
At day 7 DC were harvested from their 24 well plates, washed in PBS and 
resuspended in a concentration of 100x103 DC/ml in culture medium. 5x103 DC 
were replated in 96 round bottom well plates. CD4+ T cells from PBMCs from 
healthy controls were obtained by negative selection using microbeads and MS 
columns (Miltenyi Biotec). Next CD4+CD45RA+ naïve T cells were separated from 
the CD4+CD45RO+ T cells by the use of microbeads aimed at CD45RO. 50x103 
CD4+CD45RA+ or CD4+CD45RO+ T cells were added to the DCs in 96 round 
bottom well plates. T cell proliferation was monitored at day three during the MLR 
by tritiated thymidine incorporation (0.5 mCi). The tritiated thymidine incorporation 
is expressed as mean count per 5 min and SD of at least quadruplicate 
measurements. At day six of the MLR cells were incubated with PMA (50 ng/ml, 
Sigma) and Ionomycin (1 mg/ml, Sigma) 12 hours before the collection of 
supernatants. In some MLR experiments antibodies or recombinant human 
IL-12p70 (5 ng/ml) were added to the wells at day 1 of the MLR. Antibodies used 
were aimed against IL-12p35 (10 mg/ml), IL-12p40 (10 mg/ml), IL-6R (10 mg/ml), 
OX40L (10 mg/ml) and TGFb (100 ng/ml, kindly gifted by Dr. R. Lafyatis, Boston 
University, Boston, USA), additional experiments were performed with IL-1ra (1 
mg/ml). 
Measurement of cytokines in culture supernatants
Levels of IL-10, TNFα, IL-12p70, IL-6, MCP-1, IFNγ, IL-4, IL-13 and IL-17A were 
measured in the supernatants using commercially available kits (Bio-Rad) 
according to the manufacturer’s instructions. Cytokine levels were measured and 
analyzed with the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay 
was < 5 pg/ml for all cytokines measured. The levels of IL-23 (R&D systems, 
Minneapolis, USA), IL-1α and IL-1b (Biosource, Breda, The Netherlands) were 
measured by specific ELISA. The minimum detection limits for IL-23 was 32 pg/
ml, and for IL-1alpha and IL-1beta both 3.2 pg/ml.
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Intracellular cytokine staining
At day 6 of MLR with CD4+CD45RA+ or CD4+CD45RO+ T cells and DCs stimulated 
with pLPS and R848 with or without Pam3CSK4 the cells were stimulated for 4 
hours with PMA (50 ng/ml; Sigma) and Ionomycin (1 mg/ml, Sigma) in the presence 
of Golgiplug (BS biosciences) according to manufacturers protocol. Subsequently 
the cells were fixed and permeabilized with Cytofix/Cytoperm solution (BD 
biosciences) and then intracellularly stained with anti-IFNγ-PE (eBiosciences), 
anti-IL-17-FITC (eBiosciences) and anti-IL-13-APC (eBiosciences) or with the 
corresponding isotype controls. Samples were measured on a FACS Calibur and 
data were analyzed using the CellQuest-Pro software (BD biosciences) and 
WinMDI 2.8. 
RNA isolation and real-time PCR 
Total RNA was extracted in 1 ml of TRIzol reagent. Quantitative real-time PCR was 
performed using the ABI/Prism 7000 sequence detection system (Applied 
Biosystems). All PCRs were performed with SYBR Green Master mix (Applied 
Biosystems), 10 ng cDNA, and a primer concentration of 300 nmol/L in a total 
volume of 20 ml. Quantification of the PCR signals was performed by comparing 
the cycle threshold value (Ct) of the gene of interest of each sample with the Ct 
values of the reference genes GAPDH or GUS (DCt) and were deployed as relative 
expression (2-DCt). Software package Primer Express Version 2.0 (Applied 
Biosystems) was used to identify appropriate primer sets for IRF1, IRF7, IRF8, 
IFNα, IFNb, IFNl1, SOCS1, SOCS3 and A20. 
Human embryonal kidney 293-TLR4/MD2-CD14 cell activation assay  
Human embryonal kidney 293 (HEK293) cells stably expressing TLR4, MD2 and 
CD14 were obtained from Invivogen and cultured according to the manufacturers 
guidelines. After the cells reached confluency in flat bottom 96 well plates 
stimulations were performed. HEK293-TLR4/MD2-CD14 were stimulated with 
medium or pLPS (100 ng/ml or 1 mg/ml) together with medium or Pam3CSK4 (5 
or 10 mg/ml). After 24 hours supernatants were collected and the levels of IL-8 
were measured using commercially available kits (Bio-Rad) according to the 
manufacturer’s instructions with the Bio-Plex system.
  
Western Blot analysis
DCs were harvested at fixed time-points after stimulation, washed in PBS and 
lysed in buffer. To ascertain equal loading the protein content of all cell lysates 
was measured. 50 mg of protein was resolved on an 8% polyacrylamide gel and 
transferred to a nitrocellulose membrane. Membranes were then blocked with 5% 
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nonfat dried milk in TBST (15 mM Tris-HCL (pH 7.4), 150 mM NaCl, 0,1% Tween 
20). Blots were probed overnight with mAb specific for STAT-1 and phosphorylated 
STAT-1 (Cell signaling technologies) according to the manufacturer’s protocol. 
The membranes were subsequently treated with the appropriate secondary 
antibodies. Immunoreactive bands were visualized by the ECL Western blotting 
detection kit (Pierce).     
Statistical analysis 
Differences between groups were analyzed using paired Student’s t-tests or the 
Mann-Whitney U test. P values less than 0.05 were considered significant.
Results
TLR2 inhibits TLR4 and TLR7/8 but not TLR3 and TLR5 mediated production 
of pro-inflammatory mediators by Dendritic Cells
Previous observations indicated cross-talk between TLR2 and TLR4 on DCs27. To 
evaluate the concept that TLR2 inhibits the production of pro-inflammatory 
mediators upon TLR4 mediated activation of DCs we co-stimulated DCs with 
increasing concentrations of Pam3CSK4 (TLR2/1 ligand) and purified LPS (pLPS, 
TLR4 ligand). The release of both TNFα and IL-12p70 after the stimulation of DCs 
with pLPS was dose-dependently inhibited by the presence of Pam3CSK4 
(Figure 1A). Additional experiments using monoclonal anti-TLR2 antibodies, 
HEK293 cells expressing TLR4, MD2 and CD14, a ligand for TLR2/6 (FSL-1 or 
Pam2Cys), alternating order of ligand addition and increasing LPS dosages 
clearly demonstrated that the inhibitory effect was TLR2 specific (Figure 1B/E), 
not due to physical interaction prior to engagement of TLR4 by pLPS (Figure 1C), 
independent of the order of addition of pLPS/Pam3CSK4, as long as Pam3CSK4 
was added within two hours of pLPS (Figure 1D), and was present over all LPS 
dosages (1 ,10, 100 ng/ml and 1 and 2 mg/ml) (data not shown).
In line with these observations, the addition of Pam3CSK4 also markedly inhibited 
the secretion of IL-10, IL-6 and IL-23 whereas MCP-1 showed the opposite effect 
(Figure 2A).  Based upon apparent dissimilarities in the signalling cascades of 
the different TLR subtypes, we subsequently evaluated the effect of TLR2 on 
TLR3, TLR5 and TLR7/8. Stimulation of DCs with R848 (TLR7/8 ligand) resulted in 
the production of IL-10, TNFα, IL-12p70, IL-6, IL-1γ, IL-1γ, IL-23 and MCP-1, which 
was markedly inhibited by the addition of Pam3CSK4 for all mediators except IL-6 
and MCP-1, underscoring the potency of the inhibitory effect of TLR2 (Figure 2A). 
Strikingly, concomitant stimulation of DCs with Pam3CSK4 and poly(I:C) (TLR3 
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Figure 1
The TLR4 mediated production of TNFα and IL-12p70 is dose-dependently inhibited by the 
co-stimulation of TLR2 on human monocyte-derived DCs. (A) Monocyte-derived DCs were 
stimulated with 100 ng/ml pLPS and increasing amounts of Pam3CSK4. After 24 hours 
supernatants were collected and measured for their TNFα and IL-12p70 content by Luminex. 
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ligand) and Flagellin (TLR5 ligand) did not result in the inhibition of cytokine 
production (Figure 2B). In fact, the addition of Pam3CSK4 to either poly(I:C) or 
flagellin augmented the cytokine response compared to that of the single ligands. 
To assess the in-vivo relevance of our observations and extend the findings by 
Gerosa et al 24, we assessed whether the inhibitory effect of TLR2 was present in 
freshly isolated myeloid DCs (CD11c+/BDCA-1+). Although the level of IL-12p70 
secretion by myeloid DCs induced by the single ligands pLPS or R848 was very 
low compared to monocyte-derived DCs, the inhibitory effect of Pam3CSK4 was 
clearly present on the pLPS and R848 induced IL-12p70 and TNFα production 
(Data not shown and Figure 2C). 
The inhibitory effect of TLR2 on the release of TNFα but not of IL-12p70 
is mediated by PI3K
IL-10 has been implicated in many of the regulatory functions mediated by TLR2 
signalling27. However, in support of the findings by Gerosa et al. we demonstrate 
that the addition of IL-10 neutralising antibodies had no effect on the TLR2 
mediated suppression of pLPS and R848 induced IL-12p70 production nor on the 
inhibition of the release of TNFα (Figure 3A). The addition of IL-10 neutralising 
antibodies did however lead to the increased release of TNFα and IL-12p70 
demonstrating it’s regulatory role independent of TLR2.
The stimulation of DCs with TLR2 ligands was previously shown to lead to a 
potent phosphorylation of Erk1/2 leading to a reduced ability of the DCs to 
produce IL-12p70 upon the activation of TLR228,29. To evaluate whether the phos-
phorylation of Erk1/2 was implicated in the dampening of TLR4 and TLR7/8 
responses by TLR2, DCs were exposed to an inhibitor of Erk1/2 before the 
Bars represent mean and SEM of three independent experiments. (B) DCs were activated 
with the combination of Pam3CSK4 (5 mg/ml) and pLPS (100 ng/ml) in the presence of 
blocking antibodies for TLR2 or of isotype control antibodies. Bars represent mean and SD 
of triplicate wells. Data are representative of three independent experiments. (C) 
HEK293-TLR4/MD-2/CD14 cells were stimulated with pLPS (100 ng/ml and 1 mg/ml) and/or 
Pam3CSK4 (5 and 10 mg/ml) for 24 hours after which the levels of released IL-8 were 
measured. Bars represent mean and SD of triplicate wells. (D) Surrounding the pLPS 
activation of DCs Pam3CSK4 was added at various time-points ranging from 2 hours 
before to 2 hours after the stimulation with pLPS. Supernatants were collected after 24 
hours and the levels of TNFα and IL-12p70 were determined. Bars represent mean and SEM 
of three independent experiments. (E) DCs from three healthy volunteers were stimulated 
with pLPS (100 ng/ml) with or without FSL-1 (Pam2Cys, 1 mg/ml). In line with the results 
obtained by the activation of TLR2/1 by Pam3CSK4, the triggering of TLR2/6 by FSL-1 
inhibited TLR4 mediated TNFα and IL-12p70 secretion. Bars represent mean and SEM of 
five independent experiments.
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Figure 2
TLR2 activation on monocyte-derived and blood DCs inhibits the production of a wide 
array of cytokines induced by TLR4 and/or TLR8 activation, not by TLR3 or TLR5 activation. 
(A) DCs from 10 healthy volunteers were stimulated with  pLPS (100 ng/ml), R848 (2 mg/ml) 
or the synergistic combination of pLPS and R848 with or without Pam3CSK4 (5 mg/ml). 
TLR2/1 activation markedly inhibited most of the TLR4 and/or TLR8 mediated cytokine 
secretion, only the release of IL-6 was unchanged in the presence of R848 while the release 
of MCP-1 was increased with all stimulations. Bars represent mean and SEM of ten 
independent experiments. (B) The release of IL-10, TNFα and IL-12p70 in the supernatants 
of DCs stimulated with TLR3 ligand (Poly(I:C), 25 mg/ml) or TLR5 ligand (S. Typhimurium 
Flagellin, 1 mg/ml) for 16-24 hours were measured by Luminex (n=10 independent 
experiments, mean±SEM). (C) BDCA-1+ myeloid DCs were isolated from venous blood and 
stimulated with pLPS (100 ng/ml) in combination with R848 (2 mg/ml) in the presence or 
absence of Pam3CSK4 (5 mg/ml). Lines represent the results from five experiments with 
myeloid DCs from five healthy individuals.
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stimulation with TLR ligands. No effect on the inhibition by TLR2 was observed, 
demonstrating that the phosphorylation of Erk1/2 by TLR2 does not play a role in 
the inhibition of TLR4 and TLR7/8 responses (Figure 3A). TLR2 has been shown 
to signal through PI3K, which is a known inhibitor of the TLR4 pathway. Taking this 
into account, we used the specific inhibitor Wortmannin for the inhibition of the 
PI3K pathway. A clear dependence on the presence of functional PI3K was 
observed for TLR2 to exert its full inhibitory effect on the release of TNFα and IL-10 
(Figure 3B and data not shown). However, suppression of IL-12p70 secretion by 
TLR2 was not influenced by the blocking of the function of PI3K (Figure 3B) 
implicating that TLR2 inhibits via multiple pathways.  
The TLR2 mediated inhibition of IL-12p70 secretion is IRF1/8, STAT1 and 
SOCS1 dependent
Having demonstrated the capacity of TLR2 to potently suppress IL-12p70 
production in a PI3K-independent manner we set to determine how TLR2 induces 
this inhibitory effect. An endogenous type 1 IFN amplification loop has been 
shown to be essential in the production of IL-12p70 by DCs 14. Upon TLR ligation 
an initial production of IFNα4 and IFNb genes leads, via activation of the IFN 
receptor, to the next stage in which additional IFN genes and IL-12p35 are 
induced30,31. In order to study whether the type 1 IFN amplification loop was 
abrogated by the activation of TLR2 we measured the mRNA levels of IFNα, IFNγ 
and IFNl1 in DCs after 4 hours of stimulation with pLPS or pLPS and R848 with or 
without Pam3CSK4. IFNl1 expression was recently shown to depend on signaling 
pathways shared with IFNγ and to play a role in dampening DC induced 
development of Th232,33. The presence of TLR2 ligands potently decreased the 
mRNA levels of IFNγ and IFNl1 induced by pLPS alone and by the combination of 
pLPS and R848 underscoring that TLR2 might inhibit TLR4 and TLR7/8 responses 
by interfering in the type 1 IFN amplification loop (data not shown and Figure 
4A). IFNα mRNA was hardly detectable. Next, exogenous IFNα and IFNb were 
added to DCs in conjunction with pLPS which resulted in a synergistically 
increased secretion of IL-12p70. This however had no effect on TLR2 mediated 
inhibition, suggesting that abrogation of the initial type I IFN release is not 
essential (Figure 4B). The common IFNα receptor 2 (IFNαR2) was blocked to 
determine whether the type 1 IFN amplification loop does play a role in our 
system. The blockade of IFNαR2 led to a clearly decreased LPS and R848 
induced production of IL-12p70 but again did not affect the inhibitory capacity of 
TLR2 ligation (Figure 4C). 
To deepen our understanding of the TLR2 mediated inhibition of the type 1 IFN 
amplification loop, we studied the downstream mediators of the type 1 IFN 
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pathway IRF1, 7 and 8. Upon TLR activation IRF7 is essential for the initial type 1 
IFN production while IRF8 is indispensable for the induction of IL-12p70 production 
during the second phase of the type 1 IFN amplification loop. IRF1 has an 
important role in the amplification of IRF8 mediated IL-12p70 release. In our 
experimental setup, IRF1, IRF7 and IRF8 mRNA was readily present in the DCs 
after the activation of TLR4 alone and by the activation of both TLR4 and TLR7/8. 
Interestingly, the addition of TLR2 ligands had no effect on the mRNA level of IRF7 
6
Figure 3
The PI3K pathway is crucial in the inhibition of TLR4 and TLR8 induced TNFα by TLR2. (A) 
Monocyte-derived DCs were cultured for 6 days before the stimulation with pLPS and R848 
with or without Pam3CSK4 and either in the presence of the appropriate carrier solution 
(DMSO), neutralising antibodies against IL-10 (3 mg/ml) or the specific ERK inhibitor 
PD98059 (20 mM). After 24 hours supernatants were collected and measured for their 
content of TNFα and IL-12p70. (B) The LPS- or LPS+R848-induced TNFα and IL-12p70 
secretion with and without co-stimulation of DCs by Pam3CSK4 was measured by luminex 
technology in the absence or presence of the specific inhibitor for PI3K (100 nM 
Wortmannin). Inhibition of the PI3K pathway largely inhibited TLR2 mediated TLR4 inhibition 
of TNFα release while no effects were observed on the release of IL-12p70. Results are the 
mean and SEM of three independent experiments.
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Figure 4
The type 1 IFN amplification loop is inhibited by TLR2 activation.  (A) Real-time PCR of the 
expression of IFNα, IFNb and IFNl1 mRNA in DCs stimulated with medium or pLPS and 
R848 with or without Pam3CSK4 for 4 hours. Expression is relative to GAPDH expression. 
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but significantly reduced IRF1 and IRF8 mRNA levels induced by pLPS alone and 
by the combination of pLPS and R848 (data not shown and Figure 4D).  Next to 
IRFs, STAT1 signaling is essential for the induction of IL-12p70 production by DCs 
via the IFN amplification loop. To study the role for STAT-1 inhibition by Pam3CSK4 
in more detail we evaluated the effect of Pam3CSK4 on the level of TLR4 and 
TLR7/8 -induced phosphorylation of STAT-1. At 60, 120 and 240 minutes the 
tyrosine phosphorylation status of STAT-1 was determined upon the activation of 
DCs with pLPS and R848 in the presence and absence of Pam3CSK4. There was 
a clear inhibition of the pLPS and R848 induced phosphorylation of STAT-1 by 
Pam3CSK4 (Figure 4E).     
In order to determine whether TLR2 activation would also inhibit IFNγ induced 
STAT-1 dependent cytokine production by DCs we co-stimulated DCs with IFNγ 
and Pam3CSK4 and monitored the secretion of inflammatory mediators such as 
IL-6, TNFα, IL-10 and IL-12p70. IFNγ dependent activation of DCs resulted in a low 
production of IL-6 while IL-10, TNF and IL-12p70 were undetectable. Stimulation 
with both Pam3CSK4 and IFNγ however resulted in a synergistic release of IL-6 
suggesting that TLR2 stimulation does not act via direct inhibition of STAT-1 phos-
phorylation (Figure 4F). The production of IL-10, TNFα and IL-12p70 was 
comparable to that induced by TLR2 activation alone (data not shown). Since 
6
(B) The production of IL-12p70 by DCs stimulated with medium or pLPS with or without 
Pam3CSK4 in the presence or absence of IFNα (100 IU/ml) and IFNb (100 IU/ml) was 
measured after 24 hours. (C) The pLPS and R848 induced IL-12p70 secretion with and 
without co-stimulation of DCs by Pam3CSK4 was measured by luminex technology in the 
absence or presence of neutralising antibodies against IFNα Receptor 2. Inhibition of the 
type 1 IFN receptor inhibited TLR4 and TLR8 induced IL-12p70 release with no additive 
effect on the inhibition evoked by TLR2 co-ligation. (D) Real-time PCR of the expression of 
IRF1, IRF7 and IRF8 mRNA in DCs stimulated with medium or pLPS and R848 with or 
without Pam3CSK4 for 4 hours. Expression is relative to GAPDH expression. (E) DCs 
derived from healthy controls were stimulated for 1, 2 and 4 hours with pLPS and R848 or 
with the combination of Pam3CSK4, LPS and R848 before protein isolation for Western 
Blot. The protein content of all cell lysates was measured to ascertain equal loading. 
Analysis was done on the protein content of the DCs regarding STAT-1 and phosphorylated 
STAT-1. Blots are representative for the results from 3 independent experiments with DCs 
from 3 individuals. (F) DCs primed with IFNγ or not were stimulated with pLPS with or 
without Pam3CSK4 for 24 hours after which the IL-12p70 levels were measured in the 
supernatants. (G) DCs from 3 healthy volunteers were stimulated with medium, Pam3CSK4, 
IFNγ or the combination of Pam3CSK4 and IFNγ. The release of IL-6, IL-10, TNFα and 
IL-12p70 in the supernatants was measured after 24 hours by Luminex. Data are mean and 
SEM of three independent experiments. (H)  Real-time PCR of the expression of SOCS1, 
SOCS3 and A20 mRNA in DCs stimulated with medium or pLPS and R848 with or without 
Pam3CSK4 for 4 hours. Expression is relative to GAPDH expression. Data are presented as 
the mean ± SEM of at least five independent experiments.
146
the cross-talk between TLR4 and IFNγ requires IRF1 and IRF8 we aimed to 
investigate whether this synergy would be dampened by the presence of TLR2 
ligands. A clear synergy in the release of IL-12p70 was observed when DCs were 
activated with both IFNγ and pLPS, a response fully abrogated by the addition of 
Pam3CSK4 (Figure 4G). 
The SOCS1 protein has been implicated in the control of various cytokine and 
TLR responses by the inhibition of JAK/STAT pathways34. Recently a role for this 
protein was described in the dampening of TLR responses by the TAM receptors 
dependent on the type 1 IFN amplification loop35. Indeed, a potent facilitating 
effect of TLR2 on the expression of SOCS1 induced by pLPS and R848 was 
observed whereas the expression of SOCS3 and A20 mRNA was decreased 
(Figure 4H).
Co-stimulation with TLR2 ligands does not influence maturation of DC or 
T cell proliferation but skews T cell priming to a Th2/Th17 response
In order to investigate the inhibitory capacity of Pam3CSK4 on phenotypical DC 
maturation, DCs were stimulated with pLPS or R848 and the expression of multiple 
surface markers was studied. Both stimulation with pLPS and R848 led to a rapid 
up regulation of MHC II, CD80, CD83 and CD86 that was not influenced by the 
addition of Pam3CSK4 (Figure 5A). In line with this observation, the rate of T cell 
proliferation induced by DC stimulated with TLR4 and TLR7/8 was unaltered by 
the addition of TLR2 ligands (Figure 5B). Based on the strong inhibition of 
IL-12p70 release we postulated that co-stimulation of DCs with Pam3CSK4 alters 
DC mediated T cell priming leading to a more Th2 prone immune response even 
in combination with potent inducers of Th1 responses such as pLPS and R848. To 
test this, DCs were stimulated with pLPS and R848 in the presence or absence of 
Pam3CSK4 and subsequently co-incubated with naïve CD4+CD45RA+ T cells or 
memory CD4+CD45RO+ T cells. The stimulation of DCs with Pam3CSK4 in 
combination with pLPS and R848 suppressed the IFNγ release from the naïve T 
cell population, and resulted in an increased release of IL-4, IL-13 and IL-17 
compared to DCs stimulated with pLPS and R848 alone (Figure 6A). Additionally, 
a significant increase in IL-4, IL-13 and IL-17 release was found in cultures of 
CD4+CD45RO+ memory T cells with DCs co-activated with Pam3CSK4 (Figure 
6B). Next we performed intracellular staining for IFNγ, IL-13 and IL-17 of naïve 
CD4+CD45RA+ T cells and memory CD4+CD45RO+ T cells. In line with the levels 
of released cytokines we observed that the percentage of IL-13 as well as IL-17 
positive cells in the naïve T cell population doubled upon co-activation of the DCs 
with Pam3CSK4 (Figure 6C). In addition the level of IFNγ positive cells decreased 
with approximately 10% (data not shown). These findings were comparable to 
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Figure 5
Co-stimulation of TLR2 with TLR4 or TLR8 does not affect DC phenotypic maturation or T 
cell proliferation. (A) The up regulation of CD80, CD83, CD86 and MHC-II expression 
initiated by stimulation of TLR4 (pLPS (100 ng/ml)) or TLR8 (R848 (2 mg/ml)) is not modified 
by co-incubation of DCs with a TLR2 ligand (Pam3CSK4 (5 mg/ml)). DCs were cultured for 
24 hrs with medium, LPS (100 ng/ml) or R848 (2 mg/ml) alone or in combination with 
Pam3CSK4 (5 mg/ml). Expression of cell surface markers was performed using flow 
cytometry. (B) Co-incubation of DCs with the combination of LPS (100 ng/ml) or R848 (2 
mg/ml) and Pam3CSK4 (5 mg/ml) had no marked effect on T cell proliferation measured by 
3H-Thymidine incorporation at day 3 of the MLR compared to those stimulated with LPS or 
R848 alone. Data are mean and SEM of five independent experiments. * = p<0.05 and ** 
= p<0.01 compared to co-incubation with medium alone.
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those in the memory T cell cultures in which co-activation of DCs with Pam3CSK4 
led to a 50% increase in IL-13 producing T cells while the level of cells only 
producing IL-17 increased with 100% (data not shown and Figure 6D). As in the 
cultures with naïve T cells the level of IFNγ positive cells decreased with 
approximately 10% (Figure 6D).      
The inhibition of IL-12p70 production by co-stimulation with Pam3CSK4 
underlies the shift towards Th2 and Th17 responses 
Since the activation of TLR2 led to an almost complete abrogation of the 
production of IL-12p70 and it shifted T cell responses towards Th2 and Th17 
responses we surmised that these phenomena were related. The presence of 
neutralising antibodies for IL-12p70 and the co-stimulation of the DCs with 
Pam3CSK4 led to equal increases in IL-13 and IL-17 production. The neutralisation 
of IL-12p70 did not have an additive effect on the co-stimulation of DCs with 
Pam3CSK4 in up regulating the production of IL-13 or IL-17 (Figure 7A and 7B). In 
addition we performed MLR experiments with naive T cells in which we added 
recombinant human IL-12p70. The addition of IL-12p70 restored the production of 
IFNγ by T cells differentiated under the influence of DCs matured in the presence 
of Pam3CSK4 and pLPS and R848, up to the levels found when T cells were 
cultured with DCs exposed to pLPS and R848 alone while the production of IL-13 
was also significantly reduced (Figure 7C). These data underscore the 
fundamental principle that the activation of TLR2 on DCs abrogates their ability to 
produce IL-12p70 leading to a shift towards Th2 and Th17 cells in the naïve and 
memory T cell populations.
Nowadays, multiple factors have been identified as driving forces in the induction 
of Th17. Here we tested whether these factors were responsible for Th17 priming 
by Pam3CSK4 co-stimulated DCs. To this aim, DCs matured in the presence of 
Pam3CSK4, pLPS and R848 and allogeneic memory CD4+ T cells were cultured 
for 6 days in the presence of control IgGs, IL-1 receptor antagonist (IL-1ra) and 
antibodies against IL-6R, TGFb, OX40L, IL-12p40 or IL-12p35. After six days the 
differentiated T cells were stimulated with PMA and ionomycin after which the 
IL-17 content of the supernatants was measured. In line with literature36, the 
neutralisation of IL-6 and IL-1α/b and especially the neutralisation of both resulted 
in a clear reduction of IL-17 production by the differentiated CD4+CD45RO+ T 
cells whereas the addition of anti-TGFb, anti-OX40L, anti-IL-12p40 and anti-IL12p35 
had no effect (Figure 7C).
149
TL
R
2 
p
ro
m
ot
es
 T
h2
/T
h1
7 
re
sp
on
se
s
6
Figure 6
Co-stimulation of TLR2 with TLR4 or TLR8 skews the immune response towards Th2/Th17. 
Naive CD4+CD45RA+CD45RO- T cells (A) and memory CD4+CD45RA-CD45RO+ T cells 
(B) isolated from the venous blood of healthy controls were added to DCs activated with 
pLPS and R848 and with or without Pam3CSK4 in a ratio of 10:1 and were cultured for 6 
days before the addition of PMA (50 ng/ml) and ionomycin (1 mg/ml). After 12h supernatants 
were collected for the measurement of the released levels of IFNγ, IL-4, IL-13, IL-10 and IL-17. 
Data are mean and SEM of four independent experiments including eight individuals. 
* = p<0.05 and ** = p<0.01 compared to co-incubation with medium.
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Figure 7
TLR2 stimulation mediates its TH17 inducing effect via the inhibition of IL-12p70 secretion. 
Naive CD4+CD45RA+CD45RO- T cells (A) and memory CD4+CD45RA-CD45RO+ T cells 
(B) isolated from the venous blood of healthy controls were added to pLPS and R848 
stimulated DCs with or without co-stimulation with Pam3CSK4 in a ratio of 10:1 and were 
cultured for 6 days in the absence or presence of antibodies against IL-12p35 before the 
addition of PMA (50 ng/ml) and ionomycin (1 mg/ml). After 12h supernatants were collected 
for the measurement of the released levels of IL-13 and IL-17 for the naïve and memory T cell 
population, respectively. Levels of cytokine release were compared to those produced by 
T cells cultured with pLPS and R848 stimulated DCs. (C) Memory CD4+CD45RA-CD45RO+ 
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In the present study, we identify TLR2 as a potent modulator of TLR4 and TLR7/8 
mediated immune responses confirming the recent observations by Gerosa et al 24. 
TLR2 on the one hand suppresses the release of TLR4 and TLR7/8 induced pro-
inflammatory cytokine release but on the other hand orchestrates the skewing of 
the immune response either toward Th1 or Th2 and Th17. In addition, we unravel 
two novel pathways by which TLR2 mediates its suppressive function baring 
potential for therapeutic intervention in immune diseases. By increasing the 
transcription of SOCS1 and decreasing the phosphorylation of STAT-1, 
transcription of type 1 IFNs and the transcription factors IRF1 and IRF8, TLR2 
potently inhibits the type 1 IFN amplification loop, thereby abrogating the 
production of IL-12p70. Moreover, the production of TNFα is suppressed by the 
activation of the intracellular inhibitor PI3K by TLR2. We further demonstrate that 
the inhibition of IL-12p70 release by TLR2 underlies the shift from a Th1 to a more 
Th2/Th17 prone response. 
The combination of archetypical constituents of a certain pathogen recognized 
by different pattern recognition receptors is thought to give specificity to our 
innate immune response. In this light, it can be envisaged that the myriad of 
host-derived TLR ligands generated in inflamed or degenerated tissue are able to 
modify these responses or in itself create specific immune responses. The role 
played by the different TLRs in immune activation was scrutinized extensively 
over the last years. The combined activation of certain TLR pathways has 
demonstrated some striking synergistic responses in the release of pro-inflam-
matory cytokines. The activation of TLR4 and TLR7/8 on DCs for example leads to 
the release of IL-12p70 and IL-23 that far surpasses the release by the activation 
of either TLR alone resulting in a prominent Th1 response10,11. Since the ubiquitous 
nature of endogenous proteins able to trigger TLRs is such that if unchecked the 
host would be overwhelmed by immune activation, several immune checkpoints 
6
T cells were added to DCs activated with the combination of Pam3CSK4, pLPS and R848 
in a ratio of 10:1 and were cultured for 6 days in the presence of antibodies against IL-12p35, 
IL-12p40, OX40 Ligand, TGFb, IL-6 Receptor or IL-1ra or the combination of an antibody 
against IL-6R and IL-1ra before the addition of PMA (50 ng/ml) and ionomycin (1 mg/ml). 
After 12h supernatants were collected for the measurement of the released levels of IL-17. 
Levels of IL-17 were compared to those produced by T cells cultured with DCs activated 
with the combination of Pam3CSK4, pLPS and R848 in the absence of neutralizing 
antibodies. Data are mean and SEM of three independent experiments. * = p<0.05 and ** = 
p<0.01 compared to co-incubation with medium alone.
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must be in place. A potential inhibitory or immune tuning role of TLRs has not 
been tested to a large extent in the literature.
An inhibitory function for TLR2 has been proposed in various settings. In contrast 
to TLR4 knockout mice, TLR2-/- mice are less susceptible to lethal infections with 
Yersinia enterocolitica or Candida albicans37,38. Next to the interference in the 
removal of pathogens the inhibitory effects mediated by TLR2 seem to have a 
bright side. In the absence of TLR2, uncontrolled inflammation and excessive 
injury of tissues in response to infections or during autoimmune processes have 
been observed21,23. Thereby, these studies demonstrate that TLR2 signals might 
have important protective effects against destructive chronic immune responses 
although the underlying pathways explaining these phenomena remain 
unidentified thus far. The present study establishes a role for TLR2 in providing an 
inhibitory signaling unit able to vigorously dampen TLR4 and TLR7/8 mediated 
activation of DCs and provides rational for the downstream pathways involved. 
For instance, PI3K, which functions at the early phase of TLR signaling and 
modulates the magnitude of the primary activation, was found to mediate the 
TLR2 induced inhibition of the release of TNFα while it did not affect IL-12p70 
secretion. IL-12p70 secretion in turn was inhibited by the dampening of the type 1 
IFN amplification loop seemingly by the increased transcription of SOCS1. PI3K 
as well as SOCS1 have been implicated as crucial negative regulators of Th1 
responses by suppressing the production of IL-12p7034,39. The absence of SOCS1 
in DCs enables them to invoke a potentiated Th1 response resulting in an 
enhanced antigen-specific anti-tumour immunity40,41. Likewise in an experimental 
arthritis model the severity of synovial inflammation and joint destruction was 
increased in the absence of SOCS142. In Chlamydia pneumoniae infection it was 
shown that SOCS1 inhibited the expression of type 1 IFNs and IFNγ and 
suppressed C. pneumoniae induced lethal inflammation but impaired effective 
bacterial clearance43. These observations corroborate with our results and 
demonstrate that TLR2 is able to up regulate the expression of SOCS1 in DCs, 
thereby reducing Th1 inflammatory responses.  
The ability of the immune system to mount an apt response to the wide array of 
different microbes is seminal to the protection of the host against these invading 
pathogens as well as the limitation of damage evoked by this response. In this 
light, the paradigm that activation of multiple TLRs by pathogens acts as a 
combinatorial code to induce a desired immune response is tempting. In addition 
this conceptual framework can be translated to the situation of autoimmunity in 
that the environment is thought to orchestrate the type of immune response. 
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Although the inhibitory role of TLR2 seems clear, in the removal of gram-positive 
bacteria, such as Streptococcus Pneumoniae and Staphylococcus aureus, TLR2 
signalling is of vital importance44-46. We demonstrated that the activation of TLR2 
in the presence of ligands for TLR4 and TLR7/8 leads to a shift from Th1 to Th17 
responses. This implies that pathogens harboring archetypical constituents that 
trigger multiple TLR systems are recognized and processed resulting in an apt T 
cell response, notably a predominant Th17 response when TLR2 is added to the 
equation. In accordance with this notion Th17 cells seem to be essential in the 
clearance of both S. Pneumoniae and S. aureus47,48. Many experimental 
autoimmune models are induced in the presence of complete Freund’s adjuvant 
(CFA) and are dependent on the presence of Th17 cells while the severity of the 
disease processes is aggravated by the removal of Th1 cells or the neutralization 
of IFNγ. The active component of CFA consists of sonicated Mycobacterium 
tuberculosis. M. tuberculosis is recognized by multiple pattern recognition 
receptors among which TLR2, TLR4, TLR9 and the NOD proteins seem to be the 
most dominant. In addition, it was recently demonstrated that IL-17 producing 
CD4+ T cells are intricately involved in the first phase of the immune response 
against M. tuberculosis49. Accordingly, in our system M. tuberculosis activated 
DCs did not produce IL-12p70 and were able to induce elevated levels of IL-17 
producing T cells (unpublished results). In line with these findings in experimental 
autoimmune encephalitis, evoked in the presence of CFA, type 1 IFN receptor 
mediated signalling pathways, important for the establishment of Th1 responses, 
constrained Th17 mediated inflammation19. These recent findings put previous 
observations by our laboratory, in which it was demonstrated that STAT-1-/- mice 
show an exacerbation of zymosan induced arthritis50, in a new light. Zymosan 
was demonstrated to induce strong Th17 responses24,51, by removing the STAT-1 
mediated IL-12p70/Th1 brake a fulminate inflammatory response mediated by 
Th17 cells can be expected. This underscores the delicate balance the immune 
system has to cope with keeping the different Th cell subsets in check thereby 
regulating immunity and tolerance.   
In summary, we demonstrate that TLR2 is a potent modulator of the immune 
system by abrogating the type 1 IFN amplification loop thereby inducing a shift 
from Th1 to Th2 and Th17 responses. This puts TLR2 in the middle of the immune 
network deciding whether the effector response against microorganisms or in 
autoimmunity is mainly Th1 or Th17 mediated. Modulation of TLR2 mediated 
signalling might thus provide novel avenues for the intervention within a broad 
spectrum of immune diseases.
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Abstract
One of the major pathways underlying RA is the aberrant production of pro-
inflammatory cytokines by infiltrating CD68+CD163- macrophages. Macrophage 
activation in turn reflects the actions of a variety of pathways including those 
mediated by activated T cells and critically TLR ligands.  We investigated whether 
Abatacept might reduce proinflammatory cytokine production by macrophages 
arising upon contact with cytokine activated T cells and/or stimulation with TLR 
ligands. Peripheral blood derived proinflammatory macrophages and cytokine 
stimulated T cells (Tck) were generated in vitro and added together in the presence 
of Abatacept or a control Ig, with or without TLR ligands. The production of 
cytokines was determined by multiplex methodologies. Abatacept potently 
reduced Tck-induced production of TNFα by macrophages. Tck and TLR ligands 
synergistically induced the production of proinflammatory cytokines by macro - 
phages. This was especially the case for IL-12p70 which was solely produced 
when the macrophages were activated by both TLR ligands and Tck. Abatacept 
significantly reduced IL-12p70 production. 
Infiltrating macrophages in the RA synovium are likely targets for activated T cells 
to induce the production of TNFα. Moreover in the presence of TLR ligands Tck 
stimulate macrophages to produce highly increased levels of TNFα, IL-6 and even 
IL-12p70. Abatacept was shown to potently suppress these pathways suggesting 
that its role may extend beyond antigen specific T cell mediated effector function. 
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Introduction
One of the major pathways underlying the pathological process in RA is the 
aberrant production of proinflammatory cytokines by macrophages. RA synovium 
is highly enriched with infiltrating CD68+CD163- macrophages and their decrease 
upon treatment is correlated with changes in disease activity 1. Monocyte-derived 
CD163- macrophages differentiated in vitro in the presence of GM-CSF (mf-1) 
exhibit the same characteristics as these infiltrating macrophages 2. 
One crucial pathway mediating synovial macrophage activation is that driven by 
direct interaction with activated T cells. In particular cytokine activated T cells 
recapitulate the functional properties of synovial T cells (4). This depends on 
cell-cell contact between memory CD4+CD45RO+ T cells and macrophages via 
CD69, CD18 and CD49d and was independent of the production of soluble 
mediators 3. CD4+CD45RO+ T cells are the main infiltrating cells in the pannus 
underlining their pivotal role in the pathogenesis of RA. Brennan et al demonstrated 
that human peripheral blood lymphocytes when cultured in  the presence of IL-2, 
IL-6 and TNFα (cytokine stimulated T cells, Tck) display the same characteristics 
as activated synovial T cells 4.
Another mechanism whereby cytokine production is induced in macrophages is 
the ligation of Toll-like receptors (TLRs). Many endogenous ligands for TLRs have 
been found in the arthritic joint, such as small heat-shock protein B8 which 
activates TLR4 and self RNA and DNA which more than likely activate cells in the 
joint via TLR3 and TLR8, respectively 5-8. Combinations of TLR ligands with T cell 
derived signals such as CD40 ligand or IFNγ have been demonstrated to be 
potent in the induction of proinflammatory cytokine production by macrophages. 
Since cytokine stimulated T cells strongly resemble the T cells present in synovitis 
it is of importance to know whether these cells are indeed capable of displaying 
synergistic effects with TLR ligands thereby contributing to the deranged cytokine 
profile found in the RA synovial cavity 9.
Abatacept, CTLA4 with an Fc tail, is a new agent in the armamentarium against 
RA. It blocks the instruction of T cells by antigen-presenting cells (APC) such as 
DCs and macrophages by binding to CD80 and CD86 on the APC thereby 
preventing binding to CD28 on the T cell, necessary for full T cell activation. We 
recently demonstrated in a murine system that abatacept also modulates follicular 
helper T cell maturation 10. Memory CD4+CD45RO+ T cells possess significant 
intracellular reservoirs of CTLA-4, which, upon stimulation, are transported readily 
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to the cell surface. Activation of mouse dendritic cells via CD80/86 by CTLA-4 
expressing T cells resulted in the production of IFNγ by the dendritic cells 11. It 
was recently suggested that CTLA4-Ig, via a direct effect on macrophages, 
reduces the ability of macrophages to produce cytokines upon the stimulation 
with concanavalin-A activated Jurkat T cells 12. We therefore investigated whether 
Abatacept could influence the RA disease course by diminishing the proinflam-
matory cytokine production by macrophages induced upon contact with cytokine 
activated T cells and TLR ligands. 
Materials and Methods
Culture of monocyte-derived type-1 macrophages and Tck. PBMCs were 
isolated from buffycoats from healthy blood donors by using density-gradient 
centrifugation over Histopaque (Sigma). The local Medical Ethics Committee 
approved the study protocol. Monocytes and CD4+ T cells were obtained using 
CD14 or CD4 microbeads, respectively, and AutoMACS (Miltenyi Biotec). Mf-1 
were generated by culturing isolated monocytes in the presence of GM-CSF (800 
U/ml) for 6 days. Mf-1 were cultured in 6 wells plates in a concentration of 5x105 
in 2 ml of culture medium (RPMI 1640, 10% fetal calf serum, penicillin/streptomycin, 
and L-glutamine; Gibco, Grand Island, NY). Fresh culture medium (1 ml) with the 
same supplements was added at day 3 after which the mf-1 were harvested at 
day 6. In parallel, CD4+  T cells from the same donor were cultured in complete 
medium with recombinant human IL-2 (25 ng/ml), IL-6 (100 ng/ml) and TNFα  (25 
ng/ml) (all from R&D) at a density of 2x106/ml for 6 days after which they were also 
harvested.
 Reagents. Abatacept was provided by Bristol-Myers Squibb. Chi L6 is a chimeric 
fusion protein consisting of the V region of murine L6 Ag, combined with a human 
IgG1 C region; it was used as a control fusion protein (control Ig) in these studies. 
The proteins were used in a final concentration of 20 mg/ml.
Stimulation of monocyte-derived mf-1. Harvested day 6 mf-1 were washed, 
counted and plated in a concentration of 5x104 cells per well in 96 well culture 
plates. For the cell-contact assay after extensive washing 2x105 cytokine-activat-
ed T cells were added to the mf-1 in the absence or presence of Abatacept or the 
control protein in a concentration of 20 mg/ml. In some experiments Tck fixed in 
4% paraformaldehyde were used. After 24 hours, the supernatants were collected 
for analysis of cytokine levels. For the TLR stimulation TLR agonists were added 
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to the mf-1 either in the presence or absence of Tck and/or Abatacept/control 
protein and after 24 hours the supernatants were harvested. LPS was used in a 
concentration of 1 ng/ml (E. coli 0111:B4, Sigma-Aldrich) and R848 was used in a 
concentration of 1 mg/ml (InvivoGen). 
Measurement of cytokines in culture supernatants. Levels of TNFα, IL-12p70, 
IL-6 and IL-10 were measured in the supernatants using commercially available 
kits (BioSource International, Camarillo, CA) according to the manufacturer’s 
instructions. Cytokine levels were measured and analyzed with the Bio-Plex 
system (Bio-Rad). 
Statistical analysis. Differences between groups were analyzed using the Mann- 
Whitney U test or the paired T-test when applicable. P values less than 0.05 were 
considered significant.
Results      
After 6 days of differentiation syngeneic Mf-1 and Tck cells were harvested, 
counted and replated together in 96 wells plates for cell-contact assays. Mf-1 
readily produced TNFα upon exposure to Tck while IL-6 and IL-10 were not 
released (Figure 1A and data not shown). This effect was at least partly mediated 
by cell-cell contact as paraformaldehyde fixed Tck, which are incapable of 
secreting cytokines, displayed stimulatory capacity, albeit lower than that 
observed in live cell co-cultures (Figure 1B). Next, we evaluated whether 
Abatacept might interfere with the production of TNFα by mf-1 upon contact with 
Tck. Blocking of CD80/86 by Abatacept resulted in a markedly decreased 
production of TNFα uncovering a novel manner by which Abatacept might 
interfere in the RA disease process (Figure 1C). To additionally study the potential 
effect of Tck on TLR mediated stimulation of mf-1, we used ligands for TLR4 and 
TLR7/8 together with Tck to determine whether they would cooperate in the 
production of proinflammatory cytokines by mf-1. Synergistic release of TNFα 
and especially IL-6 was observed when mf-1 were exposed to a TLR4 or TLR7/8 
ligand together with Tck (Figure 2A and B). Abatacept did not significantly 
reduce the production of TNFα or IL-6 under these circumstances (data not 
shown).
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Figure 1
Mf-1 readily produce TNFα upon exposure to Tck which is inhibited by Abatacept. A, Mf-1 
were stimulated with Tck for 24 hours after which the supernatants were measured for the 
presence of TNFα. Data are from triplicate wells and are representative of five individual 
experiments with similar results, bars are mean and SD. B, Mf-1 were stimulated with Tck 
or Tck fixed in PFA for 24 hours after which the supernatants were measured for the 
presence of TNFα. Data are from triplicate wells and are representative of two individual 
experiments with similar results, bars are mean and SD. C, Mf-1 were stimulated with Tck 
with medium, a control Ig (20 mg/ml) or Abatacept (20 mg/ml) for 24 hours after which the 
supernatants were measured for the presence of TNFα. Data are from triplicate wells and 
are representative of three individual experiments with similar results, bars are mean and 
SD. * = p<0.05 compared to control Ig.
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The IL-12p70/IFNγ axis appears to play an important role in the pathogenesis of 
RA13;14 therefore we aimed to determine whether Abatacept might additionally 
modulate this pathway. Stimulation of mf-1 with either TLR ligands or Tck alone 
did not induce IL-12p70 production. However, stimulation with either TLR4 or 
TLR7/8 ligands in combination with Tck resulted in clear release of IL-12p70 
(Figure 3A). Blockade of CD80/86 by Abatacept resulted in a significant reduction 
in the production of IL-12p70 (Figure 3B).  Abatacept had no effect on cytokine 
production induced by TLR ligands alone providing evidence that the effect of 
Abatacept is not due to inhibitory signaling through CD80/86 but was due to the 
blockade of Tck-mf interactions (data not shown).
7
Figure 2
The combination of Tck and TLR ligands synergistically induce the production of TNFα and 
IL-6 by mf-1. Mf-1 were unstimulated or stimulated with Tck or LPS(A)/R848(B) or a 
combination of both. After 24 hours the supernatants were collected and measured for their 
TNFα (left panels) and IL-6 (right panels) content. Data are from duplicate wells and are 
representative of three individual experiments with similar results. Bars are mean and SD.
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Figure 3
The combination of Tck and TLR ligands licenses mf-1 to produce IL-12p70 which is 
dampened by the presence of Abatacept. A, Mf-1 were unstimulated or stimulated with Tck 
or LPS(left panel)/R848(right panel) or a combination of both. After 24 hours the 
supernatants were collected and measured for their IL-12p70 content. B, Mf-1 were 
stimulated with Tck and LPS (left panel) or R848(right panel) in the presence of the control 
Ig (grey bars) or Abatacept (black bars). After 24 hours the supernatants were collected 
and measured for their IL-12p70 content. Data are from duplicate wells and are representative 
of three individual experiments with similar results. Bars are mean and SD. * = p<0.05 
compared to control Ig.
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Discussion
Abatacept is a valuable new drug in the treatment of RA, but its mode of action 
remains to be fully elucidated. We provide evidence that, in addition to inhibiting 
T cell activation and the reduction of migration of T cells into B cell follicles 10, 
Abatacept inhibits the Tck-induced production of proinflammatory cytokines by 
inflammatory CD68+CD163- macrophages. 
Various pathways have been implicated in the pathogenesis of the dysregulated 
proinflammatory cytokine environment in RA. We demonstrate herein that the 
combination of TLR ligands and cytokine activated T cells results in the synergistic 
release of TNFα and IL-6 and importantly licenses macrophages for the production 
of IL-12p70. 
In a recent study it was demonstrated that Abatacept reduces inflammation of the 
synovium without disrupting cellular constituents in patients unresponsive to 
anti-TNFα therapy. Interestingly especially the expression of IFNγ was reduced by 
52% 14. We provide a mechanistic explanation for this observation. We observed 
that Abatacept, reduces the production of IL-12p70 by mf-1, activated by Tck and 
a TLR ligand, by approximately 50%, whereas the production of TNFα was 
unaffected. Th1 cells and NKT cells are capable of producing copious amounts 
of IFNγ and IL-12p70 is crucial in both the differentiation of Th1 cells and the 
induction of IFNγ production by NKT cells 15-17. The IL-12p70/IFNγ axis was 
recently demonstrated, using the K/BxN serum transfer model and IL-12p35-/- 
mice, to promote antibody-induced joint inflammation underscoring the role 
played by IL-12p70 in arthritis 13.   
The question remains how Abatacept is capable of inhibiting the release of 
cytokines by proinflammatory macrophages upon the activation by Tck. Abatacept 
might directly activate certain pathways in macrophages via CD80/86 resulting in 
the inhibition of cytokine release upon Tck stimulation. This would, however, be a 
rather specific inhibitory effect since no difference in cytokine release was 
observed upon TLR stimulation. Activation of CD80/86 by CTLA4 expressing T 
cells was demonstrated to induce IFNγ production by mouse dendritic cells 11. It 
thus appears likely that the activation of CD80/86 by CD28 or CTLA4 expressed 
by the Tck plays a role in the cytokine production by the macrophages which is 
inhibited by Abatacept. The production of IFNγ by macrophages upon Tck 
activation might explain our results regarding the highly increased release of 
IL-12p70. IFNγ is known to potently increase the release of IL-12p70 by macrophages 
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upon TLR stimulation. In addition, steric hindrance might play a role by inhibiting 
full contact in the immunological synaps between necessary components leading 
to full instruction of the macrophages by Tck. Whereas we did not add an antibody 
specifically binding a receptor known to play a role in this process, Brennan et al 
did use a blocking antibody against the b2 integrin LFA-1 in experiments with Tck 
and macrophages 4. This had no effect on the level of TNFα produced, 
substantiating that a role for steric hindrance might be minimal.    
 
In conclusion, we demonstrated that infiltrating proinflammatory macrophages in 
the RA synovium are likely targets for activated T cells to induce the production of 
TNFα. Moreover in the presence of TLR ligands, which are present plentiful in the 
arthritic joint, activated T cells stimulate mf-1 to produce highly increased levels 
of TNFα, IL-6 and even IL-12p70. Abatacept was shown to potently interfere in 
these pathways.   
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Abstract
The pathogenesis of Psoriatic Arthritis (PsA) remains poorly understood. The 
underlying chronic inflammatory immune response is thought to be triggered by 
unknown environmental factors potentially arising from a defective immune 
function. An impaired acute inflammatory response by Dendritic Cells (DCs) 
might compromise the clearance of bacteria and predispose to chronic 
inflammation. The cytokine production by DCs from healthy controls, Rheumatoid 
Arthritis, PsA and psoriasis patients towards Mycobacterium tuberculosis, 
Mycobacterium avium paratuberculosis and a range of other bacteria and TLR 
ligands was determined. Phenotypical differences involved in cellular responses 
against (myco)bacteria were determined by qPCR and flow cytometry. The 
secretion of proinflammatory cytokines by PsA DCs was impaired upon in vitro 
challenge with mycobacteria and TLR2 ligands. This impairment was associated 
with elevated serum CRP levels. The expression of TLR2 and other receptors 
known to mediate mycobacterial recognition was unaltered. In contrast, the 
intracellular TLR inhibitors SOCS3 and A20 (TNFAIP3) were more highly expressed 
in DCs from PsA patients. PsA DCs further demonstrated up regulated levels of 
ATG16L1, NOX2 and LL37; molecules implicated in the immune response against 
intracellular bacteria. 
Our findings indicate that DCs from PsA patients have a disordered immune 
response towards some species of (myco)bacteria. This might predicate to 
impaired immune responses to, and in turn impaired clearance of, these bacteria 
setting the stage for the chronic inflammation of joints, entheses, skin and the 
gut.   
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Introduction
Psoriatic arthritis (PsA) is a common heterogeneous inflammatory disease of the 
skin, joints and entheses leading to discomfort, pain and in some cases the 
aggressive destruction of joints1-3. Like other spondyloarthropathies, PsA is 
associated with HLA-B27 positivity and (sub)clinical eye and gut inflammation1. 
Although the pathogenesis of PsA is unclear the underlying chronic inflammatory 
immune response, like in psoriasis, might be triggered by unknown environmental 
factors that function on the background of a polygenic susceptibility. Current 
available data do not support the notion that (autoreactive) T cells play an 
important role in the etiology of psoriasis nor PsA4;5. Analysis of intra-articular 
T-cells demonstrated that almost all expanded T cell clones were non-autoanti-
gen driven, inflammation-related expansions underscoring the notion that 
autoreactive T cells might not be crucial in PsA5. However, T lymphocytes are 
important in the instigation and persistence of the chronic inflammatory process. 
Recent studies have implicated an impaired barrier function of the skin as playing 
a role in the induction of psoriasis. It was shown that mutations and polymorphisms 
in keratinocyte-expressed genes involved in physical barrier function or innate 
immunity are risk factors for developing psoriasis6;7. In addition GWAS studies 
demonstrated associations between inhibitors of Toll-like receptor (TLR) signaling 
(TNFAIP3 (A20) and TNIP1) and psoriasis8. These findings appear to imply that 
psoriasis is, at least in part, a disease of the innate immune system. We wondered 
whether the pathogenesis of PsA might also, at least in part, be due to a defect in 
innate immunity.  
The first line of immune defense in tissues against pathogens is made up by 
resident Dendritic Cells (DCs)4. Upon the encounter of danger signals, recognized 
by pattern recognition receptors (PRR), DCs readily release antimicrobial 
peptides, chemokines and cytokines crucial for the induction of protective 
immune responses9. An important subset of the family of PRRs consists of the 
TLRs10. DC activation through TLRs results in the production of cytokines, 
enhanced expression of co-stimulatory and MHC molecules and enhanced 
bacterial killing. The initial release of cytokines and chemokines by DCs upon the 
encounter of a threat is pivotal in the creation of a microenvironment aimed at the 
immediate containment of the inciting pathogen or environmental factor. In order 
to prevent excessive inflammation TLR signaling is under tight control of an array 
of intracellular inhibitory molecules such as the suppressor of cytokine signaling 
(SOCS) proteins and  TNFAIP3 (A20)11;12. However, it is essential to note that an 
impaired release of pro-inflammatory mediators might culminate in chronic 
8
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inflammation due to the aberrant removal of pathogens or other inciting factors. 
The inciting environmental factors in the pathogenesis of PsA are unknown. However 
evidence points towards a pathogenic role for bacteria. The compartments mostly 
affected during PsA, namely the skin, joints and entheses, are likely sites where 
bacterial components are preferentially deposited13-15. In synovial fluid from PsA 
patients a higher variety and concentration of bacterial DNAs were found 
compared to serum (13). The trapping of microbial products at specific compromised 
sites appears indicative of at least a perpetuating role for pathogens in PsA. 
Furthermore PsA patients were demonstrated to have higher antibody levels 
against various bacteria and bacterial constituents than psoriasis patients without 
articular involvement, Rheumatoid Arthritis (RA) patients or healthy controls16-18. One 
bacterial type of particular interest in the pathogenesis of PsA are myco -bacteria. 
High levels of antibodies against 65-kDa and 48/45 doublet antigens from myco- 
bacteria have been found in psoriasis and these correlated with disease severity19. 
In addition, in placebo-controlled studies immunotherapy with Mycobacterium 
vaccae for psoriatic arthritis resulted in significant reductions of important disease 
parameters20. 
These findings prompted us to hypothesize that decreased immune reactivity 
towards (myco)bacteria might underlie PsA. PsA might thus be thought of as a 
dysfunctional barrier disease in which insufficient removal of invading pathogens 
by the immune system and subsequent deposition of bacteria at distal preferential 
sites results in local chronic inflammation. To determine the validity of our hypothesis 
we aimed to define whether DCs from PsA patients have an impaired immune 
response towards (myco)bacteria. We observed a striking inability of DCs from PsA 
patients to produce pro-inflammatory cytokines upon the exposure to mycobacteria. 
The inability to react adequately to these pathogens was associated with the 
presence of elevated CRP levels and was related to a reduced function of TLR2. 
Materials and Methods
Study population
Eleven RA patients, fifteen PsA patients and eight plaque-type psoriasis patients 
attending the Department of Rheumatology or the Department of Dermatology at 
the Radboud University Nijmegen Medical Centre and thirteen Dutch healthy 
controls were included. In addition six PsA patients attending the Centre for 
Rheumatic diseases at the Glasgow Royal Infirmary and six healthy controls 
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resident in Glasgow were included. All patients fulfilled the American College of 
Rheumatology criteria for RA or the CASPAR criteria for psoriatic arthritis at the 
time of disease diagnosis and gave their informed consent. Patients using 
biological agents and/or high dose prednisolone were excluded from the study. 
The local Medical Ethics Committees approved the study protocol. 
 
Isolation and culture of monocyte-derived Dendritic Cells 
PBMCs were isolated from heparinized venous blood of patients and healthy 
volunteers by using density-gradient centrifugation over Ficoll-Paque (Amersham 
Bioscience). Monocytes were obtained using CD14 microbeads and MS columns 
or an AutoMACS (Miltenyi Biotec). Monocyte-derived DCs were generated by 
culturing isolated monocytes in the presence of IL-4 (500 U/ml; Schering-Plough) 
and GM-CSF (800 U/ml; Schering-Plough) for 6 days. Fresh culture medium with 
growth factors was added at day 3. 
Flow cytometry of monocyte-derived DCs
Using standardized flow cytometry protocols phenotypical analysis of mono cyte-
derived DCs and macrophages was performed. Cells were characterized by staining 
with mAbs against human CD80 (BD Biosciences), CD86 (BD Pharmingen), 
MHC-II DR/DP (clone Q1514) and CD14, TLR2, DC-SIGN, Mannose Receptor (all 
BD Biosciences) and Dectin-1 (R&D). Cells were analyzed for the proportion of 
positive cells and the mean fluorescence intensity. As a control cells were stained 
with the appropriate IgG isotypes. For the determination of the binding and up 
take of the TLR2/1 ligand Pam3CSK4, rhodamine-labelled Pam3CSK4 (5 mg/ml, 
Invivogen) was added for 15 or 30 minutes at 37°C to DCs in 96 wells plates 
(5x104, 100 ml total volume). 
Stimulation of monocyte-derived DCs 
Day 6 monocyte-derived DCs were plated in a concentration of 0.5x106 DCs/ml 
and transferred to 24 well (1 ml) or 96 well (100 ml) culture plates. Cells were then 
stimulated with TLR agonists for 16-24 hours. For experiments in which mRNA 
levels were determined monocyte-derived DCs were stimulated for 4 hours before 
they were put in TRIzol. The concentration in which the agonists were used was 
as follows unless stated otherwise: LPS (LPS, 100 ng/ml, E. coli 0111:B4, Sigma-
Aldrich), Pam3CSK4 (5 mg/ml, EMC microcollections), FSL-1 (Pam2Cys, 1 mg/ml, 
EMC microcollections), MDP (2 mg/ml, Invivogen), heat-killed M. tuberculosis (10 
or 100 mg/ml, Gibco), S. pyogenes cell wall fragments (1 or 10 mg/ml), heat-killed 
M. avium paratuberculosis (5x106/ml), heat-killed K. pneumoniae (1x106/ml) (all 
three were kindly gifted by L.A.B. Joosten, Department of Internal Medicine, 
8
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Radboud University Nijmegen Medical Centre), heat-killed S. mutans (1x106/ml) 
and heat-killed E. coli (1x106/ml). Supernatants were collected after 24 hours for 
cytokine measurements. 
Measurement of cytokines in culture supernatants
Levels of IL-10, TNFα, IL-12p70, IL-6, IL-8 and IL-1b were measured in the super- 
natants using commercially available kits (Bio-Rad or BioScource) according to 
the manufacturer’s instructions. Cytokine levels were measured and analyzed 
with the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay was < 5 
pg/ml for all cytokines measured. 
RNA isolation and real-time PCR 
Total RNA was extracted in 1 ml of TRIzol reagent. Quantitative real-time PCR was 
performed using the ABI/Prism 7000 sequence detection system (Applied 
Biosystems). All PCRs were performed with SYBR Green Master mix (Applied 
Biosystems), 10 ng cDNA, and a primer concentration of 300 nmol/L in a total 
volume of 20 ml. Quantification of the PCR signals was performed by comparing 
the cycle threshold value (Ct) of the gene of interest of each sample with the Ct 
values of the reference genes GAPDH (DCt) and were deployed as relative 
expression (2-DCt x100). Software package Primer Express Version 2.0 (Applied 
Biosystems) was used to identify appropriate primer sets. Primers were as 
followed: GAPDH forward ATCTTCTTTTGCGTCGCCAG, reverse TTCCCCATG-
GTGTCTGAGC; SOCS1 forward CCCTGGTTGTTGTAGCAGCTT, reverse TTGTG-
CAAAGATACTGGGTATATGT; SOCS3 forward TCGGACCAGCGCCACTT, reverse 
CACTGGATGCGCAGGTTCT; SIGIRR forward TGAAAGACGGGCTTCCATTG, 
reverse TTCAGTGCTGGTCACGTTGAC; TOLLIP forward GCAGTACGGAGGCG-
CAGTGG, reverse CAGGCGCAGTCGGCAGTAGG; A20 forward AAGAAACT-
CAACTGGTGTCGAGAA, reverse TGCCGTCACCGTTCGTT; ATG16L1 forward 
AAAGAGCTTGCAGAAGCAGC, reverse GTCATGTCCACAGATGTGCC; NOX2 
forward CCCTCCTATGACTTGGAAATGGA, reverse TGGTTTTGAAAGGGTGAGT-
GAC; LL37 forward CAGCAGTCACCAGAGGATTGT, reverse CAG-
CAGGGCAAATCTCTTGTTA; IRGM1 forward CATCACTATGGCAGGGGACT, 
reverse AGTTCTCCAGGGTTGTGGTG.  
Statistical analysis 
Differences between groups were analyzed using the Mann-Whitney U test. Paired 
student’s T-test was used when differences were evaluated between different 
stimulations within donors. P values less than 0.05 were considered significant.
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Results
Decreased proinflammatory cytokine production by PsA DCs upon exposure 
to M. tuberculosis 
Monocytes were isolated from the venous blood of PsA (n=15) and RA (n=11) 
patients attending the outpatient clinic of the Department of Rheumatic Diseases 
at the Radboud University Nijmegen Medical Centre and from healthy controls 
(n=13). All PsA patients had peripheral arthritis. Patient characteristics are shown 
in table 1. After culturing the monocytes for 6 days in the presence of GM-CSF 
and IL-4 the resulting DCs were harvested. In order to evaluate the innate immune 
reaction towards M. tuberculosis in the RA and PsA patient populations and in 
healthy controls, DCs were exposed to M. tuberculosis or were left unstimulated. 
PsA patients produced significantly lower levels of TNFα and IL-6 when stimulated 
with M. tuberculosis compared to healthy controls and RA patients (Figure 1). 
The production of IL-10 upon M. tuberculosis stimulation demonstrated the same 
trend although statistical significance was not reached (Figure 1). The levels of 
IL-8 released by healthy control, RA and PsA DCs upon the stimulation with M. 
tuberculosis were similar while the levels of IL-12p70 and IL-1b were undetectable 
in all groups (Figure 1 and data not shown). To determine whether the reduced 
8
Table 1   Patient characteristics
PsA RA
Patients, n 15 11
Age in yr, mean (range) 55 (31-78) 62 (51-81)
Disease duration (yr); mean (range) 8 (1-41) 13 (1-28)
MTX use, n 6 6
SASP use, n 3 4
Other DMARD, n 2 0
Prednisolon, n 1 3
No DMARD/prednisolon, n 4 0
NSAID use, n 5 7
BSE, mean (range) 9.5 (2-30) 12.4 (3-30)
CRP ≥ 5, n 5 4
Rheumatoid factor positivity, n 1 11
TJC, mean (range) 1.4 (0-6) 1.2 (0-10)
SJC, mean (range) 1.9 (0-6) 1.7 (0-5)
DAS28, mean (range) n.a. 3.1 (1.8-7.1)
n.a. not applicable, TJC Tender Joint Count, SJC Swollen Joint Count, DAS28 Disease Activity Score 
(28 joints)
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cytokine production was reflected in a decreased phenotypical maturation we 
measured the expression of CD80, CD86 and MHCII of healthy control and PsA 
DCs before and after the activation with M. tuberculosis. No differences were 
found in the induction of these DC maturation markers (data not shown). In 
contrast to DCs from PsA patients, DCs from psoriasis patients did not 
demonstrate a hampered cytokine production when exposed to M. tuberculosis 
(Figure 2A). To determine whether this abnormality reflected a peculiar 
geographic phenomenon, monocyte-derived DCs were cultured from six PsA 
patients attending the Centre for Rheumatic diseases and six healthy controls 
resident in Glasgow. Similar to the previous results with Dutch PsA DCs, PsA DCs 
from Scottish patients produced significantly less TNFα and IL-6 when exposed 
to heat-killed M. tuberculosis compared to healthy control DCs (Figure 2B and C). 
Figure 1
Cytokine production by DCs from healthy controls, RA and PsA patients upon M. 
tuberculosis exposure. Secretion of TNFα,  IL-6 , IL-10 and IL-8 by DCs from healthy controls 
(n=13), RA (n=11) and PsA (n=15) patients stimulated with 100 mg/ml heat-killed M. 
tuberculosis. Lines represent means. Groups were compared using the Mann-Whitney U 
test. * = p<0.05 compared between two groups.
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The dysfunctional reaction of PsA DCs towards M. tuberculosis is related 
to the presence of CRP  
To determine whether disease activity was related to the cytokine production by 
DCs upon stimulation with M. tuberculosis we looked at the venous CRP levels at 
the time when blood was obtained for our experiments. In our experimental cohort 
4 of the 11 RA patients and 5 of the 15 PsA patients had a CRP above detection 
limit (5 mg/L). DCs from RA patients with a noticeable CRP did not produce 
significantly different amounts of TNFα compared to RA patients without an 
elevated CRP upon M. tuberculosis stimulation. In contrast, the DCs from PsA 
patients with a detectable CRP did produce significantly lower amounts of TNFα 
compared to PsA patients with a CRP below 5 mg/L (Figure 2D). The production 
of TNFα by RA or PsA DCs upon stimulation with M. tuberculosis in this population 
was independent of age, medication, disease duration, erythrocyte sedimentation 
rate and gender (data not shown). 
The dysfunctional proinflammatory cytokine release by PsA DCs is selective 
for certain bacterial species
To determine whether the effects found were selective for M. tuberculosis or could 
be extrapolated to other bacteria we performed experiments in which we stimulated 
8
Figure 2
Cytokine production by DCs from psoriasis patients and DCs from healthy controls and 
PsA patients from an independent centre upon M. tuberculosis exposure. Secretion of 
TNFα by DCs from healthy controls (n=8) and psoriasis patients (n=7) stimulated with 100 
mg/ml heat-killed M. tuberculosis (A). Secretion of TNFα (B) and IL-6 (C) by DCs from 
healthy controls (n=6) and PsA patients attending the Centre for Rheumatic diseases at the 
Glasgow Royal Infirmary (n=6) stimulated with 100 mg/ml heat-killed M. tuberculosis. 
Release of TNFα by DCs from Dutch RA and PsA (D) patients with a CRP below 5 mg/L or 
equal or above 5 mg/L (RA<5 mg/L, n=7 and ≥5 mg/L, n=5; PsA<5 mg/L, n=10 and ≥5 
mg/L, n=5) upon M. tuberculosis (100 mg/ml) stimulation. Groups were compared by 
means of the Mann-Whitney U test.* = p<0.05. 
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DCs from PsA patients and healthy controls with heat-killed M. avium paratuber-
culosis, S. pyogenes cell wall fragments, heat-killed S. mutans, E. coli or K. 
pneumonia. Comparable to the stimulation with M. tuberculosis, activation of PsA 
DCs with M. avium paratuberculosis led to the release of markedly lower levels of 
TNFα (Figure 3A). Stimulation of healthy control and PsA DCs with S. pyogenes, 
S. mutans, E. coli or K. pneumonia led to the release of similar amounts of TNFα 
(Figure 3B, C, D and data not shown). These data support the notion that the 
impaired innate immune reaction of PsA DCs is restricted to certain pathogens 
and is not due to a general incompetence of the DCs. 
Figure 3
Cytokine production by DCs from healthy controls, RA and PsA patients upon M. avium 
paratuberculosis, S. pyogenes cell wall fragments, S. mutans or E. coli exposure. (A) TNFα 
release by DCs from healthy controls (n=5) and PsA (n=5) patients stimulated with 1x107/
ml M. avium paratuberculosis. (B) Secretion of TNFα by DCs from healthy controls (n=6) 
and PsA (n=7) patients stimulated with 10 mg/ml S. pyogenes cell wall fragments. TNFα 
production by DCs from healthy controls (n=5) and PsA (n=5) patients stimulated with 
1x106/ml S. mutans (C) or E. coli (D). Bars are mean and SEM. Groups were compared by 
means of the Mann-Whitney U test.* = p<0.05. 
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PsA DCs produce less proinflammatory cytokines when exposed to specific 
PRR ligands and this is correlated with a diminished reaction towards M. 
tuberculosis 
To determine whether the aberrant immune reaction towards mycobacteria by 
PsA DCs might be due to a dysfunction of specific PRRs, we stimulated DCs from 
healthy controls and PsA patients with different ligands for PRRs suspected or 
known to play a role in the innate recognition of mycobacteria by DCs. DCs from 
PsA patients produced less TNFα upon the activation of TLR2/1 (Pam3CSK4) and 
upon the activation of both NOD2 (MDP) and TLR2/1 compared to healthy control 
DCs (Figure 4A). Stimulation of TLR2/6 (FSL-1) and the activation of both NOD2 
and TLR2/6 demonstrated the same trend but did not yet reach significance. 
When TLR4 (LPS) was added to the combinations the difference in TNFα 
production by HC and PsA DCs disappeared displaying the selectivity of the 
dysregulated cytokine production by PsA DCs and the delicate interactions 
between different PRRs (data not shown). In addition, TLR4 alone or dectin-1 
activation (curdlan) of healthy control and PsA DCs did not lead to differences in 
TNFα release either (data not shown). The release of TNFα upon the stimulation 
of TLR2/1 or TLR2/1 and NOD2 was highly correlated with the production of TNFα 
upon stimulation of DCs with M. tuberculosis (Figure 4B and C). TNFα production 
upon the TLR4 or dectin-1 ligation was not correlated with the production of TNFα 
upon M. tuberculosis stimulation of DCs (data not shown). This strengthens the 
notion that signalling through TLR2 is an important determinant of the magnitude 
of the cytokine response upon the stimulation of DCs with heat-killed M. 
tuberculosis. 
PsA DCs express unaltered levels of PRRs but significantly increased 
levels of SOCS3 and A20
We next determined whether the observed deregulated innate immune response 
by PsA DCs was due to an altered expression level of specific PRRs. The 
expression of CD14 and TLR2 was not altered on PsA DCs compared to healthy 
control DCs, although the levels were, as expected, extremely low (Figure 5A). To 
determine whether there is a difference in the regulation of the expression of TLRs 
which might be overlooked due to the very low expression, we determined the 
expression of TLR2, 4, 7 and 8 mRNA in healthy control and PsA DCs. No 
significant differences were found between healthy control and PsA DCs (data 
not shown). We additionally measured the expression of Mannose Receptor, 
DC-SIGN and Dectin-1, the expression of which was also identical on DCs from 
PsA patients compared to healthy control DCs (Figure 5A and data not shown). 
To determine whether the uptake and binding of TLR2 ligands by PsA DCs was 
8
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altered compared to healthy control DCs rhodamine-labelled Pam3CSK4 was 
added to the DCs. The uptake/binding of the TLR2 ligand by PsA DCs was not 
different from that by healthy control DCs (Figure 5B). The difference in cytokine 
production between healthy control and PsA DCs is thus not due to a difference 
in expression of PRRs nor is it due to a decreased capacity to bind TLR2 ligands. 
Since TLR are under the strict control of intracellular inhibitory proteins we 
wondered whether an elevated expression of these would underlie the restricted 
cytokine production by PsA DCs. Increased mRNA levels were observed for 
SOCS3 and A20 in unstimulated DCs from PsA patients with an active disease, 
while SOCS1, TOLLIP and SIGIRR were not significantly different (Figure 5C). RA 
patient DCs demonstrated similar levels of SOCS3 and A20 compared to healthy 
control DCs (data not shown). 
Figure 4
Pattern recognition receptor stimulation of DCs from healthy controls and PsA patients. (A) 
Secretion of TNFα by DCs from healthy controls (n=6) and PsA (n=5) patients stimulated 
with ligands for NOD2 (MDP, 1 mg/ml), TLR2/6 (FSL-1, 1 mg/ml), TLR2/1 (Pam3CSK4, 5 mg/
ml), combinations of these or with 100 mg/ml M. tuberculosis. Bars are mean and SEM. 
*=p<0.05. Correlation between the secretion of TNFα by DCs stimulated with ligands for 
TLR2/1 (Pam3CSK4, 5 mg/ml) (B) or TLR2/1 and NOD2 (MDP, 1 mg/ml) (C) with 100 mg/ml 
M. tuberculosis. 
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DCs from PsA patients express enhanced levels of genes involved in the 
immune response against intracellular (myco)bacteria 
M. tuberculosis infected alveolar and monocyte-derived macrophages exhibit 
increased expression of LL37 (cathelicidin)21. We tested whether DCs from PsA 
patients with active disease also had increased expression of LL37 and found 
clearly up regulated levels of LL37 in PsA DCs compared to healthy control and 
psoriasis DCs (Figure 6A). The difference between PsA DCs and RA DCs 
demonstrated a clear trend but did not reach significance. Next we evaluated the 
mRNA levels of the autophagy genes ATG16L1 and IRGM1 and of the signalling 
molecule NOX2. Both ATG16L1 and IRGM1 have been linked with Crohn’s disease 
susceptibility and the immune response against mycobacteria, whereas NOX2 is 
known to induce LL37. In addition to LL37, increased expression levels of ATG16L1 
and NOX2 have been reported in macrophages from mice infected with myco- 
bacteria22;23. Both ATG16L1 and NOX2 were found up regulated in DCs from PsA 
patients compared to healthy control, RA and psoriasis DCs (Figure 6B and C). 
No IRGM1 mRNA was detectable in monocyte-derived DCs (data not shown). 
8
Figure 5
Expression of PRRs and intracellular signalling inhibitors. (A) Expression of TLR2, CD14, 
mannose receptor (MR) and DC-SIGN on unstimulated DCs from a healthy control (grey 
lines) and a PsA patient (black lines) cultured simultaneously. Data are representative of 
three independent experiments. (B) Binding and up take of Rhodamine-labelled Pam3CSK4 
by DCs from a healthy control and a PsA patient cultured simultaneously. Data are 
representative of two independent experiments. (C) mRNA expression of SOCS1, SOCS3, 
SIGIRR, TOLLIP and A20 relative to GAPDH expression (x100) in unstimulated DCs from 
healthy controls (n=7) and PsA patients (n=8) cultured simultaneously. Data are mean and 
SEM. Groups were compared by means of the Mann-Whitney U test.* = p<0.05.
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Discussion
Although considerable advances have been made in understanding the patho- 
genesis of PsA, the principal nature of the disease as an epithelial or immunological 
disorder are as yet enigmatic. Our observations reveal a fundamental deficit in 
innate immune recognition, particularly of mycobacterial species, that might 
underlie the initiation and/or perpetuation of PsA. This impaired function coincides 
with highly up regulated expression of molecules intimately involved in the 
regulation of the immune response against (intracellular) pathogens. These 
findings were selective for PsA patients and not even found for psoriasis patients. 
This appears to underscore that psoriasis and PsA might have a different 
underlying aetiology despite their clear clinical overlap. Genetic research is in line 
with this, demonstrating that first-relatives from PsA patients have a forty-fold 
increased risk of developing the disease which is much more than found for 
psoriasis24. This, together with a substantial body of evidence originating from 
previous studies prompted us to propose a mechanism that ultimately might lead 
to the disclosure of the environmental factor(s) fundamental to the pathology of 
PsA.
The role played by bacteria in the pathogenesis of spondyloarthropathies, such 
as Crohn’s disease, psoriatic disease and ankylosing spondylitis, has been 
subject of investigation for decades. Diseases like PsA and ankylosing spondylitis 
often coincide with (subclinical) gut inflammation reminiscent of Crohn’s disease. 
Figure 6
mRNA expression of mediators involved in the immune response against intracellular 
(myco)bacteria. The expression of Cathelicidin/LL37 (A), ATG16L1 (B) and NOX2 (C) mRNA 
was determined in DCs from healthy controls (n=8) and RA (n=5), PsA (n=8) and psoriasis 
(n=7) patients. Values are relative to GAPDH expression (x100). Groups were compared by 
means of the Mann-Whitney U test.* = p<0.05.
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Common genetic and immunological mechanisms seem to underlie skin, gut and 
joint inflammation in these diseases25. Since patients with Crohn’s disease were 
recently shown to have an impaired acute inflammatory response in the skin and 
consequently an impaired removal of bacteria, accumulating evidence suggests 
that diseases like PsA and Crohn’s disease might be two sides of the same coin26. 
An aberrant innate immune reaction by resident immune cells towards certain 
bacteria appears to underlie both diseases. Whereas Smith et al 27 demonstrated 
dysfunctional cytokine secretion upon the exposure of macrophages from Crohn’s 
disease patients to heat-killed E. coli, we show here that DCs from PsA patients 
have a grossly impaired function when stimulated with mycobacteria, possibly 
facilitating the insufficient removal of pathogens culminating in chronic inflammation. 
In Crohn’s disease primary innate immunodeficiency of macrophages leading 
to an impaired innate immune response and bacterial clearance has been 
demonstrated27. Recently a strong genetic and functional link between susceptibility 
to leprosy, a disease caused by Myco -bacterium leprae, and predisposition to 
Crohn’s disease has been established28;29. Mycobacteria are ubiquitous in the 
environment and possess considerable stealth and capacity to adapt to 
environmental changes30;31. Mycobacteria have evolved strategies to survive 
within myeloid cells by preventing phagosome-lysosome fusion32. In Crohn’s 
disease a pathogenic role for M. avium paratuberculosis has been suggested for 
years33. A possible role for mycobacteria in Crohn’s disease appears to be 
underlined by the strong genetic link between the susceptibility to leprosy and the 
predisposition to Crohn’s disease28;29. Some evidence also suggests  a role for 
mycobacteria in PsA, vaccination with mycobacteria, for example, reduces 
disease severity20.  
The impaired immune response against M. tuberculosis by PsA DCs was related 
to the presence of CRP. This presents us with the question whether the aberrant 
DC phenotype is a true contributing factor to the disease or if it’s merely a 
consequence of the disease process. If it is just a consequence of the chronic 
inflammatory process in PsA the increased expression of LL37 and ATG16L1 is 
remarkable. The antimicrobial peptide LL37 is up regulated during infection with 
M. tuberculosis in human macrophages and keratinocytes34;35. Next to its direct 
antimicrobial activity LL37 was shown to be a mediator of autophagy, an important 
anti-mycobacterial defense. In addition LL37 was shown to be highly expressed 
in psoriatic skin and able to bind self-DNA and RNA. DCs efficiently transport 
these complexes to endosomes where they activated nucleic acid-sensing TLRs 
leading to proinflammatory cytokine production36;37. Our data demonstrating that 
LL37 is highly up regulated in DCs from PsA patients thus might suggest a 
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protective mechanism of the immune system against mycobacteria whereas it 
might also perpetuate the ongoing disease process in PsA. The increased 
expression of ATG16L1 in PsA DCs also underscores the possible involvement of 
intracellular (myco)bacteria in PsA. ATG16L1 is an autophagy-related molecule 
associated with Crohn’s disease, autophagy is important in the cellular immune 
response against intracellular (myco)bacteria by increasing killing and peptide 
presentation38;39. The increased expression of ATG16L1 found in PsA DCs might 
be a forced act in response to a (myco)bacterial infection. This is in line with the 
increased expression of NADPH oxidase 2 (Nox2) in PsA DCs. Nox2 activity is a 
key signal for the production of cathelicidin/LL37 and the induction of autophagal 
degradation of phagosomes22;40. The seemingly extreme readiness of PsA DCs 
to counteract an infection with an intracellular pathogen appears contradictory to 
an impaired clearance as we have suggested. However, it is clear from literature 
that the production of proinflammatory cytokines is crucial for the prevention of 
infections41. The activation of these intracellular defenses thus appears to act as 
a rescue mechanism preventing the full-blown infection of the host.
  
The reduced immune reaction against mycobacteria by PsA DCs appears to be, 
at least in part, mediated by the increased expression of the inhibitory proteins 
A20 and SOCS3. Interestingly, genome-wide association studies linked A20 with 
psoriasis susceptibility8. A20 is an ubiquitin-modifying enzyme that restricts TNF 
receptor and TLR induced signals. A20-deficient cells in addition demonstrated 
dramatically amplified responses to NOD2 activation, a PRR linked to Crohn’s 
disease and psoriasis susceptibility12. We found that, next to TLR2 stimulation, 
NOD2 stimulation of PsA DCs was hampered, underscoring the involvement of 
A20 in the observed dysfunctional immune response by PsA DCs. SOCS proteins 
regulate JAK/STAT signaling pathways and interfere in TLR signaling42. SOCS3 is 
up regulated in human macrophages infected with mycobacteria rendering them 
unresponsive to IFNγ, and hindering the clearance of bacteria43.      
The correlation between the decreased proinflammatory cytokine production by 
PsA DCs upon the exposure to mycobacteria, NOD2 and TLR2 ligands could be 
expected since NOD2 and TLR2 activation have been shown to be crucial in the 
recognition of mycobacteria although other immunoreceptors have also been 
implicated44;45. This is in sharp contrast to S. pyogenes for which a MyD88 
dependency in its recognition was shown which was not crucially dependent on 
either TLR1, TLR2, TLR4, TLR9 or TLR2/646. This indicates that for the recognition of 
S. pyogenes a combination of multiple TLRs act in concert, which is not affected 
in PsA DCs. The recognition of E. coli and K. pneumoniae appears to be mainly 
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mediated through TLR4 which might explain the unhampered recognition of this 
gram-negative pathogen by PsA DCs47. Together these findings indicate that the 
hampered innate immune response by PsA DCs is selective for pathogens 
triggering specific combinations of PRRs, possibly mainly those triggering TLR2. 
In conclusion, we have uncovered an aberrant immune response by DCs from 
PsA patients towards specific intracellular (myco)bacteria which might underlie 
their impaired removal in the tissues affected in this condition. Intriguingly, this 
altered response was absent in psoriasis patients assuming a different pathogenic 
mechanism compared with psoriatic arthritis. Further studies are warranted to 
further define the underlying circuitry leading to this impaired immune function.
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Abstract
The pathogenesis of Psoriatic Arthritis (PsA) remains poorly understood. The 
underlying chronic inflammatory immune response is thought to be triggered by 
unknown environmental factors potentially arising from a defective barrier function 
of the skin as well as an impaired immune function of Dendritic Cells (DCs). “Anti-
inflammatory” CD163+ macrophages (mf-2) are highly present in psoriatic 
synovium. We determined whether these mf-2 have an aberrant phenotype 
compared to those from healthy controls thereby contributing to chronic 
inflammation. Mf-2 from healthy controls and PsA patients were analysed for their 
expression of various cell surface receptors as well as their cytokine production 
when exposed to a range of bacteria and single Toll-Like receptor (TLR) ligands. 
Differences between healthy control and PsA mf-2 involved in suppressing DC 
function were determined by stimulation assays and mixed leucocyte reactions. 
CCR5 was significantly increased on mf-2 from PsA patients compared to healthy 
controls while the expression of CCR1, TLR2 and CD14 was unaltered. Further 
research revealed that PsA mf-2 secreted more IL-6 upon incubation with 
heat-killed Escherichia coli and E. coli lipopolysaccharide, were less efficient in 
taking up E. coli and were incapable of suppressing pro-inflammatory cytokine 
production by autologous DCs compared with mf-2 from their healthy counterparts 
. Further reflecting their disordered function was the finding that in allogenic T cell 
assays PsA mf-2 are incapable of suppressing DC induced IL-17 and TNFα 
production by T cells. In addition naive CD4+ T cells from PsA patients already 
have an intrinsic increased tendency to polarize into IL-17 producing T cells.
In this manuscript we demonstrate the dysfunction of “anti-inflammatory” 
CD163+CCR5+ mf-2 in PsA. This implicates mf-2 as an important defective cell 
type in PsA facilitating chronic inflammation instead of exerting their normal 
function of restoring immune homeostasis. 
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Introduction
Psoriatic arthritis (PsA) is an inflammatory disease of the skin, joints and entheses 
leading to discomfort, pain and in some cases the aggressive destruction of 
joints (arthritis mutilans). Approximately 15-25% of psoriasis patients develop 
arthritis, the incidence of which rises with disease severity (1-3). Although the 
events leading to the development of psoriasis and PsA are unclear the underlying 
chronic inflammatory immune response is thought to be triggered by unknown 
environmental factors on a polygenic background with increased susceptibility. 
Recent studies have implicated an impaired barrier function of the skin as a major 
determinant in the induction of psoriasis. It was shown that mutations and 
polymorphisms in keratinocyte-expressed genes involved in physical barrier 
function or innate immunity, are risk factors for developing psoriasis (4,5). The 
pathogenic role of activated CD4+ T cells has been demonstrated by the clinical 
efficacy of drugs that inhibit T cell activation or deplete activated T cells (6). These 
findings appear to imply that the aetiology of PsA is based on aberrances in the 
innate immune system followed by a dysregulated adaptive immune response. 
In psoriatic disease the role played by DCs and macrophages is apparent from 
studies ranging from mouse models to human in vitro studies and drug trials. 
While in normal human skin only DCs are present in both the epidermis 
(Langerhans cells) and the dermis (dermal DCs) in psoriatic skin macrophages 
are also found in considerable numbers (7). The inflamed synovium and skin from 
PsA patients is characterized by a marked infiltration with “resident” CD163+ 
macrophages. CD163 is a marker for type 2 macrophages (mf-2) which are 
highly phagocytic, are resident at mucosal surfaces and the peritoneum, and 
have been been suggested to play a role in the suppression of tissue inflammation 
due to their secretion of IL-10 and their suppressive effect on the development of 
IFNγ producing T cells (8,9). By culturing monocytes with M-CSF Mf-2 can be 
differentiated in vitro (9). The function of CD163+ macrophages in psoriatic 
disease is not fully understood. Global disease activity in patients with spondylar-
thropathy, including PsA patients, correlated significantly with the infiltration of 
CD163+ macrophages (10)-(11). CD163+ macrophages were highly increased in 
psoriatic lesional skin and returned to normal levels after anti-TNFα treatment 
(12). It was shown that in psoriasis CD163+ macrophages were not immunostimu-
latory and were, like in vitro M-CSF-cultured CD163+ macrophages, (virtually) 
unable to polarize T cells to produce IL-17 or IFNγ (13). 
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Bacteria have long been thought to play a role in many autoinflammatory and 
autoimmune diseases. Macrophages of Crohn’s disease patients have been 
shown to have an aberrant immune reaction towards heat-killed E. coli leading to 
the delayed removal of these pathogens when injected intradermally, possibly 
contributing to the chronic inflammatory process (14). PsA and Crohn’s disease 
are both thought of as dysfunctional barrier diseases and both diseases share a 
remarkable clinical and genetic overlap. The compartments mostly affected 
during PsA, namely the joints and entheses, are sites where bacterial components 
are preferentially deposited (15-17). PsA patients have higher antibody levels 
against various bacteria and bacterial constituents than Rheumatoid Arthritis 
(RA) patients or healthy controls (18-20). Mycobacteria have been suspected of 
playing a role in Crohn’s disease as well as psoriatic disease (21). The presence 
of M avium subspecies paratuberculosis reactive T cells with a Th1 or Th1/Th17 
phenotype strengthens a possible role of mycobacteria in Crohn’s disease (22). 
In addition, a strong genetic and functional link between susceptibility to leprosy, 
a disease caused by Mycobacterium leprae, and predisposition to Crohn’s 
disease has been established (23,24). In psoriatic disease high levels of antibodies 
against 65-kDa and 48/45 doublet antigens from mycobacteria have been found 
and these correlated with disease severity (25). The hypothesis that certain 
bacteria might play a role in PsA was strengthened by our finding that DCs from 
PsA patients with an active disease have a severely impaired innate immune 
reaction towards mycobacteria (Wenink et al. submitted). Taken together, a 
hypothetical framework can be formed for the pathogenesis of PsA in which an 
initial decreased response by DCs towards certain (myco)bacteria would lead to 
an insufficient removal of these bacteria and the initiation of inflammatory 
responses. However, how this inflammatory response derails and becomes 
chronic is left unanswered. A potentially altered function of the abundantly present 
CD163+ Mf-2 is an interesting hypothesis to work with in an attempt to answer 
this issue.
Here we demonstrate that CD163+ macrophages from PsA patients display a 
remarkably different phenotype and function compared with those from healthy 
controls. Our data thus demonstrate that mf-2 in PsA fail to inhibit inflammatory 
responses which potentially underlies the ongoing inflammatory response in 
these patients. Therefore, restoring the function of mf-2 in PsA is an attractive 
novel therapeutic target in this condition.         
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Materials and Methods
Study population
Nine PsA patients attending the Department of Rheumatology at the Radboud 
University Nijmegen Medical Centre and nine Dutch healthy controls were 
included. In addition eight PsA patients attending the Centre for Rheumatic 
diseases at the Glasgow Royal Infirmary and eight healthy controls resident in 
Glasgow were included. All patients fulfilled CASPAR criteria for psoriatic arthritis 
at the time of disease diagnosis and gave their informed consent. Patients using 
biological agents and/or high dose prednisolone were excluded from the study or 
added separately to analyze the effect of anti-TNFα treatment. The local Medical 
Ethics Committees approved the study protocol. 
 
Isolation and culture of monocyte-derived type-2 macrophages and 
Dendritic Cells 
PBMCs were isolated from heparinized venous blood of healthy volunteers and 
PsA patients by using density-gradient centrifugation over Ficoll-Paque 
(Amersham Bioscience). Monocytes were obtained using CD14 microbeads and 
MS columns or an AutoMACS (Miltenyi Biotec). Monocyte-derived macrophages 
were generated by culturing isolated monocytes in the presence of M-CSF (50 
ng/ml, Invitrogen). Monocyte-derived DCs were generated by culturing isolated 
monocytes in the presence of IL-4 (500 U/ml; Schering-Plough) and GM-CSF 
(800 U/ml; Schering-Plough) for 6 days. Fresh culture medium with the appropriate 
growth factors was added at day 3. 
Flow cytometry of monocyte-derived type-2 macrophages
Using standardized flow cytometry protocols phenotypical analysis of monocyte-
derived macrophages was performed. Cells were characterized by staining with 
mAbs against human CCR1, CCR5 (both R&D) and CD14 and TLR2 (both BD 
Biosciences). Cells were analyzed for the proportion of positive cells and the mean 
fluorescence intensity. As a control cells were stained with the appropriate IgG 
isotypes. For the determination of the binding and up take of E. coli, E. coli (k-12) flu-
orescein-labelled Bioparticles (25 mg/ml, Invitrogen) were added for 15, 30 or 45 
minutes at 37°C to macrophages or DCs in 96 wells plates (5x104, 100 ml total volume). 
Stimulation of monocyte-derived macrophages
Day 6 monocyte-derived macrophages were replated in a concentration of 
0.5x106 /ml in 96 well (100 ml/well) culture plates. Cells were then stimulated with 
heat-killed bacteria or TLR agonists. The concentration in which the stimuli were 
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used was as follows: LPS (LPS, 100 ng/ml, E. coli 0111:B4, Sigma-Aldrich), 
Pam3CSK4 (5 mg/ml, EMC microcollections), R848 (2 mg/ml, Enzo life sciences) 
heat-killed M. tuberculosis (100 mg/ml, Gibco), heat-killed P. gingivalis (1x106/ml, 
Invitrogen) and heat-killed E. coli (1x106/ml). Supernatants were collected after 24 
hours for cytokine measurements. 
DC and macrophage co-stimulations
After harvesting at day 6 of culture 5x104 monocyte-derived macrophages and 
5x104 DCs were replated separately in 96 well culture plates. To determine the 
effect of the presence of macrophages on DC (and vice versa) 5x104 macrophages 
together with 5x104 DCs were put in 96 wells plates, as a control 1x105 macro- 
phages and 1x105 DCs were also plated separately in 96 wells plates. Cells were then 
stimulated with heat-killed M. tuberculosis (100 mg/ml, Gibco) in a total volume of 
200 ml. Supernatants were collected after 24 hours for cytokine measurements. 
T-cell assays
At day 6 monocyte-derived macrophages and DCs were harvested and 
resuspended in a concentration of 1x105 cells/ml in culture medium. 5x103 
macrophages and/or 5x103 DCs were replated in 96 round bottom well plates. 
CD4+ T cells from PBMCs from healthy controls were obtained by negative 
selection using microbeads and MS columns or AutoMacs (Miltenyi Biotec). Next 
CD4+CD45RA+ naïve T cells were separated from the CD4+CD45RO+ T cells by 
the use of microbeads aimed at CD45RO. 50x103 CD4+CD45RA+ T cells were 
added to the round bottom wells with the DCs, macrophages or macrophages+DCs. 
Next lipoarrabinomannan (10 mg/ml, Invitrogen) or heat-killed M. tuberculosis 
(100 mg/ml) was added to the round bottom wells. At day five of the MLR cells 
were incubated with PMA (50 ng/ml, Sigma) and Ionomycin (1 mg/ml, Sigma) 12 
hours before the collection of supernatants. In addition T-cell experiments were 
performed in which unstimulated or M. tuberculosis (24 hours, 100mg/ml) 
stimulated 5x103 DCs from healthy controls or CD3/CD28 expander beads in 
medium from the M. tuberculosis stimulated healthy control DCs (50 ml/well) were 
co-cultured with allogeneic CD4+CD45RA+  T cells from healthy controls or PsA 
patients for five days before the stimulation with PMA (50 ng/ml, Sigma) and 
Ionomycin (1 mg/ml, Sigma) 12 hours before the collection of supernatants. 
Measurement of cytokines in culture supernatants
Levels of IL-10, TNFα, IL-6, IFNγ, IL-17 and IL-13 were measured in the supernatants 
using commercially available kits (Bio-Rad or BioScource) according to the 
manufacturer’s instructions. Cytokine levels were measured and analyzed with 
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the Bio-Plex system (Bio-Rad). The sensitivity of the cytokine assay was < 5 pg/ml 
for all cytokines measured. 
Statistical analysis 
Differences between groups were analyzed using the Mann-Whitney U test. The 
paired students T-test was used where appropriate. P values less than 0.05 were 
considered significant.
Results
Selective increased expression of CCR5 on mf-2 from PsA patients
The inflamed synovium in Psoriatic Arthritis is characterized by the infiltration of 
high numbers of CD163+ mf-2. The role played by mf-2 in PsA not fully 
understood. Mf-2 have been suggested to suppress tissue inflammation by their 
preferential secretion of IL-10 and their suppressive effect on the development of 
IFNγ producing T cells (8,9). To determine their possible role in the perpetuation 
of tissue inflammation in PsA we first characterized their phenotype. While the 
expression of CD14, TLR2, mannose receptor (MR) and CCR1 was unaffected on 
PsA mf-2 compared to healthy control mf-2, monocyte-derived mf-2 from PsA 
patients express elevated levels of CCR5 (Figure 1a). This increased expression 
of CCR5 was not present on monocytes (Figure 1b). Mf-2 from PsA patients on 
anti-TNFα treatment demonstrated CCR5 levels comparable to healthy controls 
(Figure 1c). In contrast, type-1 GM-CSF cultured macrophages and monocyte-
derived DCs do not express considerable levels of CCR5 and Mf-2 from 
rheumatoid arthritis patients did not demonstrate elevated levels of CCR5 (data 
not shown). These findings might explain the marked and selective prevalence of 
mf-2 in the inflamed synovium of PsA patients.
Mf-2 from PsA patients produce increased levels of IL-6 when exposed 
to E. coli and phagocytose E. coli less efficiently
To further characterize PsA mf-2 we stimulated them with heat-killed Myco- 
bacterium tuberculosis, Escherichia coli or Porphyromonas gingivalis. It was 
demonstrated that exposure of PsA mf-2 to E. coli leads to an exaggerated IL-6 
production while the release of TNFα or IL-10 was not significantly altered. The 
cytokine production of PsA mf-2 was comparable to healthy control mf-2 upon 
exposure to M. tuberculosis or P. gingivalis (Figure 2A). To determine whether this 
increased released of IL-6 by PsA mf-2 was due to an altered response towards 
TLR triggering we stimulated PsA mf-2 with TLR ligands specific for TLR2/1 
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(Pam3CSK4), TLR4 (E. coli lipopolysaccharide) or TLR7/8 (R848). In line with their 
reaction towards heat-killed E. coli, PsA mf-2 produced increased levels of IL-6 
when exposed to purified E. coli lipopolysaccharide (Figure 2B).    
In Crohn’s disease deficient clearing of intradermally injected heat-killed E.coli 
has been demonstrated. Since PsA patients often have subclinical gut 
inflammation we wondered whether PsA mf-2 (and DCs) would demonstrate a 
reduced ability to phagocytose heat-killed E. coli. In comparison to healthy control 
mf-2, PsA mf-2 were less efficient in the up take of labelled E. coli (Figure 2C). 
DCs from PsA patients demonstrated the same defect. Even after 45 minutes 
there was still a significant deficiency in the uptake of E coli by the PsA DCs and 
macrophages (Figure 2D and data not shown). The uptake of E coli was due to 
active phagocytosis since the same assay on ice did not show any increase in the 
level of staining beyond the background (data not shown).
Figure 1
Increased expression of CCR5 on PsA mf-2. Staining of surface markers on mf-2 from 
healthy controls (n=8) and PsA patients (n=8) revealing no significant differences in CD14, 
TLR2, mannose receptor (MR) and CCR1 expression while the expression of CCR5 is highly 
increased on PsA mf-2 (A). Staining of CD14, TLR2, CCR1 and CCR5 on monocytes from 
healthy controls (n=4) and PsA patients (n=4) (B). Bars are mean and SEM. * = p=0.03. 
Expression of CCR5 on mf-2 from a healthy control, a PsA patient not on anti-TNFα therapy 
and a PsA patient on anti-TNFα therapy (C). Dotted lines are isotype controls, straight lines 
are CCR5 staining. Data for PsA patients on anti-TNFα therapy are representative for 2 
patients in 2 independent experiments.
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Figure 2
Increased production of IL-6 by PsA mf-2 upon stimulation with E. coli. Mf-2 from healthy 
controls (n=9) and PsA patients (n=9) stimulated with heat-killed bacteria (A) or single TLR 
ligands (B) demonstrating an increased release of IL-6 by PsA macrophages upon 
stimulation with heat-killed E. coli or E. coli lipopolysaccharide (LPS). (C) Mf-2 from a 
healthy control and a PsA patient were incubated with E. coli fluorescein-labelled 
Bioparticles for 15 minutes at 37°C. PsA mf-2 less efficiently phagocytised labelled E.coli 
compared to healthy control mf-2. Data are representative for 2 independent experiments 
with mf-2 from in total 2 healthy controls and 2 PsA patients. (D) DCs from a healthy control 
and a PsA patient were incubated with E. coli fluorescein-labelled Bioparticles for 0, 15 and 
45 minutes at 37°C. PsA DCs less efficiently phagocytised labelled E.coli compared to 
healthy control DCs after both 15 and 45 minutes. Data are representative for 3 independent 
experiments with mf-2 from in total 3 healthy controls and 3 PsA patients.
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PsA mf-2 are less capable of reducing pro-inflammatory cytokine 
production by DCs and CD4+ T cells 
Since mf-2 have been described as important mediators of tissue homeostasis 
and appear to be “anti-inflammatory” we wondered whether their suppressive 
character might be dysfunctional in PsA. Previously we demonstrated that reduced 
cytokine production by PsA DCs upon exposure to mycobacteria might underlie the 
disease process in PsA. We wondered whether the presence of mf-2 would alter 
the cytokine production of DCs upon exposure to M. tuberculosis. In co-cultures 
with autologous DCs PsA mf-2 were less capable of suppressing the M. tuberculosis 
induced production of TNFα or increasing the production of IL-10 in comparison to 
healthy control mf-2 (Figure 3A). In control experiments doubling the number of 
DCs resulted in the release of approximately twice the level of TNFα, IL-6 and IL-10 
produced while doubling the number of mf-2 resulted in an unaltered release of 
TNFα and IL-10 while the release of IL-6 was increased with fifty percent (data not 
shown). In line with these results, in MLR experiments PsA mf-2 were incapable of 
suppressing the polarization of TNFα and IL-17 while healthy control mf-2 potently 
reduced the capability of T cells to produce TNFα and IL-17 upon polarization after 
the stimulation with lipoarrabinomannan (a cell wall constituent of all mycobacteria) 
(Figure 3B). This effect was not due to an increase in the number of antigen-pre-
senting cells nor was it due to a decreased survival of PsA mf-2 and above all, 
successful treatment with anti-TNFα appeared to reinstate their capacity to 
suppress T cell polarization into TNFα and IL-17 producing cells (data not shown). 
CD4+CD45RA+ T cells from PsA patients demonstrate an increased 
tendency to polarize into IL-17 producing T cells
To determine whether naive CD4+ T cells from PsA patients possess a phenotype 
skewed towards the increased polarization of IL-17 producing T cells we stimulated 
CD4+CD45RA+ T cells from healthy controls and PsA patients with allogenic 
healthy control DCs. Naive T cells from PsA patients were more prone to polarize 
into IL-17 producing T cells compared to those from healthy controls when 
exposed to allogenic healthy control DCs stimulated with M. tuberculosis but not 
when exposed to immature unstimulated DCs (Figure 4A and B). To determine 
whether this was due to a different reaction towards (healthy control) DCs naive 
CD4+ T cells from healthy controls and PsA patients were cultured in the presence 
of CD3+CD28+ beads and supernatant from healthy control DCs stimulated with 
M. tuberculosis (to mimick an inflammatory environment). In line with the results 
obtained with healthy control DCs, PsA T cells activated with CD3+CD28+ beads 
were more prone to polarize into T cells capable of producing IL-17 compared to 
healthy control naive CD4+ T cells (Figure 4C). 
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Figure 3
PsA mf-2 are less efficient suppressors of DC mediated inflammatory responses. DCs and 
mf-2 from a healthy control (HC) and a PsA patient were stimulated separately (5x104 mf-2 
or DCs/well in a total volume of 200 ml) or together (5x104 mf-2 and 5x104 DCs/well in a total 
volume of 200 ml) with heat-killed M. tuberculosis. Released levels of TNFα, IL-6 and IL-10 in 
the supernatants were measured after 24 hours (A). Bars are mean from duplicate wells 
and SD. Data are representative for 3 independent experiments with in total 3 healthy 
controls and 3 PsA patients. (B) Allogenic CD4+ T cells from a healthy control were cultured 
during five days in the presence of DCs, mf-2 or DCs together with mf-2 from a healthy 
controls or a PsA patient, as a stimulus lipoarrabinomannan (a cell wall constituent of all 
mycobacteria) was added to the wells. After 5 days of culture the cells were activated with 
PMA and Ionomycin to induce cytokine production. After 12 hours the supernatants were 
collected and measured for their content of IL-17, IFNγ and TNFα. Bars are mean from 
duplicate wells and SD. Data are representative for 3 independent experiments with in total 
3 healthy controls and 3 PsA patients.
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Conclusion
The inflamed synovium and skin from PsA patients is characterized by a marked 
infiltration with CD163+ macrophages. CD163 is a marker for type 2 macrophages 
(mf-2) which are highly phagocytic and have been implicated in the suppression 
of tissue inflammation due to preferential IL-10 secretion and suppressive effects 
on the polarization of Th1 cells (8,9). The function of CD163+ macrophages in 
psoriatic arthritis is not fully understood. However, several observations pinpointed 
CD163+ macrophages as potential key players in PsA. For instance, PsA disease 
Figure 4
Naive CD4+ T cells from PsA patients have an increased tendency to polarize into IL-17 
producing T cells. T-cell experiments were performed in which unstimulated (A) or M. 
tuberculosis stimulated DCs (B) from healthy controls or CD3/CD28 expander beads in 
medium from M. tuberculosis stimulated healthy control DCs (C) were co-cultured with 
allogeneic CD4+CD45RA+  T cells from healthy controls (HC, n=6) or PsA patients (n=7) 
for five days. Before the collection of supernatants at day six of culture stimulation took 
place with PMA and Ionomycin for 12 hours. Levels of IL-17, IL-13 and IFNγ were measured 
in the supernatants. Bars are mean and SEM. * = p<0.05. 
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severity correlated significantly with the infiltration of CD163+ macrophages (10) 
and CD163+ macrophages were highly increased in psoriatic lesional skin but 
returned to normal levels after anti-TNFα treatment (12). 
Here we demonstrate that CD163+ type 2 macrophages from PsA patients have 
an markedly aberrant phenotype and function which suggests their direct 
implication in PsA for several reasons which will be discussed below. First, a 
higher CCR5 expression was clearly present on PsA CD163+ type 2 macrophages. 
CCR5 expression has been linked to various pathological processes. CCR5-/- 
mice, for example, demonstrated an increased activation of alternatively activated 
macrophages, a stronger Th2 response, decreased inflammation and longer 
allograft survival in a transplant model (26). Moreover, in bleomycin induced 
pulmonary fibrosis CCR5 deficiency led to a decrease in fibrotic changes induced 
by bone-marrow derived macrophages and fibrocytes (27). In this light it is 
interesting to note that psoriasis is associated with concomitant fibrotic diseases 
of the liver and the lungs (28). Fibrotic changes along the sacroiliac joints and 
spine are also common in PsA. The increased expression of CCR5 on monocytes 
and macrophages in PsA might thus be involved in these pathological changes. 
The increased expression of CCR5 on CD163+ macrophages in PsA is in line with 
the increased presence of CD163+ macrophages in the synovium of PsA patients 
since these cells were the only monocyte-derived cell type expressing CCR5 at 
substantial levels and the ligands for CCR5 are clearly present in the synovial 
cavity in PsA {Fiocco, 2010 407 /id}. A clue to why PsA patients express elevated 
levels of CCR5 might be the finding that CCR5 is elevated on monocyte-derived 
and alveolar macrophages during M. tuberculosis infection (29) and that antigens 
from M. avium complex up regulate the expression of CCR5 on monocytes. This 
is in line with our previous report demonstrating a dysfunctional response by PsA 
DCs towards mycobacteria possibly facilitating chronic inflammation due to a 
decreased removal of these pathogens (Wenink et al, submitted).
Second, mf-2 from PsA patients have an altered response to specific TLR ligands. 
Here we show that the production of IL-6 is higher in PsA mf-2 stimulated with E. 
coli. In PsA Th17 have been implicated as an important mediator of disease (30). 
In this context the increased production of IL-6 might be of importance by 
facilitating the development of Th17 since IL-6 has been shown to be crucial in the 
development of this pathogenic T cell subset (31). Besides, we demonstrated that 
DCs and mf-2 from PsA patients were less efficient in the uptake of E. coli 
compared to those from healthy individuals. This is in line with that observed in 
patients with Crohn’s disease were heat-killed E. coli is less efficiently cleared 
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when injected intradermally possibly leading to increased inflammatory responses 
(14). Deficient clearing of E. coli might thus also occur in PsA due to hampered 
phagocytosis by macrophages and DCs. Subsequently, this series of events 
might lead to a self-perpetuating loop were persistence of microorganisms lead 
to chronic activation of immune cells and might relate to the large proportion of 
PsA patients who have (subclinical) gut inflammation. Finally, PsA macrophages 
are shown to have an impaired anti-inflammatory response. This might explain 
why despite the prominent presence of “anti-inflammatory” mf-2 in inflamed 
tissues the inflammation ensues in PsA.  PsA mf-2 lack the capability to negatively 
influence pro-inflammatory DC functions while their cytokine production towards 
most ligands and mycobacteria is intact. This, in combination with the proneness 
of PsA naive T cells to polarize into IL-17 producing T cells, explains the high 
occurrence of Th1/Th17 in PsA and the chronic inflammatory responses evoked.
Altogether, these results support a hypothetical framework in which a dysfunctional 
innate immune response towards certain (myco)bacteria by resident myeloid DCs 
leads to the recruitment of type 2 macrophages which, under normal circumstances, 
would dampen the immune response. However due to a dysfunctional anti- 
inflammatory capacity and possibly the persistence of the (intracellular) bacterium 
the immune response persists, resulting in chronic inflammation enhanced by the 
influx of inflammatory Th subsets. Our observations provide important clues in 
the understanding of the pathogenesis of PsA. Further research focussed on the 
precise mechanisms underlying the aberrant response of antigen presenting 
cells in this condition is highly justified since it is likely to open novel avenues 
towards a patient tailored therapy approach.
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Final considerations
Rheumatoid and Psoriatic Arthritis are two diseases frequently seen in the clinic 
of a Rheumatology department. They are both diseases of the immune system 
and share common features like the inflammation of the small diarthrodial joints 
of the hands. While the occurrence of autoantibodies and bone destruction are 
high in RA, in PsA they are rarely seen. This underscores the distinct pathological 
mechanism underlying both diseases. While RA is thought of as a classic auto- 
immune disease characterized by autoreactive T cells, PsA appears to have more 
in common with autoinflammatory or dysfunctional barrier diseases such as 
Crohn’s disease. Recent reports, however, have demonstrated that around 15% of 
PsA patients have antibodies against citrullinated proteins, the hallmark 
autoantibodies of RA. Both diseases have in common that their pathological 
processes are characterized by a massive influx of immune cells such as T cells, 
macrophages, DCs, B cells and neutrophils. These immune cells form a complex 
network which appears to underlie the disease process. Over the last decades 
the pathways leading to the instigation and perpetuation of both diseases have 
been subject of investigation. 
In recent years the role played by TLRs in the initiation and/or perpetuation of 
both diseases has become apparent from both animal and human studies. TLRs 
are expressed by a wide range of immune and resident tissue cells. Upon TLR 
activation these cells start producing high amounts of cytokines, chemokines 
and other inflammatory mediators. In addition TLR activation of DCs leads to their 
differentiation from cells focused on sampling their environment and maintaining 
tolerance to cells capable of inducing adaptive immune responses. These 
important roles played by TLRs puts them in the spotlight as drivers of immune 
responses and possibly as agents causing autoimmunity and auto(inflammation). 
Proinflammatory cytokines such as IL-6 and TNFα have been shown to be crucial 
in the pathogenesis of synovitis. The neutralization of both cytokines has been 
proven to be efficacious in the treatment of RA and PsA. The inhibition of TLR4 
and TLR8 has been shown to decrease the TNFα production in RA synovium ex 
vivo implicating their role in the maintenance of the inflammatory milieu. Another 
pathway that leads to the production of proinflammatory cytokines in RA synovium 
is the contact between activated synovial T cells and macrophages, demonstrating 
the intricate network of immune cells perpetuating the disease process. 
Although the neutralization of TNFα or IL-6 is an effective treatment for RA it lacks 
both specificity and efficiency. The lack of specificity is due to the neutralization 
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of the cytokine targeted throughout the body. This leads to an increased risk of 
serious infections such as the well-known increased risk of the resurgence of a 
latent M tuberculosis infection. The lack in efficiency is apparent from the still 
small amount of patients that reaches true remission. The cause for this lacking 
efficiency might lie in the redundancy of many cytokines produced during immune 
activation or more, the role played by TNFα is likely taken over by other cytokines 
such as IL-1 and IL-6. For this reason studies have been done in which combinations 
of different antibodies were used. This led however, to an unacceptable increase 
in the occurrence of infections. Due to these restrictions it appears worthwhile to 
investigate the regulation of the production of these harmful inflammatory mediators. 
By understanding how the immune system gets activated and which pathways might 
be used to selectively undermine the ongoing immune response we aimed to get 
leads on novel pathways which might be used to treat diseases, such as RA, more 
targeted, leading to less side effects and possibly greater therapeutic efficacy.
Fc gamma Receptor IIb and Toll-Like Receptors
Our quest began with the question why some RA patients in time are able to 
discontinue their medication use, while the large majority of patients has to use 
potent immunosuppressive drugs for life. We observed that monocyte-derived 
DCs from patients capable of dampening their disease themselves, resulting in a 
very low disease activity without the help of medication, had a very high expression 
of the inhibitory FcγRIIb on their cell surface (Figure 1). 
These patients had a clear diagnosis at their time of entry in our outpatient clinic, 
some with a very high disease activity and already the presence of bony erosions. 
In time however their disease activity waned and they were taken of their 
medication. Since we had found that there were elevated levels of endogenous 
TLR4 ligands in serum and synovial fluid of RA patients and DCs from RA patients 
reacted more potently towards certain TLR4 ligands we wondered whether 
FcγRIIb might be able to interfere in the TLR4-mediated activation of DCs. 
Activation of DCs from RA patients who had successfully discontinued their 
medication use and thus had a high expression of the inhibitory FcγRIIb, with 
immune complexes significantly reduced the release of TNFα or IL-12p70 upon 
TLR4 activation. This inhibitory function of immune complexes was lost when 
FcγRIIb was blocked with specific antibodies demonstrating that FcγRIIb was 
responsible for the dampening effect of the immune complexes. This inhibition of 
cytokine production was shown to depend on the activation of the PI3K-Akt 
pathway by FcγRIIb. The inhibition of these intracellular molecules would increase 
the cytokine production when TLR4 was activated and it blocked the inhibitory 
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effect of FcγRIIb activation. We proposed a model by which FcγRIIb is able to 
dampen TLR4 responses. In this model the activation of a large number of FcγRIIb 
molecules draws a large part of the intracellular SHIP molecules to the cell surface 
away from the intracellular parts where it counteracts the effects of PI3K-Akt on 
TLR4. This leads to an increased inhibitory effect of phosphorylated Akt on the 
TLR4 pathways leading to a decreased proinflammatory cytokine production 
(Figure 2). This model was supported by Western Blot data demonstrating that 
activation of high numbers of FcγRIIb and TLR4 led to a highly increased 
phosphor ylation of SHIP and a decreased degradation of IkBα while the phos-
phorylation of Akt was also increased.
In addition we demonstrated that the activation of FcγRIIb on DCs has profound 
effects on the instruction of T cell responses by the DCs. FcγRIIb activation led to 
DCs capable of inducing strong Th2 responses and it would even restore the 
ability of TLR4 activated DCs to induce regulatory T cells to the same level as 
immature DCs. Both Th2 and regulatory T cells have been shown to be important 
in the restoration of immune homeostasis during Th1 and/or Th17 mediated 
inflammation. Interestingly, recently it was described that immune complexes 
containing citrullinated fibrinogen, present in seventy percent of ACPA-positive 
RA patients, would induce the vast production of TNFα by macrophages via the 
dual engagement of TLR4 and FcγRs 1. Overexpression of FcγRIIb thus seems a 
likely candidate to counteract the proinflammatory effect of these immune 
complexes on macrophages and DCs.
10
Figure 1
Highly increased expression of FcγRIIb on DCs from RA patients who were able to succesfully 
discontinue the use of immunosuppressives (RA (DMARD(-), low DAS28)). MFI = mean 
immune fluorescence as measured by flowcytometry.
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Next we aimed to determine whether the dampening effect of FcγRIIb was specific 
for TLR4. However, since RA patients capable of successfully discontinuing their 
medication use are rare we sought a cell type which would express FcγRIIb readily 
at high levels. Macrophages have been shown to express many FcγRs. As 
previously described under the influence of various factors such as M-CSF and 
GM-CSF monocytes can differentiate into different subsets of macrophages 
ranging from anti-inflammatory type 2 macrophages to proinflammatory type 1 
macrophages. GM-CSF is produced heavily at sites of inflammation, such as the 
arthritic joint, upon the activation of stromal and immune cells with endogenous 
damage associated or exogenous pathogen associated  molecular patterns. In 
addition, GM-CSF induces a proinflammatory state in many cells, especially 
Figure 2
Hypothetical model explaining the inhibition of TLR4 signalling upon the activation of 
FcγRIIb. The activation of FcγRIIb translocates SHIP molecules away from the cytoplasm 
towards the cell membrane. This drains the intracellular compartment of SHIP where it no 
longer counteracts the effects of PI3K on the processing of PIP2 into PIP3. This leads to an 
increase in phosphorylated Akt subsequently inhibiting the TLR4 signaling pathway 
resulting in a decrease in IkBα degradation and a decrease in proinflammatory cytokine 
production.
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monocytes/macrophages leading to the differentiation of type 1 macrophages 
capable of producing copious amounts of proinflammatory cytokines. Considering 
these characteristics we hypothesized that there should be mechanisms at work 
aimed at dampening the proinflammatory effect of GM-CSF to prevent chronic 
inflammation. In contrast to type 2 macrophages (and DCs) from healthy controls, 
type 1 macrophages indeed expressed very high levels of FcγRIIb. Activation of 
FcγRIIb on type 1 macrophages did not only inhibit TLR4-mediated cytokine 
release but also TLR2- and TLR7/8-mediated cytokine production but not the 
cytokine production induced by Dectin-1. In addition, FcγRIIb was found to inhibit 
the release of TNFα by type 1 macrophages induced upon contact with cytokine 
stimulated T cells further emphasizing the role played by FcγRIIb in suppressing 
inflammation. This shows that FcγRIIb has a broad but specific inhibitory effect on 
various extracellular and intracellular receptors expressed by (proinflammatory) 
monocyte-derived macrophages.      
Mac-1 and type 1 macrophages
In addition to our portrayal of the inhibitory function of FcγRIIb, many pathways/
factors have been described capable of dampening inflammation, such as IL-10 
and the intracellular expression of TLR pathway inhibitors (eg SOCS proteins, 
A20, SIGIRR etc). However, how these factors are regulated in monocytes/
macrophages/DCs prior to their initial exposure to inflammatory mediators and 
their release of (proinflammatory) cytokines is largely unknown. We demonstrated 
that the accumulation of monocyte-derived cells already has a grave impact on 
their differentiation. Type 1 macrophages differentiated at high concentrations 
produced significantly higher levels of IL-10 while they produced far lower levels 
of the proinflammatory cytokine TNFα. This anti-inflammatory phenotype seems 
in part due to the up regulation of intracellular TLR pathway inhibitors, especially 
SOCS3. These data appear to point to an in vivo mechanism in which the 
accumulation of sufficient amounts of macrophages at a site of inflammation 
induces an anti-inflammatory phenotype in the infiltrating macrophages aimed at 
dampening the immune response. Not only type 1 macrophages were subject to 
this regulatory mechanism but also DCs, leading to a potently decreased 
production of IL-12p70 and a decreased ability to support T cell responses. This 
negative feedback system depended on cell-cell contact via the b2-integrin 
Mac-1, signaling via p38 and the activation of COX2 resulting in the production of 
prostaglandins. In line with these results it was recently demonstrated that 
non-steroidal anti-inflammatory drugs (NSAIDs) which inhibit COX2 increased the 
spontaneous release of TNFα while decreasing the release of IL-10 2. This 
strengthens the notion that the mechanism we described is functioning in vivo 
10
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and regulates macrophage behavior under inflammatory conditions. TGFb, 
present in large amounts in many chronic inflammatory diseases , was capable of 
invalidating this shift towards an anti-inflammatory macrophage phenotype. The 
identification of this new inhibitory feedback mechanism and the inhibitory effect 
TGFb has on this might lead to new therapeutics or the reconsideration of old 
ones (COX2 inhibition with NSAIDs) for chronic inflammatory diseases. 
TLR2 and type 1 Interferons
Type 1 interferons (IFN), and especially IFNα, have been linked to many human 
diseases including PsA and RA. In PsA the accumulation of plasmacytoid DCs, 
the main producers of IFNα, has been shown to precede the occurrence of 
Psoriatic plaques and the application of a TLR7/8 agonist to psoriatic skin potently 
exacerbated the disease. In RA it was demonstrated that IFNα is expressed in 
synovium and its expression correlated with the expression of certain TLRs and 
proinflammatory cytokines. Another clue to the importance of type 1 IFN in the 
pathogenesis of RA is the finding that a significant proportion of RA patients 
displays a type 1 IFN signature in their mononuclear cells from peripheral blood 
and that serum of RA patients activates plasmacytoid DCs to produce IFNα 3. 
IFNα is able to prime other cells of the immune system. Importantly exposure of 
myeloid DCs to IFNα increases their reactivity to TLR ligands. Activation of 
myeloid DCs with type 1 IFN and LPS, for example, led to a synergistic release of 
IL-12p70. Recent advances in the literature have demonstrated that IL-12p70, next 
to the induction of Th1 cells, is important in the induction of follicular T helper cells 
(Tfh cells). Tfh cells help the development of antibody responses by B cells by the 
production of IL-21 and inducible costimulatory (ICOS). Tfh cells appear to play 
an important role in the development of many autoimmune diseases by facilitating 
the production of pathogenic autoantibodies and the formation of germinal 
centers 4;5. Type 1 IFN might thus underlie autoimmunity in RA by supporting the 
production of IL-12p70. In this light our finding that TLR2 is capable of potently 
inhibiting the production of IL-12p70 by abrogating the type 1 IFN loop sheds a 
new light on the role played by TLR2 in autoimmunity. 
TLR2 was demonstrated to be a potent inhibitor of TLR4 and TLR7/8 induced 
cytokine production by monocyte-derived DCs. TLR4 and TLR8 have both been 
demonstrated to play a role in the “spontaneous” cytokine production by RA 
synovial tissue. Alike for FcγRIIb the inhibition by TLR2 of TLR4 mediated TNFα 
release was prevented by inhibiting PI3K. However, whereas the inhibitory effect 
of FcγRIIb on the production of IL-12p70 was also mediated by PI3K, this was not 
the case for TLR2. TLR2 appeared to inhibit the production of IL-12p70 by up 
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regulating the transcription of SOCS1 (Figure 3). The production of IL-12p70 
depends on the type 1 interferon (IFN) amplification loop in which an initial small 
production of interferon leads to the additional transcription of interferon genes 
and IL-12p35. Interferon Regulatory Factors (IRF) 1, 7 and 8 have been 
demonstrated to be intricately involved in this process leading to IL-12p70 
production and Th1 responses. Co-activation of TLR2 with TLR4 and TLR7/8 led 
to a DC phenotype capable of inducing increased Th2 and Th17 responses while 
slightly decreasing the presence of Th1 cells compared to DCs stimulated with 
TLR4 and TLR7/8 alone. It would be interesting to determine whether the presence 
of follicular helper T cells decreases when DCs are co-incubated with TLR2 ligands.
10
Figure 3
Diagram representing the pathways TLR2 exploits to inhibit TLR4 and TLR7/8 mediated 
cytokine production. Activation of TLR2 inhibits the release of cytokines induced by TLR4 
or 7/8 stimulation via two pathways. The production of TNFα is reduced via the activation 
of the PI3K pathway while the release of IL-12p70 is hampered by interference in the inter-
feron-feedback loop probably at least in part due to the up regulation of SOCS1. A molecule 
known to inhibit STAT-1 phosphorylation. TLR2 co-activation with TLR4 and 7/8 leads to the 
inability of the DCs to produce copious amounts of IL-12p70. This has important positive 
effects on the ability of the DCs to skew T cell diffferentiation away from Th1 and  towards 
Th2 and Th17 responses. 
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These data demonstrate that TLR2 activation on DCs has pronounced effects on 
their cytokine production when other TLRs are simultaneously triggered, 
something that might occur in inflammatory conditions such as RA, and on their 
preferential Th cell induction. TLR2 might be a useful target in many autoimmune 
diseases. However due to its dual role in the immune response, activation of TLR2 
leads to the production of large amounts of proinflammatory cytokines by certain 
cell types such as type 1 macrophages, direct stimulation of TLR2 seems ill-advised.
               
Abatacept and activated T cells
The intricate network of cytokines present in arthritis joints is essential to the 
disease processes of RA and PsA. Different pathways have been proposed by 
which the production of cytokines by DCs and macrophages might be induced. 
The induction via TLRs has been discussed extensively in this thesis. Another 
stimulus important for the activation of macrophages in RA appears to be the 
direct activation via activated T cells. Monocytes/macrophages were demonstrated 
to readily produce TNFα when exposed to activated synovial T cells. This was 
shown to depend on cell-cell contact of memory CD4+CD45RO+ T cells and 
monocytes/macrophages via CD69, CD18 and CD49d and was independent of 
the production of soluble mediators by the T cells. CD4+CD45RO+ T cells are the 
main infiltrating cells in the pannus underlining their pivotal role in the pathogenesis 
of RA, possibly via the activation of other immune cells such as macrophages. 
Cytokine stimulated T cells (Tck) display the same characteristics as activated 
synovial T cells. Just like Tck, synovial T cells induced the release of TNFα but not 
Il-10 by monocytes, thereby possibly creating an unbalanced proinflammatory 
cytokine environment likely setting the stage for chronic inflammatory responses. 
Abatacept (Orencia) is a fusion protein composed of an immunoglobulin Fc part 
and the extracellular domain of CTLA-4. Abatacept is a selective costimulation 
inhibitor as it blocks costimulation via CD80/86 of T cells by DCs. The mode of 
action of Abatacept is thought to depend on the inhibition of the full activation of 
T cells. We have demonstrated a new mechanism by which Abatacept might be 
able to dampen inflammation. In vitro Abatacept prevented the activation of type 
1 macrophages by Tck implying that in vivo Abatacept might block the activation 
of synovial macrophages by activated synovial T cells resulting in an inhibition of 
the local production of TNFα. Thereby Abatacept might, in addition to its effect on 
the T cell compartment, undermine the proinflammatory cytokine network 
dampening the chronic inflammatory response. In addition we demonstrated that 
TLR activation and Tck exposure synergistically induce the production of 
especially IL-12p70 by type 1 macrophages which was dampened by the presence 
of Abatacept.   
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Psoriatic Arthritis and (myco)bacteria
Bacteria have long been thought to play a role in many (auto)inflammatory and 
autoimmune diseases. Proposed roles for bacteria range from molecular mimicry, 
in which a component from bacteria is thought to mimick a self peptide leading to 
an autoimmune response, to the deposition of bacterial constituents in synovium, 
thought to lead to pattern recognition receptor activation and the initiation/
perpetuation of joint inflammation. From animal models it is clear that the gut flora 
has a profound impact on the immune system and especially on T cell differentia-
tion. IL-1Ra-/- mice housed under germ-free conditions do not develop arthritis 
and upon stimulation splenocytes from these mice produce hardly any IL-17. 
Recently it was demonstrated that a restricted number of bacteria, prototypically 
the nonculturable segmented filamentous bacterium, were crucial in the induction 
and maintenance of intestinal immune responses, such as the differentiation of 
Th1 and Th17 6. The fact that a selective type of bacteria has the prerogative to 
shape the immune system implies that a dysfunctional handling of certain bacteria 
might lead to a thwarted immune system possibly leading to immune diseases. 
Crohn’s disease patients, for example, have been shown to have an aberrant 
immune reaction towards intradermally injected heat-killed Escherichia coli 
leading to the delayed removal of these pathogens. Eventually this impaired 
removal of pathogens might lead to chronic inflammation.  
Mycobacteria have been suspected of playing a role in Crohn’s disease as well as 
psoriatic disease 7. Recently, the presence of M avium subspecies paratuberculo-
sis reactive T cells with a Th1 or Th1/Th17 phenotype strengthened a possible role 
of mycobacteria in the inflammation seen in Chron’s disease 8.  In addition, it was 
demonstrated that M avium paratuberculosis actively invades the human gut 
epithelial goblet cells of the small intestine, inducing severe tissue damage and 
inflammation 9. In psoriatic disease high levels of antibodies against 65-kDa and 
48/45 doublet antigens from mycobacteria have been found and these correlated 
with disease severity. Significantly more psoriasis patients showed “false” positive 
tuberculin skin test results than other dermatology patients and the tuberculin 
skin test correlated with the psoriasis area and severity index score (PASI). In 
addition, in placebo-controlled studies, immunotherapy with Mycobacterium 
vaccae for psoriasis and psoriatic arthritis resulted in significant reductions of 
important disease parameters 10. 
The hypothesis that certain (myco)bacteria might play a role in PsA was 
strengthened by our finding that DCs from PsA patients with an active disease 
have a severely impaired innate immune reaction towards mycobacteria (Figure 4). 
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The cytokine production by DCs upon exposure to other bacteria such as E coli, 
Klebsiella  pneumonia and Streptococcus pyogenes was not impaired, highlighting 
the selective nature of the weakened immune response. This striking inability of 
PsA DCs to respond to mycobacteria was found in two independent cohorts of 
PsA patients, at the Radboud University Medical Centre Nijmegen and at the 
Western Infirmary Glasgow. 
The impaired cytokine production upon exposure to mycobacteria was positively 
correlated with the cytokine production upon exposure to TLR2, TLR7/8 and 
NOD2 ligands but was not dependent on their expression. The selective up 
regulation of SOCS3 and A20 mRNA found in DCs from active PsA patients might 
be an explanation for the dampened cytokine production. Further support for the 
role of certain intracellular bacteria in PsA was found in the fact that molecules 
heavily involved in the defence against intracellular pathogens (NOX2 and LL37) 
were highly up regulated in DCs from PsA patients. In mice infected with M 
tuberculosis these molecules were also found up regulated in monocytes and 
monocyte-derived macrophages. These data prompted us to hypothesize that an 
initial decreased response by DCs towards certain (myco)bacteria would lead to 
an insufficient removal of these bacteria and the initiation of an inflammatory 
response. However, why this inflammatory response derails and becomes chronic 
is another question. We demonstrated that CD163+ type 2 macrophages from 
PsA patients have an elevated expression of CCR5. CCR5-/- mice demonstrate 
Figure 4
Clearly reduced cytokine production by PsA DCs upon stimulation with M tuberculosis in 
comparison to healthy controls or RA patients. * p<0.01 compared to healthy control or RA 
patients.
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an increased activation of alternatively activated macrophages, decreased 
inflammation, longer allograft survival and less pulmonary fibrosis in allograft 
survival and fibrosis models 11;12. Psoriatic disease is characterized by an increase 
in the presence of fibrotic diseases of the liver and the lungs. Fibrotic changes 
along the sacroiliac joints and spine are also common in PsA. The increased 
expression of CCR5 on type 2 macrophages in PsA might be involved in these 
pathological changes. This is in line with the increased presence of CD163+ 
macrophages in the synovium of PsA patients since these cells were the only 
monocyte-derived cell type expressing CCR5 at considerable levels. A clue to 
why PsA patients express elevated levels of CCR5 might be the finding that CCR5 
is elevated on monocyte-derived and alveolar macrophages during M tuberculosis 
infection and that antigens from M avium complex up regulate the expression of 
CCR5 on monocytes. In addition to the preferential recruitment of CCR5+ CD163+ 
macrophages in PsA we have demonstrated that these macrophages have an 
impaired anti-inflammatory function while their cytokine production is unhampered. 
While type 2 macrophages from healthy controls were capable of suppressing 
proinflammatory cytokine production and T cell polarization by DCs, type 2 
macrophages from active PsA patients did not have these suppressive capacities. 
These results support a hypothetical framework in which a dysfunctional innate 
immune response towards certain (myco)bacteria by resident myeloid DCs leads 
to the hampered removal of these pathogens and increased inflammatory responses. 
The subsequent preferential recruitment of type 2 macrophages would, under 
normal circumstances, dampen the immune response. However, due to a dys- 
functional anti-inflammatory capacity and possibly the persistence of the (intra-
cellular) bacterium the immune response persists resulting in chronic inflammation. 
Conclusion
This thesis encompasses new insights into a range of immunological processes 
and in the pathogenesis and possible resolution of RA and PsA. The main 
hypothetical framework these studies were based on, was the idea that Toll-like 
receptors play an intricate role in many inflammatory diseases. FcγRIIb and TLR2 
activation was shown to dampen TLR4 and 7/8 responses in DCs and type 1 
macrophages, significantly down regulating their production of proinflammatory 
cytokines. Both FcγRIIb and TLR2 would shift DC induced T cell responses 
towards Th2 responses even in the presence of strong Th1 inducers like TLR4 and 
TLR7/8 ligands. Th2 responses have been shown to decrease the inflammatory 
responses in both RA and PsA. Another regulatory mechanism utilized by the 
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immune system in order to prevent chronic inflammation is the inhibitory effect of 
the accumulation of high levels of macrophages and DCs at a site of inflammation. 
Accumulation of cells led to a potently decreased ability of DCs and macrophages 
to produce proinflammatory cytokines while the production of IL-10 and VEGF 
were increased. This mechanism was dependent on the b2 integrin Mac-1 and the 
production of prostaglandins. In addition the ability of DCs to support autologous 
T cell responses was strongly reduced. Along with TLR ligands inflammatory T 
cells have been demonstrated to be potent inducers of TNFα production by 
macrophages in RA. Abatacept was capable of blocking this proinflammatory 
cross-talk leading to a marked reduction in TNFα production elucidating another 
mode of action for this effective drug. While RA is thought to be dependent on an 
overactive immune system we demonstrated that PsA might, at least in part, 
depend on an insufficient immune response towards (myco)bacteria by DCs. The 
aberrant immune reaction leading to PsA seemed to be supported by type 2 
macrophages lacking their characteristic anti-inflammatory behaviour. However, 
much more research is needed to reach the full potential of the mechanisms and 
novel findings described in this thesis.   
                     
Future perspectives
DCs regulate both central and peripheral tolerance and have successfully been 
used in treating animal models of autoimmune diseases. The central role played 
by DCs in maintaining tolerance has been supported by the finding that constitutive 
ablation of DCs results in spontaneous fatal autoimmunity 13.   In contrast, during 
the onset of autoimmunity DCs are thought to be critical for priming of self-reactive 
T cells, underscoring their central role in immunity and tolerance. The role played 
by myeloid DCs in RA has become increasingly clear over the last decade. With 
animal models demonstrating that DCs are crucial in the breach of self tolerance 
in an arthritis model 14 to the demonstration in this thesis that DCs from RA 
patients capable of successfully discontinuing treatment have a phenotype 
aimed at restoring immune balance 15, a central and regulating role for DCs in RA 
seems apparent. Dysfunctional DCs in addition seem to play a role in the 
pathogenesis of PsA as we have demonstrated that DCs from PsA patients are 
incapable of reacting appropriately to mycobacterial insults. This might lead to a 
lagged immune response and consequently an increased persistence of 
pathogens leading to chronic inflammation. It appears that for both RA and PsA 
the statement of Steinman and Banchereau “DCs are an early player in disease 
development and an unavoidable target in the design of treatments” 16 is appropriate.  
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A novel perspective of looking at disease and trying to find new treatment 
modalities and understanding is to investigate the immune system of those 
unique RA patients who reach remission and are no longer in need of medication. 
The elevated expression of FcγRIIb on DCs from these patients already appears 
to be a valid target. Increasing the expression of FcγRIIb on DCs from RA patients 
might lead to the decreased release of proinflammatory cytokines and a shift in T 
cell responses towards Th2 and regulatory T cell responses thereby restoring 
immune homeostasis. To be able to do this we first need to investigate how 
FcγRIIb expression is regulated in general and in these “disease-free” RA patients. 
Therefore we need to further elucidate on the DC phenotype of these patients, 
among others by gene expression profiling and by investigating the role played 
by epigenetics in these patients. Further research is ongoing in our lab aimed at 
delineating the factors important in the up regulation of FcγRIIb on DCs. This 
might result in our ability to exploit this novel but internal regulatory mechanism 
used by the immune system itself. Thereby we might be able to dampen 
inflammation in a more natural manner via various routes (dampening proinflam-
matory cytokine production, shifting T cell responses to Th2, increasing regulatory 
T cell numbers)  and possibly more specifically aimed at the deranged immune 
response and thus with less side effects. Preliminary data demonstrate that, like 
the induction of an anti-inflammatory type 1 macrophage phenotype, the 
expression of FcγRIIb is increased upon homotypic cell-cell contact. How this up 
regulation is mediated is currently under investigation. A possible mechanism 
might be the transfer of microparticles loaded with FcγRIIb from one cell to the 
other, a mechanism with possible therapeutic implications. 
However we should not forget to investigate other immune-inhibitory pathways in 
these specific RA patients. Potential other targets are regulatory T cells, 
plasmacytoid DCs and macrophages. These cell types have been described to 
have potent immune modulating potential. Investigation could be aimed at the 
analysis of the phenotype and anti-inflammatory potential of these cell types in 
these patients. Since monocyte-derived DCs from these patient express elevated 
levels of FcγRIIb it would be interesting to see whether macrophages from these 
patient also have an increased expression of FcγRIIB with functional consequences. 
Another interesting question is whether RA patients who have a low disease 
activity and who might be taken of their medication successfully  already have a 
tendency to express elevated levels of FcγRIIb. Answering this will unravel whether 
this might be a method to screen patients who will be able to handle their disease 
themselves and might thus be taken of medication with confidence. However, it 
might demonstrate that the use of medication suppresses the organisms own 
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tendency to up regulate FcγRIIb in order to dampen inflammation, which would 
underscore the potential therapeutic effect of up regulating FcγRIIb artificially.
Another immune inhibitory pathway laid bare in this thesis which might be 
exploited for the treatment of RA is the Mac-1 mediated anti-inflammatory DC and 
macrophage phenotype. Homotypic cell-cell contact was demonstrated to 
induce an anti-inflammatory cell phenotype in otherwise pro-inflammatory 
macrophages and DCs. This was mediated via a signalling cascade involving 
MAPK p38, COX2 and SOCS proteins leading to a suppressed TNFα production 
and a highly increased release of IL-10 upon TLR stimulation. Since TLR activation 
of DCs and macrophages appears to play an important role in the pathogenesis 
of RA exploitation of this pathway might potentially be beneficial. This appears in 
contrast to the wide-spread use of COX2 inhibiting NSAIDs in RA. However, the 
ability of NSAIDs to ameliorate pain and tenderness does not prevent disease 
progression in rheumatoid arthritis. Even more, in line with our results, it was 
established that the addition of COX2 inhibitor to RA synovial tissue increased the 
release of TNFα while the production of IL-10 was suppressed 2. This in 
combination with the notion that TLR8 inhibition potently reduced the spontaneous 
release of TNF from synovial tissue warrants the further investigation of our 
proposed feedback mechanism 17. Thus instead of inhibiting the COX2 pathway it 
might be of interest to activate Mac-1 e.g. via agonistic antibodies, stimulate the 
production of COX2 dependent prostaglandins or to induce the expression of 
SOCS proteins via, for example, small molecule agonists. These small molecule 
agonists might be used enveloped in liposomes thereby mainly targeting 
monocytes and monocyte-derived cells. However, since PGE2 has been 
implicated in the induction of Th17 responses 18 and Th17 have been described to 
mediate osteoclast activation-formation 19 caution is warranted.   
Another major inhibitory pathway we have described is the inhibitory effect of 
activating TLR2. However due to its dual role in the immune response, activation 
of TLR2 leads to the production of large amounts of proinflammatory cytokines by 
certain cell types such as type 1 macrophages, direct stimulation of TLR2 seems 
ill-advised. A possible way to go about is by learning which pathways TLR2 uses 
to exert its beneficial effects and utilize these. We have made a start by 
demonstrating that SOCS1 is specifically up regulated by TLR2 co-activation. The 
artificial up regulation of SOCS1 might tune the immune response towards a Th2 
type response and away from the deleterious Th1 response characteristic of RA. 
In addition it might prevent the production of autoantibodies by decreasing the 
presence of IL-12p70 dependent follicular T cells thereby abrogating B cell 
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maturation and memory. Modulation of TLR responses instead of completely 
blocking them might even be more effective due to a reversal of the immune 
reaction away from Th1 towards Th2. RA appears to be a mainly Th1 driven 
disease and atopic patients with RA have a marked less active disease. In 
addition, DCs from RA patients capable of halting their use of immunosuppres-
sive drugs had an highly increased capability of inducing Th2 cells and IL-4 has 
shown potent effects in suppressing inflammation in mouse models. Further 
elucidation of the inhibitory effect of TLR2 on DCs might result in targeted 
therapies aimed at inducing DCs capable of subverting Th1 responses in RA into 
Th2 or regulatory T cell responses thereby dampening inflammation.  
For PsA, other treatment modalities appear to be warranted. The apparent 
dysfunction of DCs in producing the necessary amounts of proinflammatory 
cytokines as well as the presence of large amounts of bacterial products in the 
blood and joints of patients with psoriatic disease underscores the defective 
function of the immune system as a major component of disease pathogenesis in 
PsA 20;21. Although the neutralization of TNFα has proven to be highly effective in 
PsA, additional therapy aimed at boosting or restoring the immune barrier function 
of the body might have beneficial effects on the recurrence/exacerbation of PsA. 
NSAIDs have an important part in the treatment of spondylarthropathies possibly 
in part due to the increased ability of DCs/macrophages to respond to (myco)
bacteria. Much more research is necessary to understand the complex interplay 
of the immune system and microbiota in PsA. Interesting is to investigate whether 
psoriasis patients and PsA patients differ in their response towards (myco)
bacteria to determine disease/stage specificity and using a broader panel of 
bacteria to further determine specificity. Since 16S rRNA can be used to determine 
the presence of mycobacterial ribosomal RNA it could be a tool to determine its 
presence in blood (e.g. in monocytes) and in synovial tissue and fluid. Thereby 
more circumstantial evidence for a role for mycobacteria in PsA might be 
uncovered.  Direct evidence might be found by using drugs aimed against 
mycobacteria (antibiotics, vitamin D) and correlating change in disease activity 
with the presence of (myco)bacterial components. Rifampicin, an antibiotic used 
for the treatment of mycobacterial infections, already has demonstrated some 
effectiveness in the treatment of psoriasis 22;23. Autophagy is an essential cellular 
process by which cells degrade their own components. Recent developments 
have revealed that the autophagy pathway and its proteins also play an important 
role in inflammation and immunity. In DCs autophagy processes degrade bacteria, 
influence cytokine production upon contact with bacteria and regulate the correct 
presentation of bacterial components to T cells 24. It thus appears apparent that 
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autophagy might play an important role in PsA. We found that the transcription of 
NOX2 and LL37, proteins important in the induction of autophagy following TLR2 
and NOD2 activation, are highly increased in PsA DCs. Together with the recent 
description that the induction of autophagy limits the production of proinflamma-
tory cytokines upon TLR activation 25 this underscores the possible importance in 
the aberrant immune reaction towards mycobacteria by PsA DCs. This warrants 
further in depth research into the regulation of autophagy in PsA. A dysfunction in 
autophagy might underlie PsA characterized by an aberrant innate immune and 
autophagy reaction of DCs followed by the dysfunctional presentation of bacterial 
components to T cells leading to inappropriate immune activation and eventually 
chronic inflammation. A first step might be to further delineate the autophagy 
pathway induced by TLR2 activation and investigate whether this signaling route 
is enhanced in PsA DCs (e.g. by measuring the NOX2-dependent production of 
reactive oxygen species upon the engagement of TLRs which mediate the 
recruitment of the autophagy protein LC3 to the phagosome). Understanding of 
the involvement of the autophagy pathway in DC behavior in PsA might lead to 
new therapeutic modalities specifically aimed at the causative immune dysfunction.
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Het immuunapparaat is cruciaal in de afweer tegen bedreigingen van buitenaf, 
zoals bacteriën, virusen en schimmels. Hierbij zijn veel verschillende soorten 
(immuun)cellen, betrokken. Deze cellen kunnen bedreigingen herkennen en 
hierop actie ondernemen door een ontsteking te veroorzaken gericht tegen deze 
bedreiging. Naast gevaren van buitenaf kan het immuunapparaat ook reageren 
op schade van het lichaam zelf zodat dit opgeruimd wordt. Naast alle goede 
eigenschappen van het immuunapparaat kan het zich echter ook tegen ons 
keren. Dit gebeurt bijvoorbeeld in Reumatoïde Artritis waarbij bestanddelen van 
het gewricht zelf door het immuunapparaat worden gezien als bedreigingen 
waarop er een immuunreactie ontstaat die leid tot ontsteking van het gewricht. 
Afweercellen kunnen bedreigingen en schade herkennen via Toll-like Receptoren 
waarna de immuunreactie begint. In dit proefschrift hebben we onderzoek 
gedaan naar de rol van Toll-like Receptoren en Fc gamma Receptoren op 
dendritische cellen (DCs) en macrofagen in Reumatoïde Artritis en Artritis 
Psoriatica. Daarnaast hebben we gekeken naar de regulatie van Toll-like Receptor 
reacties in deze cellen. DCs zijn cellen die belangrijk zijn in het herkennen van 
bacteriën, virussen en schimmels waarna ze een immuunreactie opstarten door 
de activatie van andere immuuncellen zoals T- en B-cellen zodat de bedreiging 
wordt beperkt. Macrofagen zijn cellen met zeer uiteenlopende functies. Er is een 
grote verscheidenheid aan macrofagen, van macrofagen die in staat zijn om veel 
ontstekingsmoleculen te produceren en zo belangrijk zijn in het ontstaan van een 
ontstekingsreactie, tot macrofagen die met name gericht zijn op juist het 
onderdrukken van immuunreacties. Toll-like Receptoren zijn receptoren die 
bestanddelen van bacteriën en virussen kunnen herkennen en vervolgens de 
betrokken cel kunnen activeren tot het produceren van stoffen die belangrijk zijn 
in de afweerreactie van het lichaam. Daarnaast kunnen Toll-like Receptoren 
stoffen herkennen die vrijkomen bij schade in het lichaam, dit om immuunreacties 
op te roepen welke belangrijk zijn voor het opruimen van de ontstane schade. Nu 
is het echter zo dat wanneer er te veel van dat soort ontstekingsstoffen vrijkomen 
of er volgt een te sterke immuunreactie er een vicieuze cirkel kan optreden 
waardoor er een blijvende (chronische) ontsteking ontstaat. In RA zijn er veel 
stoffen aanwezig in het gewricht die Toll-like Receptoren kunnen binden en 
daardoor een immuunreactie op kunnen wekken. Deze stoffen lijken belangrijk in 
het ontstaan en aanwezig blijven van de ontsteking in de gewrichten. Als 
tegen-reactie tegen de activatie van Toll-like Receptoren heeft het lichaam 
verschillende mechanismen ontwikkeld om hun reactie te onderdrukken. Wij 
hebben gevonden dat de Fc gamma Receptor IIb in staat is om Toll-like Receptor 
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reacties te onderdrukken (hoofdstuk 2 en 3). Fc gamma Receptoren zijn 
receptoren die antistoffen binden die zelf weer kunnen binden aan allerlei 
bestanddelen van bacteriën, virussen of onderdelen van het lichaam zelf. De 
meeste  Fc  gamma Receptoren hebben een activerend effect op de cel, maar Fc 
gamma Receptor IIb is uniek door zijn remmende functie. Daarnaast hebben we 
aangetoond dat patiënten met Reumatoïde Artritis die, na in het begin van de 
ziekte behandeld te zijn geweest met immuun-onderdrukkende middelen, 
uiteindelijk zonder medicijnen kunnen, een hele hoge aanwezigheid hebben van 
Fc gamma Receptor IIb op hun DCs. Daarmee kunnen deze patiënten heel goed 
Toll-like Receptor reacties onderdrukken in DCs. Hierdoor maken deze DCs 
vervolgens veel minder ontstekingseiwitten en zorgen ze ervoor dat er T cellen 
ontstaan (T helper 2 en regulatoire T cellen) die belangrijk zijn in de onderdrukking 
van immuunreacties. Dit is mogelijk een verklaring waarom deze Reumatoïde 
Artritis patiënten geen medicijnen meer nodig hebben, aangezien hun lichaam/
immuunsysteem een eigen methode heeft ontwikkeld om de ontsteking te 
onderdrukken. In andere Reumatoïde Artritis patiënten, die wel krachtige 
medicatie nodig hebben, zou het juist kunnen zijn dat de Fc gamma Receptor IIb 
onvoldoende hoog wordt waardoor ze juist de ziekte krijgen of blijven houden. 
Een mogelijke nieuwe therapie zou dus het ophogen van de aanwezigheid van Fc 
gamma Receptor IIb kunnen zijn op DCs. Hiervoor moet duidelijk zijn hoe dit in 
cellen gereguleerd is. Op dit moment wordt er aldus in ons lab onderzoek gedaan 
naar de onderliggende regel mechanismen.
Aangezien macrofagen zulke uiteenlopende functies vertonen en ze belangrijk 
zijn in zowel het starten van een immuunreactie en tevens juist het onderdrukken 
hiervan wilden wij bekijken of macrofagen die binnen komen in een ontsteking 
van aard veranderen gedurende de immuunreactie. Onze hypothese was dat 
gedurende de ontsteking de aard van de macrofagen van ontstekings-veroorza-
kend naar ontstekingsremmend zou veranderen en dat dit zou samenhangen met 
de hoeveelheid macrofagen die aanwezig is (hoe meer macrofagen hoe minder 
pro-ontsteking ze hoeven te zijn omdat er dan voldoende aanwezig zijn om de 
bedreiging aan te pakken). Wij vonden dat deze hypothese, in ieder geval in vitro 
(in het lab), klopt. Macrofagen die normaalgesproken een ontstekingsveroorzak-
ende aard hebben, kregen een ontstekingsremmende aard wanneer ze met veel 
cellen bij elkaar werden gekweekt. Ze werden in staat tot het produceren van veel 
moleculen die ontsteking onderdrukken en de productie van ontstekingsmediato-
ren werd onderdrukt na Toll-like Receptor stimulatie (hoofdstuk 4). Dit bleek te 
berusten op de productie van een oplosbare factor, meest waarschijnlijk prosta-
glandine-E2. Dit molecuul is belangrijk in de progressie van tumoren en remming 
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van dit molecuul leidt tot een toegenomen weerstand tegen bacteriën. 
Veelgebruikte pijnstillers in Reumatoïde Artritis zoals diclofenac en naproxen, die 
horen tot de groep van de NSAIDs (non-steroidal anti-inflammatory drugs), 
werken door de onderdrukking van een molecuul (COX2) wat voor de productie 
van prostaglandine-E2 zorgt. Recent heeft men laten zien dat deze middelen 
zorgen voor een verhoogde productie van pro-ontstekings moleculen in RA ge-
wrichtsweefsel. Onze resultaten laten zien dat dit wel eens zou kunnen komen 
doordat de ontwikkeling van een anti-ontstekings macrofaag wordt voorkomen.    
Er bestaan tien verschillende Toll-like Receptoren (Toll-like Receptor 1-10) met 
allemaal hun eigen mogelijkheid om verschillende moleculen te herkennen en 
vervolgens hun cel verschillende reacties te laten vertonen. Dit is belangrijk in het 
afweersysteem omdat er zo onderscheid kan worden gemaakt tussen 
verschillende bacteriën, virussen en schimmels die een bedreiging kunnen 
vormen. Uit dierproefonderzoek is gebleken dat Toll-like Receptor 2 een 
onderdrukkende werking heeft op het ontstaan van gewrichtsontstekingen 
(artritis) terwijl Toll-like Receptor 4 juist belangrijk is in het ontstaan van deze 
ontsteking. Toll-like Receptor 4 bindende moleculen (liganden) zijn aanwezig in 
het gewricht van RA patiënten. Wij hebben laten zien dat Toll-like Receptor 2 in 
staat is om de sterke Toll-like Receptor 4 (en Toll-like Receptor 7/8) reacties te 
onderdrukken in DCs (hoofdstuk 6). Deze onderdrukking vindt plaats via 
verschillende routes in de cel. Een belangrijke remming vindt plaats via de 
activatie van SOCS1, een molecuul dat activatie via interferon type 1 kan remmen 
(hoofdstuk 5). Interferon type 1 is belangrijk in de afweer tegen virussen maar 
lijkt ook een belangrijke rol te hebben in het ontstaan van autoimmuunziekten 
zoals Reumatoïde Artritis. Deze remmende route via TLR2 zou dus een aanknop-
ingspunt kunnen zijn voor nieuwe therapieën.
In Reumatoïde Artritis wordt sinds een aantal jaren gebruik gemaakt van 
moleculen die speciaal ontwikkeld zijn om specifiek in te grijpen in het immuun 
systeem. Bekende moleculen die ontwikkeld zijn,zijn de anti-TNFα middelen die 
dit eiwit, zeer belangrijk in ontsteking, neutraliseren. Daarnaast zijn er moleculen 
ontwikkeld die de communicatie tussen DCs en T-cellen beperken. Abatacept is 
zo’n molecuul. Wij hebben gevonden dat dit medicijn nog andere effecten heeft 
waardoor het ontstekingsreacties kan onderdrukken. Het blijkt dat het ervoor 
zorgt dat geactiveerde T-cellen, die aanwezig zijn in het gewricht bij Reumatoïde 
Artritis patiënten, veel minder in staat zijn om macrofagen aan te zetten tot de 
productie van TNFα (hoofdstuk 7). Dit is een direct mechanisme waardoor het 
effect van Abatacept nog beter verklaard zou kunnen worden.
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Artritis Psoriatica is een aandoening waarbij er naast gewrichtontstekingen 
sprake is van ontstekingen in de huid zoals bij psoriasis. Waar er bij Reumatoïde 
Artritis sprake is van een duidelijke auto-immuun component is dit in Artritis 
Psoriatica minder duidelijk. Artritis Psoriatica behoort tot de groep van ziekten 
genaamd spondylarthropathieën, andere ziekten in deze groep zijn onder andere 
de ziekte van Crohn en de ziekte van Bechterew. Zoals bij Crohn wordt er bij 
psoriasis gesproken over een mogelijke oorzaak door een verminderde 
afweerfunctie van weefsels tegen aanvallen van buiten af door bacteriën. In Crohn 
is er sprake van een chronische ontsteking van de darmwand. Men heeft laten 
zien dat mensen die deze ziekte hebben minder goed in staat zijn om een immuun - 
reactie op te roepen tegen bepaalde bacteriën waardoor deze waarschijnlijk 
langer aanwezig blijven in de darm en daardoor voor een chronische ontsteking 
zorgen. In dit proefschrift laten wij zien dat DCs van patiënten met PsA minder 
goed in staat zijn om te reageren op mycobacteriën(hoofdstuk 8). Mycobacteriën 
zijn overal om ons heen, op onze huid en in onze darmen. Het zou kunnen zijn dat 
door de verminderde verwijdering van mycobacteriën uit huid en darmen, door 
de slechtere herkenning door DCs, bestanddelen van deze bacteriën of hele 
bacteriën zich via het bloed verplaatsen naar de gewrichten en pezen waarna er 
daar ontstekingen ontstaan. Dit zou waarschijnlijk nog niet zo’n groot probleem 
zijn als de onderdrukkende mechanismen in het immuunsysteem goed zouden 
werken in deze patiënten. Het lijkt er echter op dat anti-ontsteking macrofagen 
die specifiek worden aangetrokken naar de ontstekingsplekken en normaal 
gesproken de immuunreactie onderdrukken, niet goed werken. Hierdoor wordt 
de immuunreactie niet geremd maar gaat juist door (hoofdstuk 9). Door een 
verminderde herkenning van mycobacteriën door DCs kunnen deze bacteriën 
zich dus mogelijk meer dan normaal vestigen in het lichaam waarna er een 
chronische ontstekingsreactie ontstaat van huid, gewrichten en pezen zoals 
gezien in Artritis Psoriatica. Vervolgens blijven deze ontstekingen chronisch 
aanwezig omdat de aangetrokken ontstekingsonderdrukkende macrofagen hun 
werk onvoldoende doen.
In dit proefschrift hebben we meerdere onderdelen van het immuunapparaat 
bekeken die betrokken zijn bij het ontstaan van Reumatoïde Artritis en Artritis 
Psoriatica. We hebben ons met name gericht op de rol die gespeeld wordt door 
DCs en hun Toll-like Receptoren. Het blijkt dat DCs mogelijk een grote rol spelen 
in Reumatoïde Artritis, patienten die namelijk uiteindelijk zonder medicijnen 
kunnen blijken een hele hoge aanwezigheid te hebben van de remmende Fc 
gamma Receptor IIb op hun DCs waarmee Toll-like Receptor reacties kunnen 
worden geremd. Mogelijk dat hierdoor hun ziekte wordt onderdrukt wat zou 
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betekenen dat DCs een centrale rol spelen in het (remmen van het) ziekteproces. 
Daarnaast hebben we een aanwijzing gevonden dat DCs niet goed werken in 
Artritis Psoriatica. Ze zijn niet goed in staat om mycobacteriën te herkennen via 
Toll-like Receptoren waardoor deze mogelijk minder makkelijk verwijderd worden 
en vervolgens zorgen voor een (te) sterke immuunreactie. Dit kan vervolgens 
leiden tot ontstekingen van onder andere huid, gewrichten en pezen zoals gezien 
in Artritis Psoriatica. Door het beter begrijpen van de ziekteprocessen in 
Reumatoïde Artritis en Artritis Psoriatica en de rol die DCs en Toll-like Receptoren 
hierin spelen kunnen we in de toekomst mogelijk nog betere en meer gerichte 
medicijnen ontwikkelen tegen deze veel voorkomende ziekten.       
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ACPA anti-citrullinated protein antibody
ACR American College of Rheumatism
APC antigen-presenting cell
ATG16L1 autophage-related protein 16-1
CCR credence clearwater revival (or in this thesis: C-C motif receptor)
CD cluster of differentiation
CRP C-reactive protein
DAMP damage associated molecular pattern
DAS28 disease activity score for 28 joints
DC dendritic cell
DClow FcγRIIb DC expressing a low Fc gamma receptor IIb  level
DChigh FcγRIIb DC expressing a high Fc gamma receptor IIb level
DMARD disease modifying anti-rheumatic drug
DMARD(-) RA RA patients having a DAS28<3.2 not on DMARD therapy
DMARD(+) RA RA patients having a DAS28<3.2 on DMARD therapy
dsRNA double-stranded ribonucleic acid
Erk extracellular signal-regulated kinase
ESR erythrocyte sedimentation rate
FACS fluorescence-activated cell sorter
FcγR Fc gamma receptor
FCS fetal calf serum
FITC fluorescein isothiocyanate
GAPDH glycerylaldehyde-3-phosphate dehydrogenase
GM-CSF granulocyte macrophage-colony stimulating factor
HAGGs heat-aggregated gamma globulins
HE heamatoxylin/eosin
HLA human leucocyte antigen
HSA  human serum albumin
HSP heat shock proteins
IC  immune complex
IFN interferon
IgG immunoglobulin G
IL interleukin
IL-1ra interleukin-1 receptor antagonist
IRAK interleukin-1 receptor associated kinase
IRF interferon regulatory factor
IVIG intravenous immunoglobulin
LPS lipopolysaccharide
Mf-1 type 1 macrophage
Mf-2 type 2 macrophage
MACS magnetic bead activated cell sorter
(m)Ab (monoclonal) antibody
MAPK mitogen-activated protein kinase
M-CSF macrophage-colony stimulating factor
MDP muramyl dipeptide
MFI mean fluorescence intensity
MHC major histocompatibility complex
MHC II MHC class II
MTX methotrexate
MyD88 myeloid differentiation factor 88
NFkB nuclear factor kappa -light-chain-enhancer of activated B cells
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NOD nucleotide-binding oligomerization domain
NOX2 nicotinamide adenine dinucleotide phosphate-oxidase 2
NSAID non-steroidal anti-inflammatory drug
Pam3CSK4 palmitoyl-3-Cys-Ser-(Lys)4
PAMP pathogen-associated molecular pattern
PBMC peripheral blood mononuclear cells
PBS phosphate buffered saline
PCR polymerase chain reaction
PE phycoerythrin 
Peg-IC immune complexes isolated by PEG precipitation from serum or synovial fluid
PI3K phosphoinositide-3-kinase
PIP2 phosphatidylinositol (4,5)-bisphosphate
PIP3 phosphatidylinositol (3,4,5)-trisphosphate
PKCd protein kinase C delta
pLPS purified LPS
PRR pattern recognition receptor
PsA psoriatic arthritis
qPCR quantitative polymerase chain reaction
RA   rheumatoid arthritis
RF rheumatoid factor
RT-PCR reverse transcriptase-polymerase chain reaction
SF  synovial fluid
SHIP src-homology 2-containing inositol 5' phosphatase
SIGIRR single Ig IL-1-related receptor
SOCS suppressor of cytokine signaling
ST synovial tissue
STAT-1 signal transducer and activator of transcription-1
TNFα tumor necrosis factor alpha
TNFAIP3 tumor necrosis factor alpha-induced protein 3
Th T helper
TOLLIP toll-interacting protein
TLR toll-like receptor
TRAF TNF receptor-associated factor
TRIF TIR-domain containing adaptor protein inducing IFNbeta 
Treg regulatory T cell
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